WO2024003535A2 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- WO2024003535A2 WO2024003535A2 PCT/GB2023/051666 GB2023051666W WO2024003535A2 WO 2024003535 A2 WO2024003535 A2 WO 2024003535A2 GB 2023051666 W GB2023051666 W GB 2023051666W WO 2024003535 A2 WO2024003535 A2 WO 2024003535A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- alkyl
- disease
- independently
- mmol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 212
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 149
- 201000010099 disease Diseases 0.000 claims abstract description 93
- 230000035772 mutation Effects 0.000 claims abstract description 78
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 85
- 229910052757 nitrogen Inorganic materials 0.000 claims description 67
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 57
- 208000035475 disorder Diseases 0.000 claims description 55
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 46
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 38
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000004429 atom Chemical group 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 19
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 10
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 9
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 claims description 8
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 7
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 7
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000033810 Choroidal dystrophy Diseases 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000017701 Endocrine disease Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 6
- 208000009292 Hemophilia A Diseases 0.000 claims description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 6
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 claims description 6
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 claims description 6
- 208000011219 Netherton syndrome Diseases 0.000 claims description 6
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 claims description 6
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 208000003571 choroideremia Diseases 0.000 claims description 6
- 208000016097 disease of metabolism Diseases 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 6
- 208000009429 hemophilia B Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 6
- 230000001926 lymphatic effect Effects 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 208000000690 mucopolysaccharidosis VI Diseases 0.000 claims description 6
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 6
- 210000000653 nervous system Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 210000002229 urogenital system Anatomy 0.000 claims description 6
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims description 5
- 241001014327 Anodontia Species 0.000 claims description 5
- 208000034076 BOR syndrome Diseases 0.000 claims description 5
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 5
- 208000025678 Ciliary Motility disease Diseases 0.000 claims description 5
- 201000007547 Dravet syndrome Diseases 0.000 claims description 5
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 5
- 208000004910 Odontodysplasia Diseases 0.000 claims description 5
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 5
- 201000003696 Sotos syndrome Diseases 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
- 208000026724 Waardenburg syndrome Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 201000007945 amelogenesis imperfecta Diseases 0.000 claims description 5
- 208000008303 aniridia Diseases 0.000 claims description 5
- 206010002583 anodontia Diseases 0.000 claims description 5
- 230000005212 anodontia Effects 0.000 claims description 5
- 206010071135 branchio-oto-renal syndrome Diseases 0.000 claims description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
- 201000003694 methylmalonic acidemia Diseases 0.000 claims description 5
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims description 5
- 210000001147 pulmonary artery Anatomy 0.000 claims description 5
- 229910003827 NRaRb Inorganic materials 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- -1 TLN486 (TLN68) Chemical class 0.000 description 209
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 184
- 239000000203 mixture Substances 0.000 description 157
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 123
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 99
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- 238000002953 preparative HPLC Methods 0.000 description 75
- 239000003643 water by type Substances 0.000 description 71
- 239000012071 phase Substances 0.000 description 70
- 239000007787 solid Substances 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 51
- 238000004128 high performance liquid chromatography Methods 0.000 description 47
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 37
- 238000013375 chromatographic separation Methods 0.000 description 35
- 238000000926 separation method Methods 0.000 description 35
- 239000000543 intermediate Substances 0.000 description 34
- 239000002245 particle Substances 0.000 description 33
- 230000002829 reductive effect Effects 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 27
- 235000019441 ethanol Nutrition 0.000 description 26
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 150000001412 amines Chemical class 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000012043 crude product Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 11
- 239000004698 Polyethylene Substances 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 11
- 150000002430 hydrocarbons Chemical group 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 230000005855 radiation Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- 108020004485 Nonsense Codon Proteins 0.000 description 9
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 9
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- IXBPPZBJIFNGJJ-UHFFFAOYSA-N sodium;cyanoiminomethylideneazanide Chemical compound [Na+].N#C[N-]C#N IXBPPZBJIFNGJJ-UHFFFAOYSA-N 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 7
- 239000012346 acetyl chloride Substances 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
- 108020005038 Terminator Codon Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000037434 nonsense mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091007054 readthrough proteins Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000012863 translational readthrough Effects 0.000 description 5
- DMFHGRVOSFEZKC-UHFFFAOYSA-N (4-methylquinazolin-2-yl)cyanamide Chemical compound C1=CC=C2C(C)=NC(NC#N)=NC2=C1 DMFHGRVOSFEZKC-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 229940126575 aminoglycoside Drugs 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102220240464 rs553587755 Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 150000003672 ureas Chemical class 0.000 description 4
- PDFYYFOKYYRSNC-UHFFFAOYSA-N (6-methoxy-4-methylquinazolin-2-yl)cyanamide Chemical compound N1=C(NC#N)N=C(C)C2=CC(OC)=CC=C21 PDFYYFOKYYRSNC-UHFFFAOYSA-N 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- RHVYWYRETWKHDC-UHFFFAOYSA-N 1-(2-amino-3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1N RHVYWYRETWKHDC-UHFFFAOYSA-N 0.000 description 3
- FFNJHEFKPCQTJQ-UHFFFAOYSA-N 1-(2-amino-5-methoxyphenyl)ethanone;hydron;chloride Chemical compound Cl.COC1=CC=C(N)C(C(C)=O)=C1 FFNJHEFKPCQTJQ-UHFFFAOYSA-N 0.000 description 3
- PVWNRLOVUZOZMF-UHFFFAOYSA-N 1-(3-methoxy-2-nitrophenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1[N+]([O-])=O PVWNRLOVUZOZMF-UHFFFAOYSA-N 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- UPYZISNDSQYZLZ-UHFFFAOYSA-N 8-methoxy-4-methyl-3h-quinazolin-2-one Chemical compound N1=C(O)N=C2C(OC)=CC=CC2=C1C UPYZISNDSQYZLZ-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108700025695 Suppressor Genes Proteins 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- FTGHZRUQDCMHRS-UHFFFAOYSA-N 1-(2-amino-4-methoxyphenyl)ethanone;hydrochloride Chemical compound Cl.COC1=CC=C(C(C)=O)C(N)=C1 FTGHZRUQDCMHRS-UHFFFAOYSA-N 0.000 description 2
- FCPBHFGFPWBXKL-UHFFFAOYSA-N 1-(2-amino-5-fluoro-3-methoxyphenyl)ethanone Chemical compound COC1=CC(F)=CC(C(C)=O)=C1N FCPBHFGFPWBXKL-UHFFFAOYSA-N 0.000 description 2
- ONQKSKDLYYDFLL-UHFFFAOYSA-N 2-(4-methylquinazolin-2-yl)guanidine Chemical compound C1=CC=C2C(C)=NC(N=C(N)N)=NC2=C1 ONQKSKDLYYDFLL-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NLMMTCDRRUCXDI-UHFFFAOYSA-N 2-bromo-4-fluoro-6-methoxyaniline Chemical compound COC1=CC(F)=CC(Br)=C1N NLMMTCDRRUCXDI-UHFFFAOYSA-N 0.000 description 2
- BQVRZLSYRZCKLF-UHFFFAOYSA-N 2-chloro-7-methoxy-4-methylquinazoline Chemical compound CC1=NC(Cl)=NC2=CC(OC)=CC=C21 BQVRZLSYRZCKLF-UHFFFAOYSA-N 0.000 description 2
- VOSQLWCTKGQTAY-UHFFFAOYSA-N 3,3,3-trifluoropropanoyl chloride Chemical compound FC(F)(F)CC(Cl)=O VOSQLWCTKGQTAY-UHFFFAOYSA-N 0.000 description 2
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000012609 Cowden disease Diseases 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 201000008251 Focal dermal hypoplasia Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000015178 Hurler syndrome Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 2
- 208000008892 Lipoid Proteinosis of Urbach and Wiethe Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 201000004253 NUT midline carcinoma Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
- 230000037437 driver mutation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003461 sulfonyl halides Chemical class 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000007482 whole exome sequencing Methods 0.000 description 2
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- VLVLNNQMURDGPM-UHFFFAOYSA-N (2,6-dichlorophenyl)methanamine Chemical compound NCC1=C(Cl)C=CC=C1Cl VLVLNNQMURDGPM-UHFFFAOYSA-N 0.000 description 1
- KXXLHPYCPKDAIG-UHFFFAOYSA-N (2-formylphenyl)azanium;chloride Chemical compound Cl.NC1=CC=CC=C1C=O KXXLHPYCPKDAIG-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FOFUOGSRVUOROJ-UHFFFAOYSA-N 1-(2-amino-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(N)=C1 FOFUOGSRVUOROJ-UHFFFAOYSA-N 0.000 description 1
- PVIZPQBLTIMSRH-UHFFFAOYSA-N 1-(2-amino-5-methoxyphenyl)ethanone Chemical compound COC1=CC=C(N)C(C(C)=O)=C1 PVIZPQBLTIMSRH-UHFFFAOYSA-N 0.000 description 1
- APTPPYQXBFFQHZ-UHFFFAOYSA-N 1-(2-aminophenyl)ethanone;hydron;chloride Chemical compound Cl.CC(=O)C1=CC=CC=C1N APTPPYQXBFFQHZ-UHFFFAOYSA-N 0.000 description 1
- PIRRWUMTIBFCCW-UHFFFAOYSA-N 1-(2-fluoro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(F)=C1 PIRRWUMTIBFCCW-UHFFFAOYSA-N 0.000 description 1
- BAYUSCHCCGXLAY-UHFFFAOYSA-N 1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1 BAYUSCHCCGXLAY-UHFFFAOYSA-N 0.000 description 1
- PFEGFUCYOHBDJF-UHFFFAOYSA-N 1-(4-fluoro-3-methoxyphenyl)ethanone Chemical compound COC1=CC(C(C)=O)=CC=C1F PFEGFUCYOHBDJF-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- ZNRLMGFXSPUZNR-UHFFFAOYSA-N 2,2,4-trimethyl-1h-quinoline Chemical compound C1=CC=C2C(C)=CC(C)(C)NC2=C1 ZNRLMGFXSPUZNR-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- TUNIZJPEKHLBPR-UHFFFAOYSA-N 2-bromo-3-methoxyaniline Chemical compound COC1=CC=CC(N)=C1Br TUNIZJPEKHLBPR-UHFFFAOYSA-N 0.000 description 1
- YBAGMTVKDRIMTB-UHFFFAOYSA-N 2-bromo-4-methoxyaniline Chemical compound COC1=CC=C(N)C(Br)=C1 YBAGMTVKDRIMTB-UHFFFAOYSA-N 0.000 description 1
- FMSHPLJQHOFMGT-UHFFFAOYSA-N 2-chloro-8-methoxy-4-methylquinazoline Chemical compound N1=C(Cl)N=C2C(OC)=CC=CC2=C1C FMSHPLJQHOFMGT-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- IYAWBVSACPDZBW-UHFFFAOYSA-N 2-morpholin-2-ylethanamine Chemical compound NCCC1CNCCO1 IYAWBVSACPDZBW-UHFFFAOYSA-N 0.000 description 1
- QTVLTMWZHMOYTR-UHFFFAOYSA-N 2-morpholin-4-ylsulfonylethanamine;hydrochloride Chemical compound Cl.NCCS(=O)(=O)N1CCOCC1 QTVLTMWZHMOYTR-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- UIWDESVQLUNCRV-UHFFFAOYSA-N 2-pyrazol-1-ylethanamine Chemical compound NCCN1C=CC=N1 UIWDESVQLUNCRV-UHFFFAOYSA-N 0.000 description 1
- HQVIIDSDPBHPBD-UHFFFAOYSA-N 2-pyridin-3-ylethanamine;hydrochloride Chemical compound Cl.NCCC1=CC=CN=C1 HQVIIDSDPBHPBD-UHFFFAOYSA-N 0.000 description 1
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- JMUCXULQKPWSTJ-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCCC1 JMUCXULQKPWSTJ-UHFFFAOYSA-N 0.000 description 1
- BNRRMRUVYDETQC-UHFFFAOYSA-N 4-fluoro-2-methoxyaniline Chemical compound COC1=CC(F)=CC=C1N BNRRMRUVYDETQC-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HJGMRAKQWLKWMH-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(N)CC2CCC1N2C HJGMRAKQWLKWMH-UHFFFAOYSA-N 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000002004 Afibrinogenemia Diseases 0.000 description 1
- 201000011374 Alagille syndrome Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007195 Andersen Syndrome Diseases 0.000 description 1
- 201000006060 Andersen-Tawil syndrome Diseases 0.000 description 1
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010002945 Aphakia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000008037 Arthrogryposis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004265 Benign familial pemphigus Diseases 0.000 description 1
- 208000001593 Bernard-Soulier syndrome Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 208000025480 CHILD syndrome Diseases 0.000 description 1
- 208000033418 CLN1 disease Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 208000000970 Carbamoyl-Phosphate Synthase I Deficiency Disease Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 206010008587 Choanal atresia Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 208000004960 Congenital Ichthyosiform Erythroderma Diseases 0.000 description 1
- 208000003799 Congenital Limb Deformities Diseases 0.000 description 1
- 208000006509 Congenital Pain Insensitivity Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- 208000030060 Congenital non-bullous ichthyosiform erythroderma Diseases 0.000 description 1
- 208000028702 Congenital thrombocyte disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000009343 Cornelia de Lange syndrome Diseases 0.000 description 1
- 201000002847 Cowden syndrome Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 206010011778 Cystinuria Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000003471 De Lange Syndrome Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 201000000913 Duane retraction syndrome Diseases 0.000 description 1
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 201000002994 Dyschromatosis symmetrica hereditaria Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000008288 Ectopia Lentis Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010014490 Elliptocytosis hereditary Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102100030667 Eukaryotic peptide chain release factor subunit 1 Human genes 0.000 description 1
- 101710175705 Eukaryotic peptide chain release factor subunit 1 Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 206010016075 Factor I deficiency Diseases 0.000 description 1
- 201000007371 Factor XIII Deficiency Diseases 0.000 description 1
- 206010016202 Familial Amyloidosis Diseases 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- 208000000486 Fetal Macrosomia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010053700 Foetal macrosomia Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000032371 Glanzmann thrombasthenia 1 Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000012571 GlutaMAX medium Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 208000031797 Harlequin ichthyosis Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000003591 Hepatoerythropoietic Porphyria Diseases 0.000 description 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 1
- 208000001825 Hereditary elliptocytosis Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 208000004592 Hirschsprung disease Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000006031 Hydrops Fetalis Diseases 0.000 description 1
- 206010020529 Hydrops foetalis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010021602 Inborn errors of amino acid metabolism Diseases 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 1
- 208000004882 Intestinal Polyposis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000003892 Kartagener syndrome Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 1
- 201000004290 Kindler syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000006302 Laron syndrome Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024202 Lens abnormality, congenital Diseases 0.000 description 1
- 208000000706 Leukocyte-Adhesion Deficiency Syndrome Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000004312 MEDNIK syndrome Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000916 Mandibulofacial dysostosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 206010027294 Menkes' syndrome Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000033161 Neutral lipid storage disease with ichthyosis Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 201000010814 Synostosis Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000000392 Thrombasthenia Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 201000003199 Treacher Collins syndrome Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 208000031900 Woolly hair Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000010206 X-Linked Mental Retardation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000022877 amino acid metabolic disease Diseases 0.000 description 1
- BVCZEBOGSOYJJT-UHFFFAOYSA-N ammonium carbamate Chemical compound [NH4+].NC([O-])=O BVCZEBOGSOYJJT-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010203 atrichia with papular lesions Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000001286 autosomal recessive congenital ichthyosis 4B Diseases 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000002006 bullous congenital ichthyosiform erythroderma Diseases 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000005973 campomelic dysplasia Diseases 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000028235 central diabetes insipidus Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- GFKJMQOPKRDGGL-UHFFFAOYSA-N dibromoboron Chemical compound Br[B]Br GFKJMQOPKRDGGL-UHFFFAOYSA-N 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 208000007150 epidermolysis bullosa simplex Diseases 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 201000007382 factor V deficiency Diseases 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 208000019692 familial woolly hair syndrome Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 208000009601 hereditary spherocytosis Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 208000009624 holoprosencephaly Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- LUOGVMPUQUBQTC-UHFFFAOYSA-N hydron;1-methylpiperidin-3-amine;dichloride Chemical compound Cl.Cl.CN1CCCC(N)C1 LUOGVMPUQUBQTC-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000026621 hypolipoproteinemia Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 206010021093 hypospadias Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014468 inherited amino acid metabolic disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000026847 isolated familial woolly hair disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005935 monilethrix Diseases 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 201000006033 mucosulfatidosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 1
- ZUXUNWLVIWKEHB-UHFFFAOYSA-N n',n'-dimethylhexane-1,6-diamine Chemical compound CN(C)CCCCCCN ZUXUNWLVIWKEHB-UHFFFAOYSA-N 0.000 description 1
- ZQEQANWXEQSAGL-UHFFFAOYSA-N n',n'-dimethylpentane-1,5-diamine Chemical compound CN(C)CCCCCN ZQEQANWXEQSAGL-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 201000007642 neuronal ceroid lipofuscinosis 1 Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 description 1
- 201000007909 oculocutaneous albinism Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 206010031281 osteopoikilosis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- KWZSCXIYGVEHOB-UHFFFAOYSA-N oxan-4-amine;hydrochloride Chemical compound [Cl-].[NH3+]C1CCOCC1 KWZSCXIYGVEHOB-UHFFFAOYSA-N 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 201000008743 palmoplantar keratosis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000014660 primary cutaneous lymphoma Diseases 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000007750 pseudohypoaldosteronism Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1
- ZXOHVTAEDNYKSP-UHFFFAOYSA-N quinazolin-2-ylcyanamide Chemical compound C1=CC=C2NC(=NC#N)N=CC2=C1 ZXOHVTAEDNYKSP-UHFFFAOYSA-N 0.000 description 1
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 208000031162 sideroblastic anemia Diseases 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- MBEGFNBBAVRKLK-UHFFFAOYSA-N sodium;iminomethylideneazanide Chemical compound [Na+].[NH-]C#N MBEGFNBBAVRKLK-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000031509 superficial epidermolytic ichthyosis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000006234 thyroid hormone resistance syndrome Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
- the termination codon is a “premature” termination codon (PTC) and the unfinished protein may not be functional.
- PTC premature termination codon
- Normal terminating stop codons are usually in a genetic and structural context that reinforces their effectiveness and are usually more resistant to read-through than PTCs arising through truncating mutations (Wangen and Green, 2020 Elife 9:e52611).
- Nonsense mutations are involved in the pathology of a range of disorders; from polygenic pathologies such as cancer to monogenic diseases such as cystic fibrosis and Duchenne muscular dystrophy for which a PTC accounts for around 10% or 5-10% of all cases respectively (Keeling, K.M. & Bedwell, D.M., Journal of Molecular Medicine 2002, 80, 367-376, Kellermayer, R. European Journal of Medical Genetics 2006, 49, 445-450).
- NTD non-sense mediated decay
- Mechanisms by which translational read-though of PTC mutations may be achieved include but are not limited to: reducing the translational fidelity of the ribosome; reducing the efficiency of the translational termination machinery; inhibiting NMD; interfering with the regulation of gene transcription or translation or stabilising mRNA against NMD (Kellermayer, R European Journal of Medical Genetics 2006, 49, 445-450, Belgrader, P. J. C., and Maquat, L.E., Proc. Natl. Acad. Sci. USA 1993, 90, 482-486).
- Agents which allow translational read-through of PTC mutations have the potential to treat any disease where the presence of a PTC in a gene is directly causative, a risk factor or an aggravating factor in disease.
- Aminoglycosides are a class of antibiotics able to reduce translational fidelity. They exert their antibacterial action through inhibition of prokaryotic protein synthesis, however, at sub-lethal doses they lower translational fidelity of ribosomes leading to an increased rate of mis-incorporation of amino acids and also to an increased rate of translational read-through of stop codons (Davies, J. & Gorini, L., Proc. Natl. Acad. Sci. USA 1964, 51 , 883-8, Weinstein, Proc. Natl. Acad. Sci. USA 1964, 52, 988-996).
- Aminoglycosides have been shown to allow read-through of PTC mutations in the CFTR gene responsible for cystic fibrosis in vitro (Bedwell, D.M., et al., Nature Medicine 1997, 3, 1280-1284) and in vivo, including patients (Ming Du, et al., Journal of Molecular Medicine 2002, 80, 595-604, Clancy, J.P. et al., Am J Respir Crit Care Med 2001 , 163, 1683- 1692, Wilschanski, M., et al., The New England Journal of Medicine 2003, 139, 1433- 1441).
- WO2021228945A1 describes compounds, including TLN486 (TLN68), for use in preventing and/or treating a disease caused by a nonsense mutation.
- TNN68 TLN486
- Certain compounds of the present invention are suitable for use in treating diseases/conditions which are associated with PTC mutations. Certain compounds of the invention show more potent read-through activity when compared to TLN468.
- the present invention provides a compound of formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: wherein
- R 1 is independently selected from H, cyano, C1-C4-haloalkyl, C0-Cs-alkylene-R 1a , C2-C6- alkylene-R 1 b , C(O)R 1c , S(O)R 1c , S(O) 2 R 1c , and C1-C 6 -alkylene-R 1d ;
- R 1a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R 1a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R 1a is optionally substituted with from 1 to 4 R 8 groups and where R 1a is phenyl or heteroaryl, R 1a is optionally substituted with from 1 to 5 R 9 groups;
- R 1 b is independently selected from NR 6a R 7a and OR 6 ;
- R 1c is independently selected from C1-Cs alkyl, C0-C4-alkylene-R 1a and C0-C4-alkylene- NR 6a R 6a ;
- R 1d is independently selected from C(O)NR 6a R 6a , SO2NR 6a R 6a and CO2R 6 ;
- R 2 is independently selected from cyano, C1-C4-haloalkyl, C0-C6-alkylene-R 2a , C2-C6- alkylene-R 2b , C(O)R 2c , S(O)R 2c , S(O) 2 R 2c , and C1-C 6 -alkylene-R 2d ;
- R 2a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl and 5-, or 6-membered heteroaryl; wherein where R 2a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R 2a is optionally substituted with from 1 to 4 R 8 groups and where R 2a is phenyl or heteroaryl, R 2a is optionally substituted with from 1 to 5 R 9 groups;
- R 2b is independently selected from NR 6a R 7a , and OR 6 ;
- R 2c is independently selected from C1-C6 alkyl, C0-C4-alkylene-R 2a and C0-C4-alkylene- NR 6a R 6a ;
- R 2d is independently selected from C(O)NR 6a R 6a , SO2NR 6a R 6a and CO2R 6 ;
- R 3 is independently selected from H and C1-C4 alkyl; or wherein R 2 and R 3 , together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups;
- R 4 is independently selected from H, cyano, nitro, OR 6b , NR 6 R 7 , CO2R 6 , C(O)R 6 , C(O)NR 6 R 6 , C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OH, OR 6b , SR 6 , SOR 6 , S(O) 2 R 6 , S(O) 2 NR 6 R 6 , CO2R 6 , C(O)R 6 , C(O)NR 6 R 6 , C1-C 4 -alkyl, C 2 -C 4 -alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
- R 6 and R 6a are each independently at each occurrence selected from H and C1-C4 alkyl; or two R 6a groups, together with the nitrogen atom to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups;
- R 6b is independently at each occurrence selected from C1-C4 alkyl
- R 7 and R 7a are each independently at each occurrence selected from H, C1-C4 alkyl and C(O)-C1-C 4 -alkyl; or R 6a and R 7a , together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups;
- R 9 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6 , SR 6 , SOR 6 , S(O) 2 R 6 , SO 2 NR 6 R 6 , CO2R 6 , C(O)R 6 , CONR 6 R 6 , C1-C 4 -alkyl, C 2 -C 4 -alkenyl, C2-C4- alkynyl, C1-C4-haloalkyl and cyclopropyl; m and x are each independently selected from 0 and 1 ; n is independently an integer selected from 0, 1 , 2, 3, and 4; wherein any of the aforementioned alkyl, alkylene, alkenyl, or cyclopropyl groups is optionally substituted, where chemically possible, by 1 to 5 substituents which are each independently at each occurrence selected from the group consisting of: C1-C4-alkyl, oxo, halo, nitro,
- the compound according to formula (I) is not a compound selected from List A and List B.
- Compounds according to formula (I) may be able to tautomerise, depending on the identity of the substituent groups, to give alternative tautomeric forms of the compound depicted above. It may be that compounds of formula (I) are a mixture of these tautomeric forms. Said tautomeric forms may be interconverting in any given sample. The relative proportion of tautomeric forms in a given sample will be determined by the position of an equilibrium between those tautomeric forms under the conditions. The position of the equilibrium, and therefore the extent to which each tautomeric form of the compound is present, may be determined by factors including, but not limited to, identity of the substituent groups, temperature, pH, and/or the solvent (where compound of formula (I) is in solution).
- the compound of formula (I) is a compound of formula (II), or a tautomeric form thereof: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (III), or a tautomeric form thereof: wherein r is selected from 2, 3, or 4;
- R 1 is independently selected from H, C(O)R 1c , and S(O)2 1c ;
- R 3 , R 4 , R 5 , R 6a , R 7a , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (IV), or a tautomeric form thereof: wherein R 1c , R 2 , R 3 , R 4 , R 5 , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (V), or a tautomeric form thereof: wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups; p is selected from 0, 1 , 2, or 3;
- R 1 is independently selected from H, C(O)R 1c , and S(O)2R 1c ;
- R 3 , R 4 , R 5 , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (VI), or a tautomeric form thereof: wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups; q is selected from 0, 1 , or 2; and R 1 is independently selected from H, C(O)R 1c , and S(O)2R 1c
- R 3 , R 4 , R 5 , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (VII), or a tautomeric form thereof: wherein R 2 , R 3 , R 4 , R 5 , and n are as defined for formula (I).
- the compound of formula (I) is a compound of formula (VIII), or a tautomeric form thereof: wherein R 1 is independently selected from H, C(O)R 1c , and S(O)2 1c ; and
- R 2 and R 3 are as defined for formula (I).
- the compound of formula (I) is a compound of formula (IX), or a tautomeric form thereof: wherein R 2 and R 3 are as defined for formula (I).
- the compound of formula (I) is a compound of formula (X): wherein r is selected from 2, 3, or 4;
- R 1 is independently selected from H, C(O)R 1c , and S(O)2R 1c ; and R 3 , R 6a , and R 7a are as defined for formula (I).
- the compound of formula (I) is a compound of formula (XI), or a tautomeric form thereof: wherein R 1c , R 2 , and R 3 are as defined for formula (I).
- the compound of formula (I) is a compound of formula (XII) or a tautomeric form thereof: wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl,
- Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups;
- p is selected from 0, 1 , 2, or 3;
- R 1 is independently selected from H, C(O)R 1c , and S(O) 2 R 1c ;
- R 3 is as defined for formula (I).
- the compound of formula (I) is a compound of formula (XIII) or a tautomeric form thereof: wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups; q is selected from 0, 1 , or 2;
- R 1 is independently selected from H, C(O)R 1c , and S(O)2R 1c ;
- R 3 is as defined for formula (I).
- R 1 is independently selected from H, cyano, C1-C4-haloalkyl, C0- C 4 -alkylene-R 1a , C 2 -C 4 -alkylene-R 1 b , C(O)R 1c , S(O)R 1c , S(O) 2 R 1c , and C1-C 4 -alkylene-R 1d
- R 1 is independently selected from H, cyano, C0-C6-alkylene-R 1a , C 2 -C6- alkylene-R 1 b , and C(O)R 1c .
- R 1 is independently selected from H, cyano, C0-C4-alkylene-R 1a , C2-C6-alkylene-R 1 b , and C(O)R 1c . In an embodiment, R 1 is independently selected from H, cyano, C0-C4-alkylene-R 1a , C2-C4-alkylene-R 1 b , and C(O)R 1c . In an embodiment, R 1 is independently selected from H, cyano, and C(O)R 1c . In an embodiment, R 1 is independently selected from H and C(O)R 1c . In an embodiment, R 1 is H. In an embodiment, R 1 is cyano.
- R 1 is C(O)R 1c . In an embodiment, R 1 is independently selected from R 1 is C(O)R 1c , S(O)R 1c and S(O)2R 1c In an embodiment, R 1 is S(O) 2 R 1C
- R 1 contains at least 1 nitrogen atom. It may be that R 1 contains 1 , 2, or 3 nitrogen atoms. It may be that R 1 contains 1 nitrogen atom. It may be that R 1 contains 2 nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least one nitrogen atom is an amine. It may be that R 1 comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
- R 1a is independently selected from 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R 1a is heterocycloalkyl or heterocycloalkenyl, R 1a is optionally substituted with from 1 to 4 R 8 groups and where R 1a is heteroaryl, R 1a is optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl, heterocycloalkenyl, or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- the heterocycloalkyl, heterocycloalkenyl, or heteroaryl group comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
- R 1a is independently selected from 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein where R 1a is heterocycloalkyl, R 1a is optionally substituted with from 1 to 4 R 8 groups and where R 1a is heteroaryl, R 1a is optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- R 1a is 3- to 8-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups.
- R 1a is 5- or 6-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- R 1a is 5- or 6-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups.
- R 1a is 5-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups. It may be that the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is basic. It may be that the at least 1 nitrogen atom is an amine.
- R 1a is 5-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups. In an embodiment, R 1a is 6-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups. It may be that the heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- nitrogen atom may be a ring atom, i.e. a component of the heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring, or a substituent on the heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring.
- R 1a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, and phenyl, wherein where R 1a is cycloalkyl, or cycloalkenyl, R 1a is optionally substituted with from 1 to 4 R 8 groups and where R 1a is phenyl, R 1a is optionally substituted with from 1 to 5 R 9 groups.
- R 1a is C3-C8 cycloalkyl, optionally substituted with from 1 to 4 R 8 groups. In an embodiment, R 1a is C4-C6 cycloalkyl, optionally substituted with from 1 to 4 R 8 groups. In an embodiment, R 1a is phenyl, optionally substituted with from 1 to 5 R 9 groups.
- R 1 b is NR 6a R 7a . In an embodiment, R 1 b is OR 6 .
- R 1c is independently selected from C1-C4 alkyl, C0-C2-alkylene-
- R 1a and C0-C2-alkylene-NR 6a R 6a are independently selected from C1- C4 alkyl and C0-C2-alkylene-R 1a .
- R 1c is NR 6a R 6a .
- R 1c is C1-C4 alkyl. In an embodiment, R 1c is C1-C4 alkyl substituted with 1 to 5 halo substituents. In an embodiment, R 1c is C1-C2 alkyl substituted with 1 to 5 halo substituents.
- R 1c is C0-alkylene-R 1a .
- R 1c is independently selected from C3-C8 cycloalkyl, phenyl, 3- to 8-membered heterocycloalkyl, and 5- or 6- membered heteroaryl; wherein where R 1c is C3-C8 cycloalkyl, or heterocycloalkyl, R 1c is optionally substituted with from 1 to 4 R 8 groups and where R 1c is phenyl or heteroaryl, R 1c is optionally substituted with from 1 to 5 R 9 groups.
- R 1c is independently selected from C3-C8 cycloalkyl optionally substituted with from 1 to 4 R 8 groups, and phenyl optionally substituted with from 1 to 5 R 9 groups.
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C2 alkyl.
- R 1d is independently selected from C(O)NR 6a R 6a and SO 2 NR 6a R 6a .
- R 1 is selected from:
- R 2 is independently selected from cyano, C1-C4-haloalkyl, C0- C 4 -alkylene-R 2a , C 2 -C 4 -alkylene-R 2b , C(O)R 2c , S(O)R 2c , S(O) 2 R 2c , and C1-C 4 -alkylene-R 2d
- R 2 is independently selected from cyano, C0-C4-alkylene-R 2a , C2-C4- alkylene-R 2b , and C(O)R 2c .
- R 2 is independently selected from C0-C4- alkylene-R 2a , C2-C4-alkylene-R 2b and C1-C4-alkylene-R 2d .
- R 2 is C0-C4-alkylene-R 2a . In an embodiment, R 2 is C1-C4- alkylene-R 2a . In an embodiment, R 2 is C3-alkylene-R 2a . In an embodiment, R 2 is C2-alkylene- R 2a . In an embodiment, R 2 is C1-alkylene-R 2a . In an embodiment, R 2 is C0-alkylene-R 2a , i.e. R 2 is R 2a .
- R 2 is C2-C4-alkylene-R 2b . In an embodiment, R 2 is C2-alkylene- R 2b . In an embodiment, R 2 is C3-alkylene-R 2b . In an embodiment, R 2 is C4-alkylene-R 2b .
- R 2 is C1-C4-alkylene-R 2d . In an embodiment, R 2 is C4-alkylene- R 2d . In an embodiment, R 2 is C3-alkylene-R 2d . In an embodiment, R 2 is C2-alkylene-R 2d . In an embodiment, R 2 is C1-alkylene-R 2d .
- R 2 contains at least 1 nitrogen atom. It may be that R 2 contains 1 , 2, or 3 nitrogen atoms. It may be that R 2 contains 1 nitrogen atom. It may be that R 2 contains 2 nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least one nitrogen atom is an amine. It may be that R 2 comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
- R 2a is independently selected from 3- to 8-membered heterocycloalkyl, 5- to 8- membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R 2a is heterocycloalkyl or heterocycloalkenyl, R 2a is optionally substituted with from 1 to 4 R 8 groups and where R 2a is heteroaryl, R 2a is optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl, heterocycloalkenyl, or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- the heterocycloalkyl, heterocycloalkenyl, or heteroaryl group comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
- R 2a is independently selected from 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein where R 2a is heterocycloalkyl, R 2a is optionally substituted with from 1 to 4 R 8 groups and where R 2a is heteroaryl, R 2a is optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is basic. It may be that the at least 1 nitrogen atom is an amine.
- R 2a is 3- to 8-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups.
- R 2a is 5- or 6-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups.
- the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- R 2a is 5- or 6-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups.
- R 2a is 5-membered heterocycloalkyl, optionally substituted with from 1 to 4 R 8 groups. It may be that the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- R 2a is 5-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups. In an embodiment, R 2a is 6-membered heteroaryl, optionally substituted with from 1 to 5 R 9 groups. It may be that the heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
- R 2c is independently selected from C0-C4-alkylene-R 2a and C0- C4-alkylene-NR 6a R 6a . In an embodiment, R 2c is independently selected from C0-C2-alkylene- R 2a and C0-C3-alkylene-NR 6a R 6a .
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C2 alkyl.
- R 2 is selected from:
- R 3 is independently selected from H and C1-C2 alkyl. In an embodiment R 3 is H. In an embodiment, R 3 is methyl.
- R 2 and R 3 together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4
- m is 0, and R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R 8 groups.
- m is 0, and R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R 8 groups.
- m is 0, and R 2 and R 3 , together with the nitrogen atom to which they are attached, form a structure selected from: ; optionally substituted with 1 to 4 R 8 groups.
- n 0, and R 2 and R 3 , together with the nitrogen atom to which they are attached, form a structure selected from:
- R 1 is independently selected from H, cyano, C(O)R 1c , S(O)R 1c and S(O)2R 1C and R 2 is independently selected from C0-C4-alkylene-R 2a , C(O)R 2a , C2-C4-R 2b or R 2 and R 3 , together with the atom or atoms to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups.
- R 1 is independently selected from H, cyano, C(O)R 1c , S(O)R 1c and S(O)2R 1c and R 2 is independently selected from C0-C4-alkylene-R 2a , C2-C6-alkylene-R 2b , and C(0)-C0-C4-alkylene-R 2a or R 2 and R 3 , together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups.
- R 1 is independently selected from H, cyano, C(O)R 1c , S(O)R 1c and S(O)2R 1c and R 2 is independently selected from C0-C4-alkylene-R 2a , C2-C4-alkylene-R 2b , and C(0)-C0-C4-alkylene-R 2a or R 2 and R 3 , together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R 8 groups.
- R 1 is independently selected from H, cyano, C1-C4-haloalkyl, C0- C4-alkylene-R 1a , C2-C6-alkylene-R 1 b , C(O)R 1c , S(O)R 1c and S(O)2R 1c and R 2 is independently selected from C0-C4-alkylene-R 2a , C2-C6-alkylene-R 2b and C1-C4-alkylene-R 2d .
- R 4 is independently selected from H, cyano, nitro, OR 6b , NR 6 R 7 , C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R 4 is independently selected from H, cyano, nitro, NR 6 R 7 , C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R 4 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R 4 is independently selected from H, and C1-C4-alkyl.
- R 4 is independently selected from C1-C4-alkyl and OR 6b .
- R 4 is C1-C2-alkyl, i.e. methyl or ethyl.
- R 4 is C1-alkyl, i.e. methyl.
- R 4 is H.
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C2 alkyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , SR 6 , SOR 6 , S(O) 2 R 6 , S(O) 2 NR 6 R 6 , CO2R 6 , C(O)R 6 , C(O)NR 6 R 6 , C1-C4- alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OH, OR 6b , SR 6 , S(O) 2 R 6 , S(O) 2 NR 6 R 6 , CO2R 6 , C(O)R 6 , C(O)NR 6 R 6 , C1-C4- alkyl, C1-C4-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , SR 6 , S(O)2R 6 , S(O)2NR 6 R 6 , CO2R 6 , C(O)R 6 , C(O)NR 6 R 6 , C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OH, OR 6b , C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , C1- C2-alkyl, C1-C2-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. [0090] In an embodiment, R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OH, OR 6b , C1-C2-alkyl, C1-C2-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , C1- C2-alkyl, C1-C2-haloalkyl, and cyclopropyl.
- R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OH, OR 6b , C1-C2-alkyl, and C1-C2-haloalkyl. In an embodiment, R 5 is independently at each occurrence selected from halo, nitro, cyano, NR 6 R 7 , OR 6b , C1-C2- alkyl, and C1-C2-haloalkyl.
- R 5 is independently at each occurrence OR 6b . In an embodiment, R 5 is independently at each occurrence OMe. In an embodiment, where n is selected from 1 , 2, 3, or 4, at least one R 5 is independently OR 6b . In an embodiment, where n is selected from 1 , 2, 3, or 4, at least one R 5 is independently OMe. In an embodiment, n is 1 and R 5 is OR 6b . In an embodiment, n is 1 and R 5 is OMe.
- R 5 is OH
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C2 alkyl.
- R 6 is independently H. In an embodiment, R 6 is independently C1-C4 alkyl. In an embodiment, R 6 is independently C1-C2 alkyl.
- R 6a is independently selected from H and C1-C4 alkyl. In an embodiment, R 6a is independently selected from H and methyl.
- two R 6a groups together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally a 6-membered heterocycloalkyl ring.
- R 6b is independently at each occurrence selected from C1-C3 alkyl. In an embodiment, R 6b is independently at each occurrence selected from C1-C2 alkyl. In an embodiment, R 6b is C1-alkyl.
- R 7 is independently H. In an embodiment, R 7 is independently C1-C4 alkyl. In an embodiment, R 7 is independently C1-C2 alkyl. In an embodiment, R 7 is independently C(O)-C1-C4-alkyl. In an embodiment, R 7 is independently C(O)-C1-C2-alkyl.
- R 7a is independently H. In an embodiment, R 7a is independently C1-C4 alkyl. In an embodiment, R 7a is independently C1-C2 alkyl. In an embodiment, R 7a is independently C(O)-C1-C4-alkyl. In an embodiment, R 7a is independently C(O)-C1-C2-alkyl.
- R 8 is independently selected from C1-C4-alkyl, C1-C4-haloalkyl and cyclopropyl.
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C 2 alkyl.
- R 6 may be R 6c , where R 6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R 6c is independently at each occurrence selected C1-C 2 alkyl.
- x is 1. In an embodiment, x is 0.
- any of the alkyl, alkylene, or alkenyl groups are optionally substituted, where chemically possible, by 1 to 5 substituents which are each independently at each occurrence selected from the group consisting of: oxo, fluoro, NR a R b , OR a , and S(O)2R a ; wherein R a is independently at each occurrence selected from H, and C1-C4-alkyl; and R b is independently at each occurrence selected from H, C1-C4-alkyl, C(O)-C1-C4-alkyl and S(O)2-C1-C4-alkyl.
- R 2 is C2-C4-alkylene-NR 6a R 7a .
- R 2 is (CH2)r- - NR 6a R 7a , wherein r is an integer from 2 to 4.
- R 2 is C0-C4-alkylene-Ring A. In an embodiment, R 2 is C0-C3- alkylene-Ring A. In an embodiment, R 2 is (CH2) P -Ring A, wherein p is selected from 0, 1 , 2, 3 or 4. In an embodiment, R 2 is (CH2) P -Ring A, wherein p is selected from 0, 1 , 2, or 3.
- Ring A is independently selected from a 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups.
- Ring A is independently selected from a 4- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups.
- Ring A is independently selected from C3-C6 cycloalkyl, phenyl, 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein Ring A is cycloalkyl or heterocycloalkyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R 9 groups.
- Ring A is independently selected from a 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl, Ring A is optionally substituted with from 1 to 4 R 8 groups and where Ring A is heteroaryl, Ring
- A is optionally substituted with from 1 to 5 R 9 groups.
- Ring A is independently selected from a 4-membered heterocycloalkyl. In an embodiment, Ring A is independently selected from a 5-membered heterocycloalkyl, In an embodiment, Ring A is independently selected from a 6-membered heterocycloalkyl. In an embodiment, where Ring A is a 4-, 5-, or 6-membered heterocycloalkyl, Ring A is substituted with from 1 to 4 R 8 groups.
- Ring A is substituted with from 1 to 4 R 8 groups.
- Ring A is selected from:
- Ring A is selected from:
- p is 0. In an embodiment, p is 1. In an embodiment, p is 2. In an embodiment, p is 3. [00132] In an embodiment, q is 0. In an embodiment, q is 1. In an embodiment, q is 2.
- r is 2. In an embodiment, r is 3. In an embodiment, r is 4.
- the compound of formula (I) is selected from:
- the present invention provides a pharmaceutical composition comprising a compound defined in the first aspect, and one or more pharmaceutically acceptable excipients. It may be that the pharmaceutical composition does not comprise a compound selected from List A. It may be that the pharmaceutical composition does not comprise a compound selected from List B. It may be that the pharmaceutical composition does not comprise a compound selected from List A and List B.
- the present invention provides a compound as defined in the first aspect or a pharmaceutical composition as defined in the second aspect, for use as a medicament. It may be that the pharmaceutical composition does not comprise a compound selected from List A. It may be that the pharmaceutical composition does not comprise a compound selected from List B. It may be that the pharmaceutical composition does not comprise a compound selected from List A and List B.
- the present invention provides the use of a compound as defined in the first aspect or a pharmaceutical composition as defined in the second aspect, for the manufacture of a medicament. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
- the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
- the present invention provides a method for the treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio- Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome, said method comprising administering to a subject, an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that
- the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treatment or prophylaxis of a disease selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman-Diamond syndrome, Mucopo
- a disease selected from: Recessive
- the present invention provides a method for the treatment or prophylaxis of a disease selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman- Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolys
- the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect for the manufacture of a medicament for the treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and
- the present invention provides a method of allowing translational read-through of PTC mutations in a subject, said method comprising administering to a subject an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
- the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treating conditions or disorders which are associated with PTC mutations in a subject, said method comprising administering to a subject an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
- a PTC mutation may be any mutation which generates a premature termination codon (PTC) in a gene.
- a PTC mutation may be any mutation which generates an in-frame premature termination codon (PTC) in a gene.
- PTC mutation occurs in the nucleotide sequence of a gene.
- a PTC mutation may occur in the coding region or non-coding region of a gene.
- a PTC mutation may occur in the coding region of a gene.
- the mutation may be a point mutation, for example a substitution, deletion or insertion mutation.
- the mutation is a substitution mutation.
- the substitution mutation may replace one nucleotide with another different nucleotide, suitably within the nucleotide sequence of a gene.
- the mutation may therefore be regarded as a nonsense mutation.
- the mutation may be a nonsense mutation which causes an in-frame PTC in a gene.
- the PTC may be any known termination codon such as TAG, TAA or TGA, suitably the PTC is TGA.
- the PTC mutation may be a substitution mutation which generates a PTC comprising TAG, TAA or TGA in a gene.
- the PTC mutation may be a substitution mutation of CGA to TGA or CAG to TAG in a gene.
- a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly or indirectly caused by a PTC mutation in a subject.
- a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly caused by a PTC mutation in a subject.
- a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is caused by a PTC mutation in one or more genes in a subject.
- a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly caused by a PTC mutation in one or more genes in a subject.
- a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is caused by a PTC mutation in one or more genes in a subject leading to a loss of function of the or each gene.
- a PTC mutation may be understood to refer to one or more PTC mutations, or a plurality of PTC mutations, suitably which may be present in one or more genes in a subject.
- the one or more genes in which the PTC mutation is present are genes relating to one or more diseases as described herein.
- the one or more genes may be directly or indirectly linked with one or more diseases described herein.
- the one or more genes may contribute to, or cause, the phenotype of one or more diseases described herein.
- the one or more genes in which the PTC mutation is present may be cell cycle genes, tumour suppressor genes etc.
- tumour suppressor genes may include TP53, PTEN, APC.
- such mutations may be regarded as driver mutations, suitably which drive a disease phenotype, such as tumour growth.
- the PTC mutation may be regarded as a driver mutation.
- the one or more genes in which the PTC mutation is present may not contribute to or cause the disease phenotype.
- Such mutations may be regarded as bystander mutations. Therefore in some embodiments, the PTC mutation may be regarded as a bystander mutation.
- Conditions or disorders associated with a PTC mutation are well known in the art, and suitable such disorders which may be treated or prevented by the present invention are described hereinbelow. However, suitably, such disorders that are associated with PTC mutations may also be identified or determined by the use of standard molecular biology techniques.
- a condition or disorder may be determined as being associated with a PTC mutation by the use of molecular biology techniques, such as sequencing, single strand conformational polymorphism, denaturing gradient gel electrophoresis, heteroduplex analysis, or restriction fragment length polymorphism.
- a PTC mutation present in one or more genes of a subject which may cause a disease or condition can be identified using such techniques.
- whole genome sequencing or whole exome sequencing may be used to identify a PTC mutation in one or more genes of a subject, suitably which may cause a disease or condition.
- Suitable methodologies may be described in Karagiannakos et al. Cancers (Basel) 2022, 14, 664, Stark et al. ‘A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders’ Genetics in Medicine, Volume 18, Issue 11 , 2016, North et al. ‘Approach to the diagnosis of congenital myopathies’ Neuromuscular Disorders, Volume 24, Issue 2, 2014, for example.
- such techniques may be applied to a sample obtained from a subject suffering from a disease or condition or suspected of suffering from a disease or condition, suitably which may be caused by a PTC mutation.
- Such techniques may comprise comparing a result from said sample, to a result obtained from a reference sample.
- a reference sample may be a sample of the same type from a healthy subject, suitably from an equivalent healthy subject of the same age, nationality, race, height, weight etc.
- Suitable samples may include: a blood sample, serum sample, CNS fluid sample, tissue sample, cell sample, and the like.
- comparing a result in the context of the techniques above may comprise comparing the sequence of one or more genes from the subject suffering from a disease or condition to the sequence of the same one or more genes of the healthy subject.
- sequence comparisons may be carried out by available software, such as alignment software.
- PTC read-through agents such as the compounds disclosed herein, may in one or more embodiments, be of value and used in the treatment or amelioration of the following non-limiting examples of disorders and diseases.
- any of the following disorders and diseases may be regarded as a disease or disorder associated with a PTC mutation in a subject.
- the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the conditions or disorders are selected from any listed in the following paragraphs.
- the disease may be a disease of the musculoskeletal system.
- the disease of the musculoskeletal system may be a disease selected from Shwachman-Diamond Syndrome, Rickets, Laron Syndrome, Muscular Dystrophies (e.g.
- Duchenne muscular dystrophy (DMD)), Microcephaly, congenital limb deformities, Muscle Spasticity, Dwarfism, Gigantism, Osteopoikilosis, Cleidocranial Dysplasia, Synostosis, Mitochondrial Myopathies and Encephalomyopathies, Craniosynostoses, Mandibulofacial Dysostosis, Scoliosis, Osteoporosis, Osteopetrosis, Hyperostosis, Osteosclerosis, Osteogenesis Imperfecta, Holoprosencephaly, Acromegaly, Arthrogryposis, and Campomelic Dysplasia.
- DMD Duchenne muscular dystrophy
- Microcephaly congenital limb deformities
- Muscle Spasticity Dwarfism
- Gigantism Osteopoikilosis
- Cleidocranial Dysplasia Synostosis
- the disease may be a metabolic disease.
- the metabolic disease may be selected from Congenital Adrenal Hyperplasia, Inborn errors of Amino Acid Metabolism, Hypertriglyceridemia, Diabetes Mellitus, Type 1 and Type 2, Glycogen Storage Disease, Optic Atrophy, Calcinosis, Multiple Sulfatase Deficiency Disease, Fabry Disease, Hyperinsulinism, Familial Hypophosphatemia, Pseudohypoaldosteronism, Tangier Disease, Amyotrophic Lateral Sclerosis, Lactic Acidosis, Familial Amyloidosis, Mucopolysaccharidosis, Anemia, Sandhoff Disease, Cytochrome-c Oxidase Deficiency, Pyruvate Dehydrogenase Complex Deficiency Disease, Hypoglycemia, Neuronal Ceroid- Lipofuscinoses, Severe Combined Immunodeficiency, , Chronic Idiopathic Jaundice, Progeria, Hyponatremia, Wasting
- the disease may be a disease of the Nervous System.
- the disease of the Nervous System may be selected from Rett Syndrome, Ataxias, Sensorineural Hearing Loss, Epilepsy, Charcot-Marie-Tooth Disease, Spinal Muscular Atrophy, Spastic Paraplegia, Hydrocephalus, Migraine with Aura, Chorea, Tremor, Usher Syndromes, De Lange Syndrome, Duane Retraction Syndrome, Dementia, Myoclonus, Hereditary Sensory and Autonomic Neuropathies, Intellectual Disability, X-linked Mental Retardation, Fragile X Syndrome, Hypopituitarism, Leukoencephalopathies, Dystonia, Congenital Pain Insensitivity, Tourette Syndrome, Alzheimers Disease, Parkinsons Disease, Angelman Syndrome, Apraxias, Cerebral Palsy, and Frontotemporal Dementia.
- the disease may be a Cardiovascular disease.
- the cardiovascular disease may be selected from Coronary Disease, Ventricular Fibrillation, Telangiectasis, Kartagener Syndrome, Alagille Syndrome, Andersen Syndrome, Atrioventricular Block, and Cardiomyopathies.
- the disorder may be an Endocrine disorder.
- the Endocrine disorder may be selected from Hypogonadism, Goiter, Fetal Macrosomia, Thyroid Hormone Resistance Syndrome, Gonadal Dysgenesis, Hypoparathyroidism, Neurogenic Diabetes Insipidus, and Androgen-Insensitivity Syndrome.
- the disease may be a disease of the eye.
- the disease of the eye may be selected from Leber syndrome, Hereditary Optic Atrophies, Ectopia Lentis, Coloboma, Aphakia, and Choroideremia.
- the disease may be a disease affecting the urogenital system.
- the disease affecting the urogenital system may be selected from Hypospadias, Hydrops Fetalis, Interstitial Nephritis, Polycystic Kidney Diseases, and Azoospermia.
- the disease may be a respiratory disease.
- the respiratory disease may be selected from Cystic Fibrosis, Pulmonary Hypertension, Lipoid Proteinosis of Urbach and Wiethe, Newborn Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Chronic Obstructive, Asthma, and Choanal Atresia.
- the disease or disorder may be an inflammatory or autoimmune condition.
- the inflammatory or autoimmune condition may be selected from Immunologic Deficiency Syndromes, and Leukocyte-Adhesion Deficiency Syndrome.
- the disease may be a disease of the Gastrointestinal system.
- Diseases of the gastrointestinal system may be selected from Chronic Hepatitis B, Colitis, Intestinal Polyposis, Inflammatory Bowel Diseases, Hirschsprung Disease, Exocrine Pancreatic Insufficiency, Crohn’s Disease, and Cholestasis.
- the disease or disorder may be a Neoplasm.
- the Neoplasm may be selected from Acute Myeloid Leukemia, Paraganglioma, Rhabdoid Tumor, Rhabdomyoma, Adenoid Cystic Carcinoma, Large Cell Carcinoma, Lobular Carcinoma, Skin Appendage Carcinoma, Squamous Cell Carcinoma, Alveolar Rhabdomyosarcoma, Neuroectodermal Tumors, Multiple Hamartoma Syndrome, Pheochromocytoma, Nevus, Osteosarcoma, Teratoma, and Adenoma.
- the disease or disorder may be cancer.
- the cancer may be selected from acoustic neuroma, anal cancer, bladder cancer, Bowen's disease, brain cancer, breast cancer, carcinomas including basal cell carcinoma, bile duct carcinoma, bronchogenic carcinoma, choriocarcinoma, embryonal carcinoma, cystadenocarcinoma, epithelial carcinoma, medullary carcinoma, NUT midline carcinoma (NMC), papillary carcinoma, papillary adenocarcinomas, renal cell carcinoma, sebaceous gland carcinoma, small cell lung carcinoma, squamous cell carcinoma, and sweat gland carcinoma, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, dysproliferative changes (dysplasias and metaplasias), endometrial cancer, ependymoma, esophageal cancer, essential thrombocythemia, estrogen-receptor positive breast cancer, Ewing’s tumour, genital cancer,
- the disease or disorder may be selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome (all of which will be referred to as “ PTC conditions”).
- the disease or disorder may be selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman- Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, and Primary Ciliary Dyski
- the disease or disorder may be selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Duchenne Muscular Dystrophy, Cystic Fibrosis, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, and Familial adenomatous polyposis.
- Such disorders may be associated with a PTC mutation in a subject.
- the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the condition or disorder associated with PTC mutations in a subject is selected from recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman-Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, Primary Ciliary Dyskinesia and Alport
- the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the condition or disorder associated with PTC mutations in a subject is selected from recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Duchenne Muscular Dystrophy, Cystic Fibrosis, and Familial adenomatous polyposis.
- PTC read-through agents such as the compounds disclosed herein, may in one or more embodiments, also be of value and used in the palliation, diagnosis or prevention of any disease, disorder or condition in humans of one or more of the aforesaid non-limiting examples of disorders and diseases.
- any of the aforesaid disorders and diseases may be regarded as a disease or disorder associated with a PTC mutation in a subject.
- the present invention further provides a method of palliation, diagnosis or prevention of conditions or disorders which are associated with PTC mutations in a subject, wherein the conditions or disorders are selected from any listed in the aforesaid paragraphs.
- Treatment or amelioration with PTC read-through agents such as compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof), in some embodiments may be effective if administered orally. In some other embodiments may be effective if applied topically, and in some further embodiments may be effective if applied topically and orally.
- compositions comprising a novel compound disclosed herein or salt thereof (or combinations thereof) may be administered to young children. In some embodiments, compositions comprising a compound of the invention or salt thereof (or combinations thereof) may be administered to adolescents or teenagers. In some embodiments, compositions comprising a compound of the invention or salt thereof (or combinations thereof) may be administered to adults.
- Figure 1 shows the effect of treatment of HDQ-P1 cells with Example 3 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
- Figure 2 shows the effect of treatment of HDQ-P1 cells with Example 4 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
- C m -C n refers to a group with m to n carbon atoms.
- Co refers to a group with 0 carbon atoms.
- alkyl refers to a monovalent linear or branched saturated hydrocarbon chain.
- C1-C6-alkyl may refer to methyl, ethyl, n-propyl, /so-propyl, n-butyl, sec- butyl, tert-butyl, n-pentyl and n-hexyl.
- the alkyl groups may be unsubstituted or substituted by one or more substituents.
- alkylene refers to a bivalent linear saturated hydrocarbon chain.
- C1-C3-alkylene may refer to methylene, ethylene or propylene.
- the alkylene groups may be unsubstituted or substituted by one or more substituents.
- C0-alkylene refers to a group in which an alkylene chain is absent.
- C0-alkylene-R a refers to an R a .
- haloalkyl refers to a hydrocarbon chain substituted with at least one halogen atom independently chosen at each occurrence from: fluorine, chlorine, bromine and iodine.
- the halogen atom may be present at any position on the hydrocarbon chain.
- C1-C6-haloalkyl may refer to chloromethyl, fluoromethyl, trifluoromethyl, chloroethyl e.g. 1 -chloromethyl and 2-chloroethyl, trichloroethyl e.g. 1 ,2,2-trichloroethyl, 2,2,2-trichloroethyl, fluoroethyl e.g.
- a haloalkyl group may be a fluoroalkyl group, i.e. a hydrocarbon chain substituted with at least one fluorine atom.
- a haloalkyl group may have any amount of halogen substituents.
- the group may contain a single halogen substituent, it may have two or three halogen substituents, or it may be saturated with halogen substituents.
- alkenyl refers to a branched or linear hydrocarbon chain containing at least one double bond.
- the double bond(s) may be present as the E or Z isomer.
- the double bond may be at any possible position of the hydrocarbon chain.
- C2-C6-alkenyl may refer to ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl.
- the alkenyl groups may be unsubstituted or substituted by one or more substituents.
- alkynyl refers to a branched or linear hydrocarbon chain containing at least one triple bond.
- the triple bond may be at any possible position of the hydrocarbon chain.
- C2-C6-alkynyl may refer to ethynyl, propynyl, butynyl, pentynyl and hexynyl.
- the alkynyl groups may be unsubstituted or substituted by one or more substituents.
- cycloalkyl refers to a saturated hydrocarbon ring system containing 3, 4, 5 or 6 carbon atoms.
- C3-C6-cycloalkyl may refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
- the cycloalkyl groups may be unsubstituted or substituted by one or more substituents.
- y- to z-membered heterocycloalkyl refers to a y- to z- membered heterocycloalkyl group.
- it may refer to a monocyclic or bicyclic saturated or partially saturated group having from y to z atoms in the ring system and comprising 1 or 2 heteroatoms independently selected from O, S and N in the ring system (in other words 1 or 2 of the atoms forming the ring system are selected from O, S and N).
- partially saturated it is meant that the ring may comprise one or two double bonds. This applies particularly to monocyclic rings with from 5 to 6 members. The double bond will typically be between two carbon atoms but may be between a carbon atom and a nitrogen atom.
- heterocycloalkyl groups examples include; piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, tetra hydrofuran, tetrahydrothiophene, dihydrofuran, tetrahydropyran, dihydropyran, dioxane, azepine.
- a heterocycloalkyl group may be unsubstituted or substituted by one or more substituents.
- Aryl groups may be any aromatic carbocyclic ring system (i.e. a ring system containing 2(2n + 1)TT electrons).
- Aryl groups may have from 6 to 10 carbon atoms in the ring system.
- Aryl groups will typically be phenyl groups.
- Aryl groups may be naphthyl groups or biphenyl groups.
- heterocyclyl group refers to rings comprising from 1 to 4 heteroatoms independently selected from O, S and N.
- the rings may be heterocycloalkyl rings (including both saturated and partially saturated rings) or heteroaryl rings.
- heterocyclyl also encompasses groups that are tautomers of hydroxy heteroaryl groups, such pyridones, and tautomers of hydroxy heteroaryl groups that are substituted on the nitrogen, such as N-alkyl pyridones.
- heterocycloalkenyl refers to partially saturated rings comprising from 1 to 2 heteroatoms independently selected from O, S and N.
- heteroaryl refers to any aromatic (i.e. a ring system containing 2(2n +
- any heteroaryl groups may be independently selected from: 5 membered heteroaryl groups in which the heteroaromatic ring is substituted with 1-4 heteroatoms independently selected from O, S and N; and 6- membered heteroaryl groups in which the heteroaromatic ring is substituted with 1-3 (e.g.1-
- heteroaryl groups may be independently selected from: pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, triazole, oxadiazole, thiadiazole, tetrazole; pyridine, pyridazine, pyrimidine, pyrazine, triazine.
- Certain compounds of the invention comprise a ‘basic nitrogen’.
- a basic nitrogen may be an amine (including primary, secondary and tertiary amines) or it may be a nitrogen in a heteroaromatic ring (e.g. a pyridine, pyrimidine, pyridazine, pyrazine, imidazole or pyrazole).
- Amines include cyclic amines.
- the term ‘basic nitrogen’ does not include the nitrogen of an amide or a sulfonamide.
- Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
- the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
- a suitable optically active compound for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
- the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
- Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, 1994).
- Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, malic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.
- pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, n
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
- the activity of the compounds of the present invention can be assessed by a variety of in silico, in vitro and in vivo assays. In silico analysis of a variety of compounds has been demonstrated to be predictive of ultimate in vitro and even in vivo activity.
- references to “treating” or “treatment” include prophylaxis as well as the alleviation of established symptoms of a condition.
- “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, /.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, /.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
- a “therapeutically effective amount” includes the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to affect such treatment for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- a compound of the invention, or pharmaceutically acceptable salt thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the compounds of the invention, or pharmaceutically acceptable salt thereof, is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- compositions may be administered topically (e.g. to the skin) in the form, e.g., of creams, ointments, gels, lotions, solutions, suspensions; or systemically, e.g. by oral administration in the form of tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs; or by parenteral administration in the form of a sterile aqueous or oily solution, suspension or emulsion for injection (including intravenous, intracoronary, subcutaneous, intramyocardial, intraperitoneal, intramuscular, intravascular or infusion); by rectal administration in the form of suppositories or enemas; by inhalation for example as a finely divided powder or a liquid aerosol; or for administration by insufflation (for example as a finely divided powder).
- oral administration in the form of tablets, lozenges, hard
- the compounds of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets.
- a carrier for example, lactose, saccharose, sorbitol, mannitol
- a starch for example, potato starch, corn starch or amylopectin
- a cellulose derivative for example, gelatine or polyvinylpyrrolidone
- a lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and
- compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
- the compounds of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol.
- Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets.
- liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
- Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
- such liquid preparations may contain colouring agents, flavouring agents, sweetening agents (such as saccharine), preservative agents and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
- the compounds of the invention may be administered as a sterile aqueous or oily solution.
- the size of the dose for therapeutic or prophylactic purposes of a compound of the invention will naturally vary according to the nature and severity of the conditions, the concentration of the compound required for effectiveness in isolated cells, the concentration of the compound required for effectiveness in experimental animals, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
- Dosage levels, dose frequency, and treatment durations of compounds of the invention are expected to differ depending on the formulation and clinical indication, age, and co-morbid medical conditions of the patient.
- An effective amount of a compound of the present invention for use in therapy of a condition is an amount sufficient to achieve symptomatic relief in a warm-blooded animal, particularly a human of the symptoms of the condition, to mitigate the physical manifestations of the condition, or to slow the progression of the condition.
- the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
- a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
- the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
- a daily dose in the range, for example, a daily dose selected from 0.1 mg/kg to 100 mg/kg, 1 mg/kg to 75mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg or 5 mg/kg to 10 mg/kg body weight is received, given if required in divided doses.
- a daily dose selected from 0.1 mg/kg to 100 mg/kg, 1 mg/kg to 75mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg or 5 mg/kg to 10 mg/kg body weight is received, given if required in divided doses.
- lower doses will be administered when a parenteral route is employed.
- a dose in the range for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used.
- a dose in the range for example, 0.05 mg/kg to 25 mg/kg body weight will be used.
- the compound of the invention is administered orally, for example in the form of a tablet, or capsule dosage form.
- the daily dose administered orally may be, for example a total daily dose selected from 1 mg to 1000 mg, 5 mg to 1000 mg, 10 mg to 750 mg or 25 mg to 500 mg.
- unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 19*150 mm, 5 pm particle size; Mobile phase, water+0.05% NH 3 .H 2 O/acetonitrile, linear gradient: 80:20 to 40:60 over 8 min, flow rate: 25 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a Xselect CSH F-Phenyl OBD column, 19*150 mm, 5 pm particle size; Mobile phase, water+0.1 %FA /acetonitrile, linear gradient: 3:97 to 11 :89 over 8 min, flow rate: 25 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Prep OBD C18 Column, 30*150 mm, 5 pm particle size; Mobile phase, water +10 mmol/L NH4HCO3+0.1 %NH3.H2O/MeOH; linear gradient from 66:34 to 38:62 in 8 min, flow rate: 25 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shieid RP18 OBD Column 30 *150 mm 5 pm; Mobile phase, water+10 mmol/L NH ⁇ COs/acetonitrile, linear gradient from 75:25 to 60:40 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Sunfire prep C18 Column 30 *150 mm 5 pm; Mobile phase, water+0.1% TFA/acetonitrile, linear gradient from 93:7 to 80:20 over 8 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XB-C18 Column 50 *250 mm 10 pm; Mobile phase, water+0.1 % FA/acetonitrile, linear gradient from 62:38 to 42:58 over 20 min, flow rate: 100 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 74:26 to 42:58 in 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 95:5 to 80:20 in 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 98:2 to 92:8 in 7 min, flow rate: 60 mL/ min -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile Phase: Water+0.05%TFA/acetonitrile; linear gradient, 90:10 to 50:50 in 7 min, flow rate: 60 mL/ min -1 .
- Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCOs+0.1%NH3 H2O /acetonitrile, liner gradient: 75:25 to 45:55 over 8 min, flow rate: 60 mLmin' 1 .
- L Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05%TFA/MeOH, liner gradient: 84:16 to 57:43 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 50*250 mm, 5 pm particle size; Mobile phase, water+0.1 %FA I MeOH, liner gradient: 80:20 to 50:50 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.1 %FA I acetonitrile, liner gradient: 95:5 to 85:15 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XB-C18 Column, 50*250 mm, 10 pm particle size; Mobile phase, 5 mmol NH4HCO3 + water/acetonitrile, linear gradient: 67:33 to 47:53 over 20 min, flow rate: 100 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05 %TFA /acetonitrile, liner gradient: 82:18 to 58:42 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xbridge Shied RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCO3 /acetonitrile, liner gradient: 85:15 to 55:45 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD, 30*150 mm, 5 pm particle size; Mobile Phase, water+0.05%TFA/MeOH, linear gradient from 83:17 to 57:43 in 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150mm, 5 pm particle size; Mobile phase, water+0.1 %FA /acetonitrile, linear gradient: 95:5 to 70:30 over 7 min, flow rate: 60 mLmin' 1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water + 10 mmol/L NH4HCO31 acetonitrile, liner gradient: 85:15 to 75:25 over 7 min, flow rate: 60 mLmin' 1 .
- Preparative HPLC separations were performed with a Biotage isolera. HPLC chromatographic separations were conducted using C18 silica gel; Mobile phase, water+0.1% FA/acetonitrile, liner gradient: 95:5 to 0:100 over 20 min, flow rate: 60 mLmin' 1 .
- X Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05% HCI/acetonitrile, linear gradient: 98:2 to 88:12 over 7 min, flow rate: 60 mLmin' 1 .
- Y Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm particle size; Mobile phase: water+0.1% NH3 H2O/ acetonitrile, linear gradient: 90:10 to 72:28 over 7 min; flow rate: 60 mLmin' 1 .
- Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water + 0.05%TFA/ MeOH, liner gradient: 79:21 to 70:30 over 9 min, flow rate: 60 mLmin' 1 .
- AA Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm; Mobile phase: water+10 mmol/L NH4HCO3/ MeOH, linear gradient: 55:45 to 45:55 over 8 min; flow rate: 60 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Sunfire prep C18 Column 30 *150 mm 5 pm; Mobile phase, water+0.05% TFA/acetonitrile, linear gradient from 92:8 to 78:22 over 8 min, flow rate: 60 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH4HCO3+0.1% NH 3 H 2 O/acetonitrile, linear gradient from 77:33 to 50:50 in 9 min, flow rate: 60 mLmin -1 .
- AF Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm; Mobile phase: water+0.05% NH3 H2O/ acetonitrile, linear gradient: 98:2 to 83:17 over 10 min; flow rate: 60 mLmin -1 .
- HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCO3+0.1%NH3 H2O /acetonitrile, liner gradient: 98:2 to 80:20 over 9 min, flow rate: 60 mLmin -1 .
- HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector.
- HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH4HCC>3+0.1% NHs ⁇ O/acetonitrile, linear gradient from 69:31 to 55:45 in 9 min, flow rate: 60 mLmin -1 .
- Liquid chromatography-mass spectra were recorded using the following systems and running conditions:
- N Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %TFA/ acetonitrile+0.1 %TFA, linear gradient from 95:5 to 40:60 over 2.00 min, then linear gradient to 0:100 over 0.20 min, and then held for 0.40 min. flow rate: 1.50 mLmin' 1 .
- T Shimadzu LCMS-2020 connected to Ascentis Express 90 A C18 4.6 mm x 100 mm. mobile phase, water+0.1 %FA /acetonitrile+0.1 % FA, linear gradient from 95:5 to 5:95 over 6 min and held for 2 min; flow rate: 0.8 mLmin' 1 .
- AA Shimadzu LCMS-2020 connected to EC-C18, 30 mmx3.0 mm, 1.9 pm particle size.
- Mobile phase water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 95:5 to 40:60 over 1.80 min, , then linear gradient to 0:100 over 0.2 min, and then held for 0.70 min. flow rate: 1.50 mLmin' 1 .
- AD AC: Shimadzu LCMS-2020 connected to HPH, 50 mmx3.0 mm, 2.7 pm particle size. Mobile phase, water+0.04% NH 3 H 2 O/acetonitrile, linear gradient from 100:0 to 30:70 over 2.00 min, and linear gradient to 5:95 over 0.20 min, then held for 0.40 min. flow rate: 1 .50 mLmin -1 .
- AE Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 mm. mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 100:0 to 30:70 over 1.90 min, and then linear gradient to 0:100 over 0.35 min, and then held for 0.35 min. flow rate: 1.50 mLmin -1 .
- AF Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 mm. mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 100:0 to 0:100 over 2.00 min, and then held for 0.70 min. flow rate: 1.50 mLmin -1 .
- Certain compounds of the invention may be synthesised according to the general methods disclosed herein. Certain compounds of the invention may be synthesised according to general schemes 1 to 4. Certain compounds of the invention may be synthesised according to or analogously to the syntheses provided in examples 1 to 54 and 97 to 110.
- alkylation can be achieved by using an appropriate reagent (for example an alkyl halide, mesylate, tosylate or cyanogen halide), with an appropriate base (for example triethylamine, DIPEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example an alkyl halide, mesylate, tosylate or cyanogen halide
- an appropriate base for example triethylamine, DIPEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Acylation can be achieved by using an appropriate reagent (for example an acyl halide or anhydride), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example an acyl halide or anhydride
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Acylation may also be achieved by activating a carboxylic acid with common coupling reagents (for example EDC, HATLI, T3P), with an appropriate base (for example triethylamine, DIPEA, DMAP) in an appropriate solvent (for example DCM DMF, NMP, THF, ethyl acetate) with heating (conventional or by microwave irradiation) if necessary.
- common coupling reagents for example EDC, HATLI, T3P
- an appropriate base for example triethylamine, DIPEA, DMAP
- an appropriate solvent for example DCM DMF, NMP, THF, ethyl acetate
- Sulfonylation can be achieved by using an appropriate reagent (for example a sulfonyl halide), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example a sulfonyl halide
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Ureas may be formed by using an appropriate reagent (for example an isocyanate), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example an isocyanate
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Ureas may also be formed by first activating an amine with a reagent such as GDI, phosgene or triphosgene with an appropriate base if necessary (for example triethylamine, DI PEA, potassium carbonate, DMAP), in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- a reagent such as GDI, phosgene or triphosgene
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Acylation can be achieved by using an appropriate reagent (for example an acyl halide or anhydride), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example an acyl halide or anhydride
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Acylation may also be achieved by activating a carboxylic acid with common coupling reagents (for example EDC, HATU, T3P), with an appropriate base (for example triethylamine, DIPEA, DMAP) in an appropriate solvent (for example DCM DMF, NMP, THF, ethyl acetate) with heating (conventional or by microwave irradiation) if necessary.
- common coupling reagents for example EDC, HATU, T3P
- an appropriate base for example triethylamine, DIPEA, DMAP
- an appropriate solvent for example DCM DMF, NMP, THF, ethyl acetate
- Sulfonylation can be achieved by using an appropriate reagent (for example a sulfonyl halide), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example a sulfonyl halide
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Ureas may be formed by using an appropriate reagent (for example an isocyanate), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
- an appropriate reagent for example an isocyanate
- an appropriate base for example triethylamine, DI PEA, potassium carbonate, DMAP
- an appropriate solvent for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane
- Example 3 To a solution of Example 3 (37 mg, 0.124 mmol) in DMSO (1.0 mL) was added AC2O (12.6 mg, 0.124 mmol). The resulting mixture was stirred for overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC d to afford N-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide (20 mg, 45%) as a white solid.
- Example 8 (348 mg, 1.21 mmol), triethylamine (0.37 mL, 2.65 mmol) and 4- (dimethylamino)pyridine (16 mg, 0.13 mmol) were dissolved in DCM (15 mL) and cooled in an ice bath. Acetyl chloride (0.10 mL) was added drop-wise and the mixture stirred for 2 h.
- Example 11 By analogous method to that described for Example 1, with 1-(2- aminoethyl)pyrrolidine (73 ⁇ L) as the nucleophilic base. Afforded 1-(4-methylquinazolin-2-yl)-3-(2-(pyrrolidin-1- yl)ethyl)guanidine (30 mg, 19%). LCMS V : Rt 0.5 min, MH + 299. Example 11 : 1 -(2-( 1 -Methylpyrrolidin-2-yl)ethyl)-3-(4-methylquinazolin-2-yl)guanidine
- Example 8 (75 mg, 0.26 mmol), triethylamine (73 pl, 0.52 mmol) and 4- (dimethylamino)pyridine (3 mg, 0.02 mmol) were dissolved in 1 ,4-dioxane (4 mL). Cyclobutanecarbonyl chloride (26 pl, 0.23 mmol) added drop-wise and the mixture stirred for 2 h.
- Example 18 (50 mg, 0.17 mmol), triethylamine (69 ⁇ L, 0.50 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Acetyl chloride (15 ⁇ L, 0.21 mmol) was added drop-wise and the mixture stirred 2h. The mixture was evaporated and the residue purified by preparative HPLC e to give N-(((2- (diethylamino)ethyl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (57 mg, 98%).
- LCMS V Rt 0.3 min, MH + 343.
- Example 20 N-((4-methylquinazolin-2-yl)amino)((pyridin-4- ylmethyl)amino)methylene)acetamide
- Example 8 (50 mg, 0.17 mmol), triethylamine (68 ⁇ L, 0.48 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Isobutyryl chloride (21 ⁇ L, 0.20 mmol) was added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by preparative HPLC e to give N-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2-yl)amino)methylene)isobutyramide (48 mg, 79%).
- LCMS V Rt 0.5 min, MH + 357.
- Example 5 (50 mg, 0.16 mmol), triethylamine (65 ⁇ L, 0.48 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Acetyl chloride (14 ⁇ L, 0.21 mmol) was added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by preparative HPLC e to give N-(((4- methylquinazolin-2-yl)amino)((2-(piperidin-1 -yl)ethyl)amino)methylene)acetamide (34 mg, 60%).
- LCMS V Rt 0.4 min, MH + 355.
- Example 25 By analogous method to that described for Example 21 , with Example 25 (50 mg) and acetyl chloride (14 ⁇ L). Afforded N-(((4-methylquinazolin-2-yl)amino)((2- morpholinoethyl)amino)methylene)acetamide (34 mg, 56%).
- LCMS V Rt 0.3 min, MH + 357.
- Example 15 By analogous method to that described for Example 21 , with Example 15 (50 mg, 0.15 mmol) and acetyl chloride (14 ⁇ L). Afforded N-(((4-methylquinazolin-2-yl)amino)((3- morpholinopropyl)amino)methylene)acetamide (43 mg, 77%).
- LCMS X Rt 3.9 min, MH + 371.
- Example 31 2,2-Difluoro-N-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
- Example 3 ABy analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and difluoroacetic anhydride (20 ⁇ L). Afforded 2,2-difluoro-/V-(((1-methylpiperidin-4- yl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (22 mg, 34%).
- LCMS W Rt 5.2 min, MH + 377.
- Example 32 N-(((3-(Dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-3,3,3-trifluoropropanamide
- Example 8 By analogous method to that described for Example 21 , with Example 8 (75 mg, 0.26 mmol), triethylamine (73 ⁇ L) and 3,3,3-trifluoropropionyl chloride (28 ⁇ L). Afforded N-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2-yl)amino)methylene)-3,3,3- trifluoropropanamide (16 mg, 16%).
- LCMS W Rt 5.1 min, MH + 397.
- Example 3 By analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and trifluoroacetic anhydride (22 ⁇ L). Afforded 2,2,2-trifluoro-N-(((1-methylpiperidin-4- yl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (21 mg, 31 %).
- LCMS W : 5.6 min, MH + 395.
- Example 36 By analogous method to that described for Example 21 , with Example 36 (50 mg, 0.19 mmol) and acetyl chloride (14 ⁇ L). Afforded N-(((2-(dimethylamino)ethyl)amino)(quinazolin-2- ylamino)methylene)acetamide (20 mg, 35%).
- LCMS b Rt 4.7 min, MH + 301.
- Example 45 120 mg, 0.33 mmol) in DMSO (4.0 mL) was treated with AC2O (31.5 ⁇ L, 0.33 mmol) for 4 h at room temperature. Evaporated to dryness and the residue was purified by Prep-HPLC 9 to afford N-(((2,6-dichlorobenzyl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide (62 mg, 46%) as a white solid.
- Step 1 1 -(2-((2,4-dimethoxybenzyl)amino)-4-methoxyphenyl)ethan-1 -one
- Step 2 1-(2-amino-4-methoxyphenyl) ethan-1-one hydrochloride
- Step 3 N-(7-methoxy-4-methylquinazolin-2-yl)cyanamide 1-(2-amino-4-methoxyphenyl)ethan-1-one hydrochloride (4.60 g, 22.9 mmol) was dissolved in ethyl alcohol (46 mL). To the above solution was added sodium dicyanoazanide (6.20 g, 69.6 mmol) in portions at room temperature. The resulting mixture was stirred for overnight at 80 °C. The precipitated solids were collected by filtration and washed with water and MTBE (3 x 100 mL).
- Step 4 1-(7-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
- Step 1 1 -(3-methoxy-2-nitrophenyl) ethanone m-Methoxyacetophenone (50.0 g, 0.33 mol) had HNO3 (250 mL) added at 0 °C. The resulting mixture was stirred for 3 days at room temperature. The reaction was quenched by the addition of water (1.00 L) at 0 °C. The precipitated solid was collected by filtration, the filter cake was washed with water (100 mL) and ethanol (50 mL). The solid was further dried under vacuum to give 1-(3-methoxy-2-nitrophenyl) ethanone (30 g) as a yellow solid which was used directly in the next step. LCMS: MH + 196.
- Step 6 N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide
- Step 7 1-(8-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
- Example 50 1 -(6-Methoxy-4-methylquinazolin-2-yl)-3-(1 -methylpiperidin-4- yl)guanidine Step 1: 1 -(2-amino-5-methoxyphenyl)ethan-1 -one hydrochloride
- Step 1 1 -(2-amino-6-methoxyphenyl)ethan-1 -one hydrochloride
- Example 97 1 -(4-Methoxyquinazolin-2-yl)-3-(1 -methylpiperidin-4-yl)guanidine
- Step 3 1-( 1-methylpiperidin-4-yl)-3-(4-oxo- 1, 4-dihydroquinazolin-2-yl)guanidine
- Step 5 1-(4-Methoxyquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
- a solution of /V'-(4-chloroquinazolin-2-yl)-/V-(1-methylpiperidin-4-yl)guanidine (100 mg, 0.31 mmol) and MeONa (20.3 mg, 0.37 mmol) in MeOH (12.1 mL) was stirred at room temperature for 2 h.
- Step 2 1-(8-hydroxy-4-methylquinazolin-2-yl)-3-(1-methylpiperidin-4-yl) guanidine
- Example 48 To a solution of Example 48 (100 mg, 0.304 mmol) in DCE (1.00 mL) was added a 1 M solution of BBrs in DCM (1.82 ml, 1.82 mmol) dropwise at 0 °C. The resulting mixture was stirred overnight at 80 °C. The mixture was allowed to cool down to room temperature and quenched by the addition of water/lce (10.0 mL) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLC Y to afford the title compound (18.6 mg, 19.4%) as a white solid.
- Example 102 1 -methyl-1 -(1 -methylpiperidin-4-yl)-3-(4-methylquinazolin-2-yl) guanidine
- Example 102 To a solution of Example 102 (100 mg, 0.320 mmol) in DMSO (3.0 mL) was added acetic anhydride (32.7 mg, 0.320 mmol). The mixture was stirred for 8 h at 60 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep-HPLC AB to afford the title compound (40 mg, 35.4%) as an orange solid.
- 1 H NMR 400 MHz, DMSO-cfe
- Example 8 To a solution of Example 8 (180 mg, 0.629 mmol) in DMSO (1.5 mL) was added AC2O (64.2 mg, 0.629 mmol) dropwise at 0 °C. The resulting mixture was stirred for 3 h at room temperature. The mixture was purified by Prep-HPLC AD directly to afford the title compound (55 mg, 26.7%) as a yellow solid.
- Step 3 1-(3-(dimethylamino)propyl)-3-(8-hydroxy-4-methylquinazolin-2-yl)guanidine
- N-(8-hydroxy-4-methylquinazolin-2-yl) cyanamide 70.0 mg, 0.350 mmol
- dimethylaminopropylamine 66.0 ⁇ L, 0.525 mmol
- the reaction mixture was irradiated with microwave radiation for 1 h at 160 °C.
- the mixture was allowed to cool down to room temperature.
- the mixture was purified by Prep-HPLC AE to afford the title compound (4.7 mg, 4.45%) as a yellow solid.
- Step 2 1-(2-amino-4-fluoro-3-methoxyphenyl) ethanone To a solution of 1-(4-fluoro-3-methoxy-2-nitrophenyl) ethanone (2.79 g, 13.1 mmol) in the mixture of EtOH (20.0 mL), THF (20.0 mL) and H 2 O (10.0 mL) were added Fe (2.93 g, 52.4 mmol) and NH4CI (1.40 g, 26.2 mmol). The resulting mixture was stirred for 2 h at 60 °C. The mixture was allowed to cool down to room temperature. The mixture was filtered through a short pad of Celite. The pad was washed with EtOH (10 mL).
- Step 3 [(7-fluoro-8-methoxy-4-methylquinazolin-2-yl) amino] formonitrile
- Step 5 1-(7-fluoro-8-hydroxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
- DMSO 0.5 mL
- 1-methylpiperidin-4-amine 16.5 mg, 0.144 mmol, 1 .50 eq.
- the reaction mixture was irradiated with microwave radiation for 30 min at 160 °C.
- the residue was purified Prep-HPLC AF to afford the title compound (8.8 mg, 27.51 %) as a yellow solid.
- Step 2 1-(2-amino-5-fluoro-3-methoxyphenyl) ethanone
- Step 3 [(6-fluoro-8-methoxy-4-methylquinazolin-2-yl) amino] formonitrile
- Step 4 [(6-fluoro-8-hydroxy-4-methylquinazolin-2-yl)amino]formonitrile
- Step 5 1-(6-fluoro-8-hydroxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
- DMSO DMSO
- 1-methylpiperidin-4-amine 105 mg, 0.916 mmol, 2.0 eq.
- Example 3 To a solution of Example 3 (100 mg, 0.335 mmol) in DCM (1.0 mL) was added Et 3 N (116 ⁇ L, 0.838 mmol) and 2,2-dimethylpropanoyl chloride (45.4 ⁇ L, 0.369 mmol) at 0 °C. The resulting mixture was stirred for additional 1 h at 0 °C. The resulting mixture was diluted with H2O (2.0 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLC AH to afford the title compound (43.8 mg, 34.2%) as a white solid.
- ADXC8 cells in assay media were seeded into 96-well tissue culture treated white plates (Greiner) to a density of 13,000 cells per well and incubated for 24 hours at 37 °C in an atmosphere of 5% CO2.
- Compounds were solubilised in DMSO at a top concentration of 10 mM, serially diluted with assay media to 25 times final concentration and added to the plate to achieve a range of final concentrations of 100 pM to 0.045 pM in a final volume of 100 ⁇ L. Plates were incubated for a further 24 hours at 37 °C in an atmosphere of 5% CO2.
- Cells treated with 200 pM G418 (with 1% DMSO) were used as a positive control.
- Cell viability and firefly luciferase activity were measured in the same assay wells.
- CellTiter- FluorTM reagent was prepared as per manufacturer’s instructions (Promega E7120) and 20 pl of 5X CellTiter-FluorTM reagent was added to all wells, briefly mixed by orbital shaking (300-500 rpm for ⁇ 30 seconds) and the plates incubated for 30-45 minutes at 37 °C in an atmosphere of 5% CO2.
- Cell viability was measured by monitoring fluorescence on a CLARIOstar® plate reader (BMG Labtech). Cells containing 1% DMSO were used as a positive control and cells without addition of reagent was used as a negative control to define 100 and 0% respectively.
- ONE-GloTM luciferase assay buffer (Promega E7120) was prepared according to manufacturer’s instructions and 100 pl of luciferase reagent was added to each well and the plate incubated at RT for 3 mins before measuring the luminescence on the CLARIOstar® plate reader (BMG Labtech). Cells treated with 200 pM G418 (with 1% DMSO) were used as a positive control and arbitrarily assigned a value of 100%. Cells treated with 1 % DMSO were used as the negative control to define 0% response.
- Concentration effect curves were analysed using non-linear regression using the CDD Vault from Collaborative Drug Discovery (Burlingame, CA). Where datapoints at the highest concentrations tested showed bell-shaped dose-response behaviour (due to cell toxicity confirmed by viability assay), they were removed from the analysis. The bottom and top of the curves were constrained to 0 and the maximum measured response respectively. From the fitted curves, the software derived C100% values (the concentration giving the same response as 200 pM G418) for each compound. The negative logarithm of C100% is reported as pC100%. In addition to pC100% values, the maximum fold response relative to 200 pM G418 was also captured.
- Concentration effect curves were fitted using non-linear regression with Activitybase XE (I DBS). Where datapoints at the highest concentrations tested showed bell-shaped dose- response behaviour, they were removed from the analysis. From the fitted curves, the software derived C10F values (the concentration giving 10-fold response) for each compound. The negative logarithm of C10F is reported as pC10F. In addition to pC10F values, the maximum fold response over vehicle control was also captured.
- Cells suspended in DM EM + glutamax media containing 10% FCS were seeded into clear 384 well plates (Greiner) to a density of 3200 cells per well in a volume of 25 pl and incubated for 24 hours at 37 °C in an atmosphere of 5% CO2.
- Compounds were solubilised in DMSO at a top concentration of 10 mM and serially diluted with media in half log steps to achieve a range of final assay concentrations of 100 pM to 1 nM. 5 ⁇ L compound at each concentration (6-fold final) was added to plates so that the final assay volume was 30 ⁇ L and they were incubated for 24 hours at 37 °C in an atmosphere of 5% CO2.
- Steady Gio® Luciferase Assay System (Promega) was prepared according to manufacturers’ instructions. 30 pl of Steady Gio® Luciferase Assay System was added to each well and the plates were shaken on platform at 450 rpm for 5 minutes before reading on a PHERAstar® plate reader using LUM plus protocol and calculating fold change in signal relative to DMSO only controls. Concentration effect curves were fitted using non-linear regression with Activitybase XE (I DBS). Where datapoints at the highest concentrations tested showed bell-shaped dose- response behaviour, they were removed from the analysis. From the fitted curves, the software derived C10F values (the concentration giving 10-fold response) for each compound. The negative logarithm of C10F is reported as pC10F. In addition to pC10F values, the maximum fold response over vehicle control was also captured.
- I DBS Activitybase XE
- HDQ-P1 cells (R213X) were treated with DMSO (0.3%), or test article for 24 h at various concentrations.
- Cells were washed once with ice cold 1X PBS and lysed in MRC lysis buffer (1 M Tris-HCI, pH 7.4, 0.5 M EDTA, 0.25 mM EGTA (Ethylene glycol-bis(2- aminoethylether)-N,N,N',N'-tetraacetic acid), 0.5 M sodium fluoride, 0.1 M sodium pyrophosphate, 0.2 M sodium 2-glycerol 1 -phosphate, 0.2 M sodium orthovanadate, 0.27 M sucrose, 10% (v/v) Triton X-100, 0.1 mM phenylmethylsulphonyl fluoride, 1 M dithiothreitol) and protease inhibitor mixture (Roche) centrifuged at 4 °C for 15 min at 16000xg, the supernatants, termed cell extract
- the membranes were incubated with the secondary antibody (horseradish peroxidase-conjugated anti-mouse IgG [1/10,000]) for 1 hr at room temperature.
- the membranes were washed three times with TBST and chemiluminescence was detected with ECL Western Blot reagent kit (Cytiva-VWR) or Clarity Max ECL substrate (Bio-rad).
- the signal was quantified with Imaged software (NIH).
- Figure 1 shows the effect of treatment of HDQ-P1 cells with Example 3 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
- Figure 2 shows the effect of treatment of HDQ-P1 cells with Example 4 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suitable for use in treating diseases/conditions which are associated with PTC mutations. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in treating conditions or disorders which are associated with PTC mutations in a subject.
Description
Compounds
[0001] This invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
BACKGROUND
[0002] When a ribosome encounters a termination sequence during the process of messenger RNA (mRNA) translation no cognate transfer RNA (tRNA) can bind. This leads to a halt in protein production, release factor (RF) proteins binding to the empty site on the ribosome and conformational changes in the ribosome that lead to the break-up of the ribosomal complex. Although accurate, translational termination is not 100% effective and its efficiency depends on competition between the recognition of the stop codon by eRF1 , and the decoding of the stop codon by a near-cognate tRNA (i.e. a natural suppressor tRNA). The latter case leads to the suppression of translation termination, also called “read- through”, where an amino acid is incorporated in place of the stop (Dabrowski, M. et al., RNA Biology 2015, 12, 950-958).
[0003] If the halt in protein production occurs before the full length protein is made then the termination codon is a “premature” termination codon (PTC) and the unfinished protein may not be functional. In other words, if the terminating codon occurs before the full length protein is made then the termination codon is a “premature” termination codon (PTC) and the truncated protein may not be functional. Normal terminating stop codons are usually in a genetic and structural context that reinforces their effectiveness and are usually more resistant to read-through than PTCs arising through truncating mutations (Wangen and Green, 2020 Elife 9:e52611).
[0004] Over 1800 separate inherited genetic disorders have been identified where the causative mutation in a proportion of individuals is a nonsense mutation where an in-frame, premature termination codon (PTC) leads to a loss of gene function (Kellermayer, R. European Journal of Medical Genetics 2006, 49, 445-450). Over 9,600 PTC mutations have been published, representing around 10% of all reported gene mutations (Krawczak, M. et al., Human Mutation 2000, 15, 45-51 , Mort, M. et al., Human Mutation 2008, 29, 1037- 1047).
[0005] Nonsense mutations are involved in the pathology of a range of disorders; from polygenic pathologies such as cancer to monogenic diseases such as cystic fibrosis and Duchenne muscular dystrophy for which a PTC accounts for around 10% or 5-10% of all
cases respectively (Keeling, K.M. & Bedwell, D.M., Journal of Molecular Medicine 2002, 80, 367-376, Kellermayer, R. European Journal of Medical Genetics 2006, 49, 445-450).
[0006] Whereas monogenetic diseases arise from either an inherited or de novo germline mutation, resulting in a PTC, in for example cancer, somatic mutations, can give rise to PTC mutations in tumour suppressor genes for example.
[0007] One of the surveillance systems used by the cell to remove abnormal mRNA transcripts that prematurely terminate translation is the non-sense mediated decay (NMD) pathway. It targets mRNA containing a PTC sequence more than ~50 base pairs upstream from the penultimate exon-exon junction (Maquat, L.E., Nature Reviews, Molecular Cell biology 2004, 5, 89-99).
[0008] The combination of premature termination of protein production and NMD of mRNA containing PTCs, can lead to almost total loss of protein production for mutant genes encoding a PTC.
[0009] Mechanisms by which translational read-though of PTC mutations may be achieved include but are not limited to: reducing the translational fidelity of the ribosome; reducing the efficiency of the translational termination machinery; inhibiting NMD; interfering with the regulation of gene transcription or translation or stabilising mRNA against NMD (Kellermayer, R European Journal of Medical Genetics 2006, 49, 445-450, Belgrader, P. J. C., and Maquat, L.E., Proc. Natl. Acad. Sci. USA 1993, 90, 482-486).
[0010] Agents which allow translational read-through of PTC mutations have the potential to treat any disease where the presence of a PTC in a gene is directly causative, a risk factor or an aggravating factor in disease.
[0011] Aminoglycosides (such as paromomycin, gentamicin, G418/geneticin) are a class of antibiotics able to reduce translational fidelity. They exert their antibacterial action through inhibition of prokaryotic protein synthesis, however, at sub-lethal doses they lower translational fidelity of ribosomes leading to an increased rate of mis-incorporation of amino acids and also to an increased rate of translational read-through of stop codons (Davies, J. & Gorini, L., Proc. Natl. Acad. Sci. USA 1964, 51 , 883-8, Weinstein, Proc. Natl. Acad. Sci. USA 1964, 52, 988-996).
[0012] Aminoglycosides have been shown to allow read-through of PTC mutations in the CFTR gene responsible for cystic fibrosis in vitro (Bedwell, D.M., et al., Nature Medicine 1997, 3, 1280-1284) and in vivo, including patients (Ming Du, et al., Journal of Molecular Medicine 2002, 80, 595-604, Clancy, J.P. et al., Am J Respir Crit Care Med 2001 , 163, 1683- 1692, Wilschanski, M., et al., The New England Journal of Medicine 2003, 139, 1433- 1441).
[0013] In an animal model of Duchenne muscular dystrophy (DMD), 7 of 8 male mdx mice treated with 34 mg/kg gentamicin showed increased protection from contractile injury and 10-20% restoration of wild-type dystrophin levels (Barton-Davis, E.R., et al., Journal of Clinical Investigation 1999, 104, 375-381).
[0014] Gentamicin treatment induced functional type VII collagen in recessive dystrophic epidermolysis bullosa patients (Woodley, D. T. et al. Journal of Clinical Investigation 2017, 127, 3028-3038) with in vitro evidence supporting a read-through mechanism (Has, C. et al. Journal of Investigative Dermatology 2022, 142, 1227-1230).
[0015] The read-through of genes containing PTC mutations relevant to cystinosis, Hurler syndrome, inherited blindness and cancer genes have all been demonstrated following aminoglycoside treatment (Helip- Wooley, A., et al., Molecular Genetics and Metabolism 2002, 75, 128-133, Keeling, K.M., et al., Human Molecular Genetics 2001 , 10, 291-299, Moosajee, M.K., et al., Human Molecular Genetics 2008,17, 3987-4000). However, aminoglycosides are not suitable as PTC read-through agents due to the severe toxicity observed with high doses or repeated treatments
[0016] WO2021228945A1 describes compounds, including TLN486 (TLN68), for use in preventing and/or treating a disease caused by a nonsense mutation.
[0017] Certain compounds of the present invention are suitable for use in treating diseases/conditions which are associated with PTC mutations. Certain compounds of the invention show more potent read-through activity when compared to TLN468.
[0018] A structurally novel class of compounds has now been found which provides PTC read-through agents.
BRIEF SUMMARY OF THE DISCLOSURE
[0019] In accordance with a first aspect, the present invention provides a compound of formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof:
wherein
R1 is independently selected from H, cyano, C1-C4-haloalkyl, C0-Cs-alkylene-R1a, C2-C6- alkylene-R1 b, C(O)R1c, S(O)R1c, S(O)2R1c, and C1-C6-alkylene-R1d;
R1a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R1a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R1a is optionally substituted with from 1 to 4 R8 groups and where R1a is phenyl or heteroaryl, R1a is optionally substituted with from 1 to 5 R9 groups;
R1 b is independently selected from NR6aR7a and OR6;
R1c is independently selected from C1-Cs alkyl, C0-C4-alkylene-R1a and C0-C4-alkylene- NR6aR6a;
R1d is independently selected from C(O)NR6aR6a, SO2NR6aR6a and CO2R6;
R2 is independently selected from cyano, C1-C4-haloalkyl, C0-C6-alkylene-R2a, C2-C6- alkylene-R2b, C(O)R2c, S(O)R2c, S(O)2R2c, and C1-C6-alkylene-R2d;
R2a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl and 5-, or 6-membered
heteroaryl; wherein where R2a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R2a is optionally substituted with from 1 to 4 R8 groups and where R2a is phenyl or heteroaryl, R2a is optionally substituted with from 1 to 5 R9 groups;
R2b is independently selected from NR6aR7a, and OR6;
R2c is independently selected from C1-C6 alkyl, C0-C4-alkylene-R2a and C0-C4-alkylene- NR6aR6a;
R2d is independently selected from C(O)NR6aR6a, SO2NR6aR6a and CO2R6;
R3 is independently selected from H and C1-C4 alkyl; or wherein R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R4 is independently selected from H, cyano, nitro, OR6b, NR6R7, CO2R6, C(O)R6, C(O)NR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, SR6, SOR6, S(O)2R6, S(O)2NR6R6, CO2R6, C(O)R6, C(O)NR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
R6 and R6a are each independently at each occurrence selected from H and C1-C4 alkyl; or two R6a groups, together with the nitrogen atom to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R6b is independently at each occurrence selected from C1-C4 alkyl;
R7 and R7a are each independently at each occurrence selected from H, C1-C4 alkyl and C(O)-C1-C4-alkyl; or R6a and R7a, together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R8 is independently at each occurrence selected from =0, =S, halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, cyclopropyl, C1-C3-alkylene-NR6R7, and C0-C3- alkylene-phenyl;
R9 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4- alkynyl, C1-C4-haloalkyl and cyclopropyl; m and x are each independently selected from 0 and 1 ; n is independently an integer selected from 0, 1 , 2, 3, and 4;
wherein any of the aforementioned alkyl, alkylene, alkenyl, or cyclopropyl groups is optionally substituted, where chemically possible, by 1 to 5 substituents which are each independently at each occurrence selected from the group consisting of: C1-C4-alkyl, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Ra is independently at each occurrence selected from H, and C1-C4-alkyl; and Rb is independently at each occurrence selected from H, C1-C4-alkyl, C(O)-C1-C4-alkyl and S(O)2- C1-C4-alkyl.
[0020] It may be that the compound according to formula (I) is not a compound selected from List A: List A:
5 [0021] It may be that the compound according to formula (I) is not a compound selected from List B:
tautomer thereof.
[0022] It may be that the compound according to formula (I) is not a compound selected from List A and List B.
[0023] Compounds according to formula (I) may be able to tautomerise, depending on the identity of the substituent groups, to give alternative tautomeric forms of the compound depicted above. It may be that compounds of formula (I) are a mixture of these tautomeric forms. Said tautomeric forms may be interconverting in any given sample. The relative proportion of tautomeric forms in a given sample will be determined by the position of an equilibrium between those tautomeric forms under the conditions. The position of the equilibrium, and therefore the extent to which each tautomeric form of the compound is
present, may be determined by factors including, but not limited to, identity of the substituent groups, temperature, pH, and/or the solvent (where compound of formula (I) is in solution).
[0024] In an embodiment, the compound of formula (I) is a compound of formula (II), or a tautomeric form thereof:
wherein R1, R2, R3, R4, R5, and n are as defined for formula (I).
[0025] In an embodiment, the compound of formula (I) is a compound of formula (III), or a tautomeric form thereof:
wherein r is selected from 2, 3, or 4;
R1 is independently selected from H, C(O)R1c, and S(O)2 1c; and
R3, R4, R5, R6a, R7a, and n are as defined for formula (I).
[0026] In an embodiment, the compound of formula (I) is a compound of formula (IV), or a tautomeric form thereof:
wherein R1c, R2, R3, R4, R5, and n are as defined for formula (I).
[0027] In an embodiment, the compound of formula (I) is a compound of formula (V), or a tautomeric form thereof:
wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups; p is selected from 0, 1 , 2, or 3;
R1 is independently selected from H, C(O)R1c, and S(O)2R1c; and
R3, R4, R5, and n are as defined for formula (I).
[0028] In an embodiment, the compound of formula (I) is a compound of formula (VI), or a tautomeric form thereof:
wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups; q is selected from 0, 1 , or 2; and
R1 is independently selected from H, C(O)R1c, and S(O)2R1c
[0029] R3, R4, R5, and n are as defined for formula (I). In an embodiment, the compound of formula (I) is a compound of formula (VII), or a tautomeric form thereof:
wherein R2, R3, R4, R5, and n are as defined for formula (I).
[0030] In an embodiment, the compound of formula (I) is a compound of formula (VIII), or a tautomeric form thereof:
wherein R1 is independently selected from H, C(O)R1c, and S(O)2 1c; and
R2 and R3 are as defined for formula (I).
[0031] In an embodiment, the compound of formula (I) is a compound of formula (IX), or a tautomeric form thereof:
wherein R2 and R3 are as defined for formula (I).
[0032] In an embodiment, the compound of formula (I) is a compound of formula (X):
wherein r is selected from 2, 3, or 4;
R1 is independently selected from H, C(O)R1c, and S(O)2R1c; and R3, R6a, and R7a are as defined for formula (I).
[0033] In an embodiment, the compound of formula (I) is a compound of formula (XI), or a tautomeric form thereof:
wherein R1c, R2, and R3 are as defined for formula (I). [0034] In an embodiment, the compound of formula (I) is a compound of formula (XII) or a tautomeric form thereof:
wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl,
3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or
heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups; p is selected from 0, 1 , 2, or 3;
R1 is independently selected from H, C(O)R1c, and S(O)2R1c; and
R3 is as defined for formula (I).
[0035] In an embodiment, the compound of formula (I) is a compound of formula (XIII) or a tautomeric form thereof:
wherein Ring A is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6- membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups; q is selected from 0, 1 , or 2;
R1 is independently selected from H, C(O)R1c, and S(O)2R1c; and
R3 is as defined for formula (I).
[0036] The following embodiments apply to compounds of any of formulae (l)-(XI 11) . These embodiments are independent and interchangeable. Any one embodiment may be combined with any other embodiment, where chemically allowed. In other words, any of the features described in the following embodiments may (where chemically allowable) may be combined with the features described in one or more other embodiments. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the embodiments listed below, expressed at any level of generality, which encompass that compound may be combined to provide a further embodiment which forms part of the present disclosure.
[0037] In an embodiment, R1 is independently selected from H, cyano, C1-C4-haloalkyl, C0- C4-alkylene-R1a, C2-C4-alkylene-R1 b, C(O)R1c, S(O)R1c, S(O)2R1c, and C1-C4-alkylene-R1d In an embodiment, R1 is independently selected from H, cyano, C0-C6-alkylene-R1a, C2-C6-
alkylene-R1 b, and C(O)R1c. In an embodiment, R1 is independently selected from H, cyano, C0-C4-alkylene-R1a, C2-C6-alkylene-R1 b, and C(O)R1c. In an embodiment, R1 is independently selected from H, cyano, C0-C4-alkylene-R1a, C2-C4-alkylene-R1 b, and C(O)R1c. In an embodiment, R1 is independently selected from H, cyano, and C(O)R1c. In an embodiment, R1 is independently selected from H and C(O)R1c. In an embodiment, R1 is H. In an embodiment, R1 is cyano. In an embodiment, R1 is C(O)R1c. In an embodiment, R1 is independently selected from R1 is C(O)R1c, S(O)R1c and S(O)2R1c In an embodiment, R1 is S(O)2R1C
[0038] It may be that R1 contains at least 1 nitrogen atom. It may be that R1 contains 1 , 2, or 3 nitrogen atoms. It may be that R1 contains 1 nitrogen atom. It may be that R1 contains 2 nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least one nitrogen atom is an amine. It may be that R1 comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
[0039] In an embodiment, R1a is independently selected from 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R1a is heterocycloalkyl or heterocycloalkenyl, R1a is optionally substituted with from 1 to 4 R8 groups and where R1a is heteroaryl, R1a is optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl, heterocycloalkenyl, or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine. It may be that the heterocycloalkyl, heterocycloalkenyl, or heteroaryl group comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
[0040] In an embodiment, R1a is independently selected from 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein where R1a is heterocycloalkyl, R1a is optionally substituted with from 1 to 4 R8 groups and where R1a is heteroaryl, R1a is optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0041] In an embodiment, R1a is 3- to 8-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R1a is 5- or 6-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0042] In an embodiment, R1a is 5- or 6-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R1a is 5-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. It may be that the heterocycloalkyl contains
at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is basic. It may be that the at least 1 nitrogen atom is an amine.
[0043] In an embodiment, R1a is 5-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. In an embodiment, R1a is 6-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. It may be that the heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0044] It may be that, where a heterocycloalkyl, heterocycloalkenyl, or heteroaryl group contains a nitrogen atom, said nitrogen atom may be a ring atom, i.e. a component of the heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring, or a substituent on the heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring.
[0045] In an embodiment, R1a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, and phenyl, wherein where R1a is cycloalkyl, or cycloalkenyl, R1a is optionally substituted with from 1 to 4 R8 groups and where R1a is phenyl, R1a is optionally substituted with from 1 to 5 R9 groups.
[0046] In an embodiment, R1a is C3-C8 cycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R1a is C4-C6 cycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R1a is phenyl, optionally substituted with from 1 to 5 R9 groups.
[0047] In an embodiment, R1 b is NR6aR7a. In an embodiment, R1 b is OR6.
[0048] In an embodiment, R1c is independently selected from C1-C4 alkyl, C0-C2-alkylene-
R1a and C0-C2-alkylene-NR6aR6a. In an embodiment, R1c is independently selected from C1- C4 alkyl and C0-C2-alkylene-R1a. In an embodiment, R1c is NR6aR6a.
[0049] In an embodiment, R1c is C1-C4 alkyl. In an embodiment, R1c is C1-C4 alkyl substituted with 1 to 5 halo substituents. In an embodiment, R1c is C1-C2 alkyl substituted with 1 to 5 halo substituents.
[0050] In an embodiment, R1c is C0-alkylene-R1a. In an embodiment, R1c is independently selected from C3-C8 cycloalkyl, phenyl, 3- to 8-membered heterocycloalkyl, and 5- or 6- membered heteroaryl; wherein where R1c is C3-C8 cycloalkyl, or heterocycloalkyl, R1c is optionally substituted with from 1 to 4 R8 groups and where R1c is phenyl or heteroaryl, R1c is optionally substituted with from 1 to 5 R9 groups.
[0051] In an embodiment, R1c is independently selected from C3-C8 cycloalkyl optionally substituted with from 1 to 4 R8 groups, and phenyl optionally substituted with from 1 to 5 R9 groups.
[0052] In embodiments where R1d is CO2R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[0053] In an embodiment, R1d is independently selected from C(O)NR6aR6a and SO2NR6aR6a.
[0055] In an embodiment, R2 is independently selected from cyano, C1-C4-haloalkyl, C0- C4-alkylene-R2a, C2-C4-alkylene-R2b, C(O)R2c, S(O)R2c, S(O)2R2c, and C1-C4-alkylene-R2d In an embodiment, R2 is independently selected from cyano, C0-C4-alkylene-R2a, C2-C4- alkylene-R2b, and C(O)R2c. In an embodiment, R2 is independently selected from C0-C4- alkylene-R2a, C2-C4-alkylene-R2b and C1-C4-alkylene-R2d.
[0056] In an embodiment, R2 is C0-C4-alkylene-R2a. In an embodiment, R2 is C1-C4- alkylene-R2a. In an embodiment, R2 is C3-alkylene-R2a. In an embodiment, R2 is C2-alkylene- R2a. In an embodiment, R2 is C1-alkylene-R2a. In an embodiment, R2 is C0-alkylene-R2a, i.e. R2 is R2a.
[0057] In an embodiment, R2 is C2-C4-alkylene-R2b. In an embodiment, R2 is C2-alkylene- R2b. In an embodiment, R2 is C3-alkylene-R2b. In an embodiment, R2 is C4-alkylene-R2b.
[0058] In an embodiment, R2 is C1-C4-alkylene-R2d. In an embodiment, R2 is C4-alkylene- R2d. In an embodiment, R2 is C3-alkylene-R2d. In an embodiment, R2 is C2-alkylene-R2d. In an embodiment, R2 is C1-alkylene-R2d.
[0059] It may be that R2 contains at least 1 nitrogen atom. It may be that R2 contains 1 , 2, or 3 nitrogen atoms. It may be that R2 contains 1 nitrogen atom. It may be that R2 contains 2 nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be
that the at least one nitrogen atom is an amine. It may be that R2 comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
[0060] R2a is independently selected from 3- to 8-membered heterocycloalkyl, 5- to 8- membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R2a is heterocycloalkyl or heterocycloalkenyl, R2a is optionally substituted with from 1 to 4 R8 groups and where R2a is heteroaryl, R2a is optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl, heterocycloalkenyl, or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine. It may be that the heterocycloalkyl, heterocycloalkenyl, or heteroaryl group comprises 1 , 2, or 3 amine groups, optionally 1 amine group.
[0061] In an embodiment, R2a is independently selected from 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein where R2a is heterocycloalkyl, R2a is optionally substituted with from 1 to 4 R8 groups and where R2a is heteroaryl, R2a is optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl or heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is basic. It may be that the at least 1 nitrogen atom is an amine.
[0062] In an embodiment, R2a is 3- to 8-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R2a is 5- or 6-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. It may be that the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0063] In an embodiment, R2a is 5- or 6-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R2a is 5-membered heterocycloalkyl, optionally substituted with from 1 to 4 R8 groups. It may be that the heterocycloalkyl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0064] In an embodiment, R2a is 5-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. In an embodiment, R2a is 6-membered heteroaryl, optionally substituted with from 1 to 5 R9 groups. It may be that the heteroaryl contains at least 1 (e.g. 1 , 2, or 3) nitrogen atoms. It may be that the at least 1 nitrogen atom is a basic nitrogen. It may be that the at least 1 nitrogen atom is an amine.
[0065] It may be that, where a heterocycloalkyl, heterocycloalkenyl, or heteroaryl group contains a nitrogen atom, said nitrogen atom may be a ring atom, i.e. a component of the
heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring, or a substituent on the heterocycloalkyl, heterocycloalkenyl, or heteroaryl ring.
[0066] In an embodiment, R2a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, and phenyl, wherein where R2a is cycloalkyl, or cycloalkenyl, R2a is optionally substituted with from 1 to 4 R8 groups and where R2a is phenyl, R2a is optionally substituted with from 1 to 5 R9 groups.
[0067] In an embodiment, R2a is C3-C8 cycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R2a is C4-C6 cycloalkyl, optionally substituted with from 1 to 4 R8 groups. In an embodiment, R2a is phenyl, optionally substituted with from 1 to 5 R9 groups.
[0068] In an embodiment, R2b is independently NR6aR7a. In an embodiment, R2b is independently OR6.
[0069] In an embodiment, R2c is independently selected from C0-C4-alkylene-R2a and C0- C4-alkylene-NR6aR6a. In an embodiment, R2c is independently selected from C0-C2-alkylene- R2a and C0-C3-alkylene-NR6aR6a.
[0070] In an embodiment, R2d is independently C(O)NR6aR6a. In an embodiment, R2d is independently SO2NR6aR6a.
[0071] In embodiments where R2d is CO2R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[0072] In an embodiment, R2 is selected from:
[0073] In an embodiment, R3 is independently selected from H and C1-C2 alkyl. In an embodiment R3 is H. In an embodiment, R3 is methyl.
[0074] In an embodiment, R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4
R8 groups. In an embodiment, R2 and R3, together with the atom or atoms to which they are attached, form a 5-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R8 groups. In an embodiment, R2 and R3, together with the atom or atoms to which they are attached, form a 6-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R8 groups.
[0075] In an embodiment, m is 0, and R2 and R3, together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups.
[0076] In an embodiment, m is 0, and R2 and R3, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R8 groups. In an embodiment, m is 0, and R2 and R3, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring, optionally substituted with 1 to 4 R8 groups.
[0077] In an embodiment, m is 0, and R2 and R3, together with the nitrogen atom to which they are attached, form a structure selected from:
; optionally substituted with 1 to 4 R8 groups.
[0078] In an embodiment, m is 0, and R2 and R3, together with the nitrogen atom to which they are attached, form a structure selected from:
[0079] In an embodiment, R1 is independently selected from H, cyano, C(O)R1c, S(O)R1c and S(O)2R1C and R2 is independently selected from C0-C4-alkylene-R2a, C(O)R2a, C2-C6-R2b or R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups.
[0080] In an embodiment, R1 is independently selected from H, cyano, C(O)R1c, S(O)R1c and S(O)2R1C and R2 is independently selected from C0-C4-alkylene-R2a, C(O)R2a, C2-C4-R2b or R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups.
[0081] In an embodiment R1 is independently selected from H, cyano, C(O)R1c, S(O)R1c and S(O)2R1c and R2 is independently selected from C0-C4-alkylene-R2a, C2-C6-alkylene-R2b, and C(0)-C0-C4-alkylene-R2a or R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups.
[0082] In an embodiment R1 is independently selected from H, cyano, C(O)R1c, S(O)R1c and S(O)2R1c and R2 is independently selected from C0-C4-alkylene-R2a, C2-C4-alkylene-R2b,
and C(0)-C0-C4-alkylene-R2a or R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups.
[0083] In an embodiment R1 is independently selected from H, cyano, C1-C4-haloalkyl, C0- C4-alkylene-R1a, C2-C6-alkylene-R1 b, C(O)R1c, S(O)R1c and S(O)2R1c and R2 is independently selected from C0-C4-alkylene-R2a, C2-C6-alkylene-R2b and C1-C4-alkylene-R2d.
[0084] In an embodiment R1 is independently selected from H, cyano, C1-C4-haloalkyl, C0- C4-alkylene-R1a, C2-C4-alkylene-R1 b, C(O)R1c, S(O)R1c and S(O)2R1c and R2 is independently selected from C0-C4-alkylene-R2a, C2-C4-alkylene-R2b and C1-C4-alkylene-R2d.
[0085] In an embodiment, R4 is independently selected from H, cyano, nitro, OR6b, NR6R7, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R4 is independently selected from H, cyano, nitro, NR6R7, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R4 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R4 is independently selected from H, and C1-C4-alkyl. In an embodiment, R4 is independently selected from C1-C4-alkyl and OR6b. In an embodiment, R4 is C1-C2-alkyl, i.e. methyl or ethyl. In an embodiment, R4 is C1-alkyl, i.e. methyl. In an embodiment, R4 is H.
[0086] In embodiments where R4 is CO2R6 or C(O)R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[0087] In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, SR6, SOR6, S(O)2R6, S(O)2NR6R6, CO2R6, C(O)R6, C(O)NR6R6, C1-C4- alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl.
[0088] In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, SR6, S(O)2R6, S(O)2NR6R6, CO2R6, C(O)R6, C(O)NR6R6, C1-C4- alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, SR6, S(O)2R6, S(O)2NR6R6, CO2R6, C(O)R6, C(O)NR6R6, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl.
[0089] In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl. In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, C1- C2-alkyl, C1-C2-haloalkyl, and cyclopropyl. In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, C1-C4-alkyl, C1-C4-haloalkyl, and cyclopropyl.
[0090] In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, C1-C2-alkyl, C1-C2-haloalkyl, and cyclopropyl. In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, C1- C2-alkyl, C1-C2-haloalkyl, and cyclopropyl.
[0091] In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, C1-C2-alkyl, and C1-C2-haloalkyl. In an embodiment, R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6b, C1-C2- alkyl, and C1-C2-haloalkyl.
[0092] In an embodiment, R5 is independently at each occurrence OR6b. In an embodiment, R5 is independently at each occurrence OMe. In an embodiment, where n is selected from 1 , 2, 3, or 4, at least one R5 is independently OR6b. In an embodiment, where n is selected from 1 , 2, 3, or 4, at least one R5 is independently OMe. In an embodiment, n is 1 and R5 is OR6b. In an embodiment, n is 1 and R5 is OMe.
[0093] In an embodiment, R5 is OH.
[0094] In embodiments where R5 is CO2R6 or C(O)R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[0095] In an embodiment, R6 is independently H. In an embodiment, R6 is independently C1-C4 alkyl. In an embodiment, R6 is independently C1-C2 alkyl.
[0096] In an embodiment, R6a is independently selected from H and C1-C4 alkyl. In an embodiment, R6a is independently selected from H and methyl.
[0097] In an embodiment, two R6a groups, together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally a 6-membered heterocycloalkyl ring.
[0098] In an embodiment, R6b is independently at each occurrence selected from C1-C3 alkyl. In an embodiment, R6b is independently at each occurrence selected from C1-C2 alkyl. In an embodiment, R6b is C1-alkyl.
[0099] In an embodiment, R7 is independently H. In an embodiment, R7 is independently C1-C4 alkyl. In an embodiment, R7 is independently C1-C2 alkyl. In an embodiment, R7 is independently C(O)-C1-C4-alkyl. In an embodiment, R7 is independently C(O)-C1-C2-alkyl.
[00100] In an embodiment, R7a is independently H. In an embodiment, R7a is independently C1-C4 alkyl. In an embodiment, R7a is independently C1-C2 alkyl. In an embodiment, R7a is independently C(O)-C1-C4-alkyl. In an embodiment, R7a is independently C(O)-C1-C2-alkyl.
[00101] In an embodiment, R8 is independently at each occurrence selected from =0, =S, halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C1-C4-haloalkyl, cyclopropyl, C1-C3-alkylene-NR6R7, and C0-C3-alkylene-phenyl.
[00102] In an embodiment, R8 is independently at each occurrence selected from =0, halo, nitro, cyano, NR6R7, OR6, SR6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C1-C4-haloalkyl, cyclopropyl, C1-C3-alkylene-NR6R7, and C0-C3-alkylene-phenyl.
[00103] In an embodiment, R8 is independently at each occurrence selected from =0, halo, nitro, cyano, NR6R7, OR6, CO2R6, C1-C4-alkyl, C1-C4-haloalkyl, cyclopropyl, C1-C3-alkylene- NR6R7, and C0-C3-alkylene-phenyl.
[00104] In an embodiment, R8 is independently at each occurrence selected from =0, NR6R7, CO2R6, C1-C4-alkyl, C1-C3-alkylene-NR6R7, and C0-C3-alkylene-phenyl.
[00105] In an embodiment, R8 is independently selected from C1-C4-alkyl, C1-C4-haloalkyl and cyclopropyl.
[00106] In embodiments where R8 is OR6, CO2R6, or C(O)R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[00107] In an embodiment, R9 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4- alkyl, C1-C4-haloalkyl and cyclopropyl.
[00108] In an embodiment, R9 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6, C1-C4-alkyl, C1-C4-haloalkyl and cyclopropyl.
[00109] In an embodiment, R9 is independently at each occurrence selected from C1-C4- alkyl, C1-C4-haloalkyl and cyclopropyl.
[00110] In an embodiment, R9 is independently at each occurrence C1-C4-alkyl.
[00111] In embodiments where R9 is OR6, CO2R6, or C(O)R6, R6 may be R6c, where R6c is independently at each occurrence selected C1-C4 alkyl; optionally wherein R6c is independently at each occurrence selected C1-C2 alkyl.
[00112] In an embodiment, m is 1. In an embodiment, m is 0.
[00113] In an embodiment, x is 1. In an embodiment, x is 0.
[00114] In an embodiment, m is 0 and x is 0.
[00115] In an embodiment, n is 4. In an embodiment, n is 3. In an embodiment, n is 2. In an embodiment, n is 1. In an embodiment, n is 0. In an embodiment, n is an integer selected from 1 , 2 and 3. In an embodiment, n is an integer selected from 1 and 2.
[00116] In an embodiment, any of the alkyl, alkylene, or alkenyl groups are optionally substituted, where chemically possible, by 1 to 5 substituents which are each independently at each occurrence selected from the group consisting of: oxo, fluoro, NRaRb, ORa, and S(O)2Ra; wherein Ra is independently at each occurrence selected from H, and C1-C4-alkyl; and Rb is independently at each occurrence selected from H, C1-C4-alkyl, C(O)-C1-C4-alkyl and S(O)2-C1-C4-alkyl.
[00117] In an embodiment, R2 is C2-C4-alkylene-NR6aR7a. In an embodiment, R2 is (CH2)r- - NR6aR7a, wherein r is an integer from 2 to 4.
[00118] In an embodiment, R2 is C0-C4-alkylene-Ring A. In an embodiment, R2 is C0-C3- alkylene-Ring A. In an embodiment, R2 is (CH2)P-Ring A, wherein p is selected from 0, 1 , 2, 3 or 4. In an embodiment, R2 is (CH2)P-Ring A, wherein p is selected from 0, 1 , 2, or 3.
[00119] In an embodiment, R2 is C(0)-C0-C4-alkylene-Ring A. In an embodiment, R2 is C(O)- C0-C2-alkylene-Ring A. In an embodiment, R2 is C(O)-(CH2)q-Ring A, wherein q is selected from 0, 1 , 2, 3 or 4. In an embodiment, R2 is C(O)-(CH2)q-Ring A, wherein q is selected from 0, 1 , 2 or 3.
[00120] In an embodiment, Ring A is independently selected from a 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups.
[00121] In an embodiment, Ring A is independently selected from C3-C6 cycloalkyl, C5-Ce cycloalkenyl, phenyl, 4- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein Ring A is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups.
[00122] In an embodiment, Ring A is independently selected from a 4- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl or heterocycloalkenyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups.
[00123] In an embodiment, Ring A is independently selected from C3-C6 cycloalkyl, phenyl, 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein Ring A is cycloalkyl or heterocycloalkyl, Ring A is optionally substituted with from 1 to 4 R8 groups and
where Ring A is phenyl or heteroaryl, Ring A is optionally substituted with from 1 to 5 R9 groups.
[00124] In an embodiment, Ring A is independently selected from a 3- to 8-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; wherein Ring A is heterocycloalkyl, Ring A is optionally substituted with from 1 to 4 R8 groups and where Ring A is heteroaryl, Ring
A is optionally substituted with from 1 to 5 R9 groups.
[00125] In an embodiment, Ring A is independently selected from a 4-membered heterocycloalkyl. In an embodiment, Ring A is independently selected from a 5-membered heterocycloalkyl, In an embodiment, Ring A is independently selected from a 6-membered heterocycloalkyl. In an embodiment, where Ring A is a 4-, 5-, or 6-membered heterocycloalkyl, Ring A is substituted with from 1 to 4 R8 groups.
[00126] In an embodiment, Ring A is 5-membered heteroaryl. In an embodiment, Ring A is 6-membered heteroaryl. In an embodiment, where Ring A is heteroaryl, Ring A is substituted with from 1 to 5 R9 groups. [00127] In an embodiment, Ring A is selected from:
Optionally wherein Ring A is substituted with from 1 to 4 R8 groups.
[00128] In an embodiment, Ring A is selected from:
. Optionally wherein Ring A is substituted with from 1 to 5 R9 groups.
[00130] In an embodiment, Ring A is selected from:
[00131] In an embodiment, p is 0. In an embodiment, p is 1. In an embodiment, p is 2. In an embodiment, p is 3. [00132] In an embodiment, q is 0. In an embodiment, q is 1. In an embodiment, q is 2.
[00133] In an embodiment, r is 2. In an embodiment, r is 3. In an embodiment, r is 4.
[00135] In accordance with a second aspect, the present invention provides a pharmaceutical composition comprising a compound defined in the first aspect, and one or more pharmaceutically acceptable excipients. It may be that the pharmaceutical composition does not comprise a compound selected from List A. It may be that the pharmaceutical composition does not comprise a compound selected from List B. It may be that the pharmaceutical composition does not comprise a compound selected from List A and List B.
[00136] In accordance with a third aspect, the present invention provides a compound as defined in the first aspect or a pharmaceutical composition as defined in the second aspect, for use as a medicament. It may be that the pharmaceutical composition does not comprise a compound selected from List A. It may be that the pharmaceutical composition does not comprise a compound selected from List B. It may be that the pharmaceutical composition does not comprise a compound selected from List A and List B.
[00137] In accordance with a fourth aspect, the present invention provides the use of a compound as defined in the first aspect or a pharmaceutical composition as defined in the second aspect, for the manufacture of a medicament. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00138] In accordance with a fifth aspect, the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00139] In accordance with a sixth aspect, the present invention provides a method for the treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio- Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome, said method comprising administering to a subject, an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00140] In accordance with a seventh aspect, the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treatment or prophylaxis of a disease selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman-Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, and Primary Ciliary Dyskinesia. It may be that the compound is not selected from List A. It
may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00141] In accordance with an eighth aspect, the present invention provides a method for the treatment or prophylaxis of a disease selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman- Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, and Primary Ciliary Dyskinesia.
[00142] In accordance with a ninth aspect, the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect for the manufacture of a medicament for the treatment or prophylaxis of a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00143] In accordance with a tenth aspect, the present invention provides a method of allowing translational read-through of PTC mutations in a subject, said method comprising administering to a subject an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00144] In accordance with an eleventh aspect, the present invention provides a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect, for use in a method of treating conditions or disorders which are associated with PTC mutations in a subject, said method comprising administering to a subject an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It
may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00145] In accordance with a twelfth aspect, the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, said method comprising administering to a subject an effective amount of a compound as defined in the first aspect, or a pharmaceutical composition as defined in the second aspect. It may be that the compound is not selected from List A. It may be that the compound is not selected from List B. It may be that the compound is not selected from List A and List B.
[00146] Suitably a PTC mutation may be any mutation which generates a premature termination codon (PTC) in a gene. Suitably a PTC mutation may be any mutation which generates an in-frame premature termination codon (PTC) in a gene. Suitably a PTC mutation occurs in the nucleotide sequence of a gene. Suitably a PTC mutation may occur in the coding region or non-coding region of a gene. Suitably a PTC mutation may occur in the coding region of a gene.
[00147] Suitably the mutation may be a point mutation, for example a substitution, deletion or insertion mutation. Suitably the mutation is a substitution mutation. Suitably the substitution mutation may replace one nucleotide with another different nucleotide, suitably within the nucleotide sequence of a gene. Suitably the mutation may therefore be regarded as a nonsense mutation. Suitably the mutation may be a nonsense mutation which causes an in-frame PTC in a gene. Suitably the PTC may be any known termination codon such as TAG, TAA or TGA, suitably the PTC is TGA. Suitably therefore in some embodiments, the PTC mutation may be a substitution mutation which generates a PTC comprising TAG, TAA or TGA in a gene. Suitably therefore in some embodiments, the PTC mutation may be a substitution mutation of CGA to TGA or CAG to TAG in a gene.
[00148] A condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly or indirectly caused by a PTC mutation in a subject. Suitably a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly caused by a PTC mutation in a subject. Suitably a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is caused by a PTC mutation in one or more genes in a subject. Suitably a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is directly caused by a PTC mutation in one or more genes in a subject. Suitably a condition or disorder associated with a PTC mutation in a subject may be a condition or disorder which is caused by a PTC mutation in one or more genes in a subject leading to a loss of function of the or each gene. Suitably reference herein to ‘a’ PTC
mutation may be understood to refer to one or more PTC mutations, or a plurality of PTC mutations, suitably which may be present in one or more genes in a subject.
[00149] Suitably the one or more genes in which the PTC mutation is present are genes relating to one or more diseases as described herein. Suitably the one or more genes may be directly or indirectly linked with one or more diseases described herein. Suitably the one or more genes may contribute to, or cause, the phenotype of one or more diseases described herein. In some embodiments, for example in which the disease is cancer, the one or more genes in which the PTC mutation is present may be cell cycle genes, tumour suppressor genes etc. Such tumour suppressor genes may include TP53, PTEN, APC. Suitably such mutations may be regarded as driver mutations, suitably which drive a disease phenotype, such as tumour growth. Therefore, in some embodiments, the PTC mutation may be regarded as a driver mutation. In other embodiments, the one or more genes in which the PTC mutation is present may not contribute to or cause the disease phenotype. Suitably such mutations may be regarded as bystander mutations. Therefore in some embodiments, the PTC mutation may be regarded as a bystander mutation.
[00150] Conditions or disorders associated with a PTC mutation are well known in the art, and suitable such disorders which may be treated or prevented by the present invention are described hereinbelow. However, suitably, such disorders that are associated with PTC mutations may also be identified or determined by the use of standard molecular biology techniques. Suitably a condition or disorder may be determined as being associated with a PTC mutation by the use of molecular biology techniques, such as sequencing, single strand conformational polymorphism, denaturing gradient gel electrophoresis, heteroduplex analysis, or restriction fragment length polymorphism. Suitably a PTC mutation present in one or more genes of a subject which may cause a disease or condition can be identified using such techniques. Suitably, whole genome sequencing or whole exome sequencing may be used to identify a PTC mutation in one or more genes of a subject, suitably which may cause a disease or condition. Suitable methodologies may be described in Karagiannakos et al. Cancers (Basel) 2022, 14, 664, Stark et al. ‘A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders’ Genetics in Medicine, Volume 18, Issue 11 , 2016, North et al. ‘Approach to the diagnosis of congenital myopathies’ Neuromuscular Disorders, Volume 24, Issue 2, 2014, for example.
[00151] Suitably such techniques may be applied to a sample obtained from a subject suffering from a disease or condition or suspected of suffering from a disease or condition, suitably which may be caused by a PTC mutation. Suitably such techniques may comprise comparing a result from said sample, to a result obtained from a reference sample. Suitably
a reference sample may be a sample of the same type from a healthy subject, suitably from an equivalent healthy subject of the same age, nationality, race, height, weight etc. Suitable samples may include: a blood sample, serum sample, CNS fluid sample, tissue sample, cell sample, and the like. Suitably comparing a result in the context of the techniques above may comprise comparing the sequence of one or more genes from the subject suffering from a disease or condition to the sequence of the same one or more genes of the healthy subject. Suitably to identify PTC mutations therein. Suitably such sequence comparisons may be carried out by available software, such as alignment software.
[00152] PTC read-through agents, such as the compounds disclosed herein, may in one or more embodiments, be of value and used in the treatment or amelioration of the following non-limiting examples of disorders and diseases. Suitably any of the following disorders and diseases may be regarded as a disease or disorder associated with a PTC mutation in a subject. Suitably therefore the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the conditions or disorders are selected from any listed in the following paragraphs.
[00153] The disease may be a disease of the musculoskeletal system. The disease of the musculoskeletal system may be a disease selected from Shwachman-Diamond Syndrome, Rickets, Laron Syndrome, Muscular Dystrophies (e.g. Duchenne muscular dystrophy (DMD)), Microcephaly, congenital limb deformities, Muscle Spasticity, Dwarfism, Gigantism, Osteopoikilosis, Cleidocranial Dysplasia, Synostosis, Mitochondrial Myopathies and Encephalomyopathies, Craniosynostoses, Mandibulofacial Dysostosis, Scoliosis, Osteoporosis, Osteopetrosis, Hyperostosis, Osteosclerosis, Osteogenesis Imperfecta, Holoprosencephaly, Acromegaly, Arthrogryposis, and Campomelic Dysplasia.
[00154] The disease may be a disease of the skin. The disease of the skin may be a disease selected from Ectodermal Dysplasia, Epidermolysis Bullosa, Focal Dermal Hypoplasia, Ichthyosis Vulgaris, Autosomal Recessive Congenital Ichthyosis (ARCI), Recessive X-linked Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Harlequin Ichthyosis, Epidermolytic Ichthyosis, Superficial Epidermolytic Ichthyosis, CHILD syndrome, Netherton syndrome, MEDNIK syndrome, Neutral lipid storage disease with ichthyosis, Atopic Dermatitis, Alopecia, Atrichia with papular lesions, Hypotrichosis, Incontinentia Pigmenti, Epidermolysis Bullosa Simplex, Lipodystrophy, Hidradenitis Suppurativa, Hyperpigmentation, Junctional Epidermolysis Bullosa, Oculocutaneous Albinism, Chronic Mucocutaneous Candidiasis, Chronic Mucocutaneous Ichthyosis, X-Linked Hypopigmentation, Cutis Laxa, Menkes Kinky Hair Syndrome, Palmoplantar Keratoderma, Ehlers-Danlos Syndrome, Congenital Monilethrix, Onychomycosis, Benign Familial Pemphigus, Albinism; Kindler syndrome, Cowden Syndrome, Xeroderma pigmentosum,
epidermodysplasia verruciformis, Lipoid proteinosis, dyschromatosis symmetrica hereditaria, Striate keratodermas, Autosomal Recessive Congenital Anonychia, Focal dermal hypoplasia, and Skin fragility/woolly hair syndrome.
[00155] The disease may be a metabolic disease. The metabolic disease may be selected from Congenital Adrenal Hyperplasia, Inborn errors of Amino Acid Metabolism, Hypertriglyceridemia, Diabetes Mellitus, Type 1 and Type 2, Glycogen Storage Disease, Optic Atrophy, Calcinosis, Multiple Sulfatase Deficiency Disease, Fabry Disease, Hyperinsulinism, Familial Hypophosphatemia, Pseudohypoaldosteronism, Tangier Disease, Amyotrophic Lateral Sclerosis, Lactic Acidosis, Familial Amyloidosis, Mucopolysaccharidosis, Anemia, Sandhoff Disease, Cytochrome-c Oxidase Deficiency, Pyruvate Dehydrogenase Complex Deficiency Disease, Hypoglycemia, Neuronal Ceroid- Lipofuscinoses, Severe Combined Immunodeficiency, , Chronic Idiopathic Jaundice, Progeria, Hyponatremia, Wasting Syndrome, Cystinuria, Glycogen Storage Disease, Gaucher Disease, Hypolipoproteinemias, Oculocerebrorenal Syndrome, Smith-Lemli-Opitz Syndrome, Adrenoleukodystrophy, Ataxia Telangiectasia, Canavan Disease, Carbamoyl- Phosphate Synthase I Deficiency Disease, beta-Mannosidosis, and lyosomal storage diseases, wherein the lyosomal storage disease may be selected from Niemann-Pick Disease Mucopolysaccharidosis type 1 (Hurler syndrome), Mucopolysaccharidosis type 6, Mucopolysaccharidosis type 7, CLN1 disease, and CL3 disease.
[00156] The disease may be a disease of the Nervous System. The disease of the Nervous System may be selected from Rett Syndrome, Ataxias, Sensorineural Hearing Loss, Epilepsy, Charcot-Marie-Tooth Disease, Spinal Muscular Atrophy, Spastic Paraplegia, Hydrocephalus, Migraine with Aura, Chorea, Tremor, Usher Syndromes, De Lange Syndrome, Duane Retraction Syndrome, Dementia, Myoclonus, Hereditary Sensory and Autonomic Neuropathies, Intellectual Disability, X-linked Mental Retardation, Fragile X Syndrome, Hypopituitarism, Leukoencephalopathies, Dystonia, Congenital Pain Insensitivity, Tourette Syndrome, Alzheimers Disease, Parkinsons Disease, Angelman Syndrome, Apraxias, Cerebral Palsy, and Frontotemporal Dementia.
[00157] The disease may be a Cardiovascular disease. The cardiovascular disease may be selected from Coronary Disease, Ventricular Fibrillation, Telangiectasis, Kartagener Syndrome, Alagille Syndrome, Andersen Syndrome, Atrioventricular Block, and Cardiomyopathies.
[00158] The disorder may be an Endocrine disorder. The Endocrine disorder may be selected from Hypogonadism, Goiter, Fetal Macrosomia, Thyroid Hormone Resistance Syndrome, Gonadal Dysgenesis, Hypoparathyroidism, Neurogenic Diabetes Insipidus, and Androgen-Insensitivity Syndrome.
[00159] The disease may be a disease of the eye. The disease of the eye may be selected from Leber syndrome, Hereditary Optic Atrophies, Ectopia Lentis, Coloboma, Aphakia, and Choroideremia.
[00160] The disease may be a disease affecting the urogenital system. The disease affecting the urogenital system may be selected from Hypospadias, Hydrops Fetalis, Interstitial Nephritis, Polycystic Kidney Diseases, and Azoospermia.
[00162] The disease or disorder may be a haemic or lymphatic condition. The haemic or lymphatic condition may be selected from alpha- and beta-Thalassemia, Afibrinogenemia, Hemophagocytic Lymphohistiocytosis, Factor XI Deficiency, Hemophilia A, von Willebrand Diseases, Factor V Deficiency, Sideroblastic Anemia, Hereditary Elliptocytosis, Neutropenia, Chronic Granulomatous Disease, Hereditary Spherocytosis, Polycythemia, Hemophilia B, Factor VII Deficiency, Bernard-Soulier Syndrome, Dyserythropoietic Anemia, Hemolytic Anemia, Idiopathic Thrombocytopenic Purpura, Thrombasthenia, Factor XIII Deficiency, Hepatoerythropoietic Porphyria, and Acute Intermittent Porphyria.
[00163] The disease may be a respiratory disease. The respiratory disease may be selected from Cystic Fibrosis, Pulmonary Hypertension, Lipoid Proteinosis of Urbach and Wiethe, Newborn Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Chronic Obstructive, Asthma, and Choanal Atresia.
[00164] The disease or disorder may be an inflammatory or autoimmune condition. The inflammatory or autoimmune condition may be selected from Immunologic Deficiency Syndromes, and Leukocyte-Adhesion Deficiency Syndrome.
[00165] The disease may be a disease of the Gastrointestinal system. Diseases of the gastrointestinal system may be selected from Chronic Hepatitis B, Colitis, Intestinal Polyposis, Inflammatory Bowel Diseases, Hirschsprung Disease, Exocrine Pancreatic Insufficiency, Crohn’s Disease, and Cholestasis.
[00166] The disease or disorder may be a Neoplasm. The Neoplasm may be selected from Acute Myeloid Leukemia, Paraganglioma, Rhabdoid Tumor, Rhabdomyoma, Adenoid Cystic Carcinoma, Large Cell Carcinoma, Lobular Carcinoma, Skin Appendage Carcinoma, Squamous Cell Carcinoma, Alveolar Rhabdomyosarcoma, Neuroectodermal Tumors, Multiple Hamartoma Syndrome, Pheochromocytoma, Nevus, Osteosarcoma, Teratoma, and Adenoma.
[00167] The disease or disorder may be cancer. The cancer may be selected from acoustic neuroma, anal cancer, bladder cancer, Bowen's disease, brain cancer, breast cancer, carcinomas including basal cell carcinoma, bile duct carcinoma, bronchogenic carcinoma, choriocarcinoma, embryonal carcinoma, cystadenocarcinoma, epithelial carcinoma,
medullary carcinoma, NUT midline carcinoma (NMC), papillary carcinoma, papillary adenocarcinomas, renal cell carcinoma, sebaceous gland carcinoma, small cell lung carcinoma, squamous cell carcinoma, and sweat gland carcinoma, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, dysproliferative changes (dysplasias and metaplasias), endometrial cancer, ependymoma, esophageal cancer, essential thrombocythemia, estrogen-receptor positive breast cancer, Ewing’s tumour, genital cancer, cancer of the cervix, cancer of the vulva, vulvar intraepithelial neoplasia (VI N), cancer of the vagina, germ cell testicular cancer, gastrointestinal cancers, gastric cancer, glioblastoma, glioma, heavy chain disease, hemangioblastoma, hepatocellular cancer, hepatoma, hormone insensitive prostate cancer, keratinocyte carcinomas, kidney cancer, leukaemias including acute leukaemia, acute lymphocytic leukaemia, acute myeloid leukaemia, acute myelocytic leukaemia (monocyctic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukaemia, chronic leukaemia, chronic lymphocytic leukaemia, chronic myelocytic (granulocytic) leukaemia, chronic myelogenous leukaemia, erythroleukemia, lymphoblastic leukaemia, and myelogenous leukaemia, liver cancer, lung cancer, lymphoid malignancies of T-cell or B-cell origin, lymphomas (Hodgkin’s and non-Hodgkin’s) including cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma, cutaneous (skin) lymphomas, malignancies and hyperproliferative disorders including of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, advanced malignancies, medulloblastoma, melanoma, meningioma, Merkel cell cancer mesothelioma, metastatic cancer, multiple myeloma, myeloma, pancreatic cancer, myelofibrosis, myeloproliferative neoplasms, neuroblastoma, non-small cell lung cancer, head and neck cancer, oligodendroglioma, oral cancer, ovarian cancer, pancreatic cancer, pinealoma, polycythemia vera, prostate cancer, rectal cancer, retinoblastoma, sarcomas including chondrosarcoma, endotheliosarcoma, fibrosarcoma, gliosarcoma, leiomyosarcoma, liposarcoma, lymphagioendotheliosarcoma, lymphangiosarcoma, myxosarcoma, Castleman's disease and Kaposi's sarcoma, osteogenic sarcoma, and rhabdomyosarcoma, seminoma, skin cancer, skin adnexal tumors, and sarcomas, small cell lung cancer, solid tumors, stomach cancer, synovioma, testicular tumours, thyroid cancer, uterine cancer, Waldenstrom’s macroglobulinemia, and Wilms’ tumour.
[00168] The disease or disorder may be selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome (all of which will be referred to as “ PTC conditions”).
[00169] The disease or disorder may be selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Xeroderma pigmentosum, Netherton syndrome,
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman- Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, and Primary Ciliary Dyskinesia.
[00170] The disease or disorder may be selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Duchenne Muscular Dystrophy, Cystic Fibrosis, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, and Familial adenomatous polyposis. Suitably such disorders may be associated with a PTC mutation in a subject.
[00171] Suitably therefore the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the condition or disorder associated with PTC mutations in a subject is selected from recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia, Methylmalonic Acidemia, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman-Diamond syndrome, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, Primary Ciliary Dyskinesia and Alport Syndrome. In some embodiments, the present invention provides a method of treating conditions or disorders which are associated with PTC mutations in a subject, wherein the condition or disorder associated with PTC mutations in a subject is selected from recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Duchenne Muscular Dystrophy, Cystic Fibrosis, and Familial adenomatous polyposis.
[00172] PTC read-through agents, such as the compounds disclosed herein, may in one or more embodiments, also be of value and used in the palliation, diagnosis or prevention of any disease, disorder or condition in humans of one or more of the aforesaid non-limiting examples of disorders and diseases. Suitably any of the aforesaid disorders and diseases may be regarded as a disease or disorder associated with a PTC mutation in a subject. Suitably therefore the present invention further provides a method of palliation, diagnosis or prevention of conditions or disorders which are associated with PTC mutations in a subject, wherein the conditions or disorders are selected from any listed in the aforesaid paragraphs.
[00173] Treatment or amelioration with PTC read-through agents, such as compositions comprising the compounds disclosed herein or salts thereof (or combinations thereof), in some embodiments may be effective if administered orally. In some other embodiments may be effective if applied topically, and in some further embodiments may be effective if applied topically and orally.
[00174] In some embodiments, compositions comprising a novel compound disclosed herein or salt thereof (or combinations thereof) may be administered to young children. In some embodiments, compositions comprising a compound of the invention or salt thereof (or combinations thereof) may be administered to adolescents or teenagers. In some embodiments, compositions comprising a compound of the invention or salt thereof (or combinations thereof) may be administered to adults.
BRIEF DESCRIPTION OF THE DRAWINGS
[00175] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:
Figure 1 shows the effect of treatment of HDQ-P1 cells with Example 3 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
Figure 2 shows the effect of treatment of HDQ-P1 cells with Example 4 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
[00176]
DETAILED DESCRIPTION
[00177] The term Cm-Cn refers to a group with m to n carbon atoms. For the absence of doubt, the term “Co” refers to a group with 0 carbon atoms.
[00178] The term “alkyl” refers to a monovalent linear or branched saturated hydrocarbon chain. For example, C1-C6-alkyl may refer to methyl, ethyl, n-propyl, /so-propyl, n-butyl, sec- butyl, tert-butyl, n-pentyl and n-hexyl. The alkyl groups may be unsubstituted or substituted by one or more substituents.
[00179] The term “alkylene” refers to a bivalent linear saturated hydrocarbon chain. For example, C1-C3-alkylene may refer to methylene, ethylene or propylene. The alkylene groups may be unsubstituted or substituted by one or more substituents. For the absence of doubt, the term “C0-alkylene” refers to a group in which an alkylene chain is absent. For example, “C0-alkylene-Ra” refers to an Ra.
[00180] The term “haloalkyl” refers to a hydrocarbon chain substituted with at least one halogen atom independently chosen at each occurrence from: fluorine, chlorine, bromine and iodine. The halogen atom may be present at any position on the hydrocarbon chain. For
example, C1-C6-haloalkyl may refer to chloromethyl, fluoromethyl, trifluoromethyl, chloroethyl e.g. 1 -chloromethyl and 2-chloroethyl, trichloroethyl e.g. 1 ,2,2-trichloroethyl, 2,2,2-trichloroethyl, fluoroethyl e.g. 1 -fluoromethyl and 2-fluoroethyl, trifluoroethyl e.g. 1 ,2,2- trifluoroethyl and 2,2,2-trifluoroethyl, chloropropyl, trichloropropyl, fluoropropyl, trifluoropropyl. A haloalkyl group may be a fluoroalkyl group, i.e. a hydrocarbon chain substituted with at least one fluorine atom. Thus, a haloalkyl group may have any amount of halogen substituents. The group may contain a single halogen substituent, it may have two or three halogen substituents, or it may be saturated with halogen substituents.
[00181] The term “alkenyl” refers to a branched or linear hydrocarbon chain containing at least one double bond. The double bond(s) may be present as the E or Z isomer. The double bond may be at any possible position of the hydrocarbon chain. For example, “C2-C6-alkenyl” may refer to ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl. The alkenyl groups may be unsubstituted or substituted by one or more substituents.
[00182] The term “alkynyl” refers to a branched or linear hydrocarbon chain containing at least one triple bond. The triple bond may be at any possible position of the hydrocarbon chain. For example, “C2-C6-alkynyl” may refer to ethynyl, propynyl, butynyl, pentynyl and hexynyl. The alkynyl groups may be unsubstituted or substituted by one or more substituents.
[00183] The term “cycloalkyl” refers to a saturated hydrocarbon ring system containing 3, 4, 5 or 6 carbon atoms. For example, “C3-C6-cycloalkyl” may refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. The cycloalkyl groups may be unsubstituted or substituted by one or more substituents.
[00184] The term “y- to z-membered heterocycloalkyl” refers to a y- to z- membered heterocycloalkyl group. Thus it may refer to a monocyclic or bicyclic saturated or partially saturated group having from y to z atoms in the ring system and comprising 1 or 2 heteroatoms independently selected from O, S and N in the ring system (in other words 1 or 2 of the atoms forming the ring system are selected from O, S and N). By partially saturated it is meant that the ring may comprise one or two double bonds. This applies particularly to monocyclic rings with from 5 to 6 members. The double bond will typically be between two carbon atoms but may be between a carbon atom and a nitrogen atom. Examples of heterocycloalkyl groups include; piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, tetra hydrofuran, tetrahydrothiophene, dihydrofuran, tetrahydropyran, dihydropyran, dioxane, azepine. A heterocycloalkyl group may be unsubstituted or substituted by one or more substituents.
[00185] Aryl groups may be any aromatic carbocyclic ring system (i.e. a ring system containing 2(2n + 1)TT electrons). Aryl groups may have from 6 to 10 carbon atoms in the ring system. Aryl groups will typically be phenyl groups. Aryl groups may be naphthyl groups or biphenyl groups.
[00186] The term ‘heterocyclyl’ group refers to rings comprising from 1 to 4 heteroatoms independently selected from O, S and N. The rings may be heterocycloalkyl rings (including both saturated and partially saturated rings) or heteroaryl rings. The term “heterocyclyl” also encompasses groups that are tautomers of hydroxy heteroaryl groups, such pyridones, and tautomers of hydroxy heteroaryl groups that are substituted on the nitrogen, such as N-alkyl pyridones.
[00187] The term ‘heterocycloalkenyl’ refers to partially saturated rings comprising from 1 to 2 heteroatoms independently selected from O, S and N.
[00188] The term “heteroaryl” refers to any aromatic (i.e. a ring system containing 2(2n +
1 )TT electrons) 5 or 6 membered ring system comprising from 1 to 4 heteroatoms independently selected from O, S and N (in other words from 1 to 4 of the atoms forming the ring system are selected from O, S and N). Thus, any heteroaryl groups may be independently selected from: 5 membered heteroaryl groups in which the heteroaromatic ring is substituted with 1-4 heteroatoms independently selected from O, S and N; and 6- membered heteroaryl groups in which the heteroaromatic ring is substituted with 1-3 (e.g.1-
2) nitrogen atoms. Specifically, heteroaryl groups may be independently selected from: pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, triazole, oxadiazole, thiadiazole, tetrazole; pyridine, pyridazine, pyrimidine, pyrazine, triazine.
[00189] Certain compounds of the invention comprise a ‘basic nitrogen’. A basic nitrogen may be an amine (including primary, secondary and tertiary amines) or it may be a nitrogen in a heteroaromatic ring (e.g. a pyridine, pyrimidine, pyridazine, pyrazine, imidazole or pyrazole). Amines include cyclic amines. The term ‘basic nitrogen’ does not include the nitrogen of an amide or a sulfonamide.
[00190] Compounds of the invention containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of the invention contains a double bond such as a C=C or C=N group, geometric cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism (‘tautomerism’) can occur. This can take the form of proton tautomerism in compounds of the invention containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
[00191] Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of the invention, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counter ion is optically active, for example, d-lactate or l-lysine, or racemic, for example, dl-tartrate or dl-arginine.
[00192] It will be apparent to those skilled in the art that the compounds of Formula I can by drawn in various tautomeric forms, non-exhaustive examples of which are illustrated below. Equally, it will be apparent to those skilled in the art that where substituent R groups are capable of resonance (for example OR, NRR, CN, NO2, C(O)R etc.), additional tautomers may be possible. All possible tautomeric or resonance forms are encompassed by the present invention.
[00193] Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
[00194] Conventional techniques for the preparation/isolation of individual enantiomers when necessary include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). Thus, chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and for specific examples, 0 to 5% by volume of an alkylamine e.g. 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
[00195] Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography
and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
[00196] When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
[00197] While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, 1994).
[00198] Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, malic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
[00199] The activity of the compounds of the present invention can be assessed by a variety of in silico, in vitro and in vivo assays. In silico analysis of a variety of compounds has been demonstrated to be predictive of ultimate in vitro and even in vivo activity.
[00200] It is to be appreciated that references to “treating” or “treatment” include prophylaxis as well as the alleviation of established symptoms of a condition. “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, /.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, /.e., causing
regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
[00201] A “therapeutically effective amount” includes the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to affect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
[00202] A compound of the invention, or pharmaceutically acceptable salt thereof, may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the compounds of the invention, or pharmaceutically acceptable salt thereof, is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
[00203] Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
[00204] Depending on the mode of administration of the compounds of the invention, the pharmaceutical composition which is used to administer the compounds of the invention will preferably comprise from 0.05 to 99 % w/w compounds of the invention, more preferably from 0.05 to 80 % w/w compounds of the invention, still more preferably from 0.10 to 70 % w/w compounds of the invention, and even more preferably from 0.10 to 50 % w/w compounds of the invention (all percentages by weight being based on total composition).
[00205] The pharmaceutical compositions may be administered topically (e.g. to the skin) in the form, e.g., of creams, ointments, gels, lotions, solutions, suspensions; or systemically, e.g. by oral administration in the form of tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs; or by parenteral administration in the form of a sterile aqueous or oily solution, suspension or emulsion for injection (including intravenous, intracoronary, subcutaneous, intramyocardial, intraperitoneal, intramuscular, intravascular or infusion); by rectal administration in the form of suppositories or enemas; by inhalation for example as a finely divided powder or a liquid aerosol; or for administration by insufflation (for example as a finely divided powder).
[00206] For oral administration the compounds of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example,
gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
[00207] For the preparation of soft gelatine capsules, the compounds of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules. Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, sweetening agents (such as saccharine), preservative agents and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
[00208] For intravenous (parenteral) administration the compounds of the invention may be administered as a sterile aqueous or oily solution.
[00209] The size of the dose for therapeutic or prophylactic purposes of a compound of the invention will naturally vary according to the nature and severity of the conditions, the concentration of the compound required for effectiveness in isolated cells, the concentration of the compound required for effectiveness in experimental animals, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
[00210] Dosage levels, dose frequency, and treatment durations of compounds of the invention are expected to differ depending on the formulation and clinical indication, age, and co-morbid medical conditions of the patient.
[00211] An effective amount of a compound of the present invention for use in therapy of a condition is an amount sufficient to achieve symptomatic relief in a warm-blooded animal, particularly a human of the symptoms of the condition, to mitigate the physical manifestations of the condition, or to slow the progression of the condition.
[00212] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate
and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
[00213] For the above-mentioned compounds of the invention the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. In using a compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, a daily dose selected from 0.1 mg/kg to 100 mg/kg, 1 mg/kg to 75mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg or 5 mg/kg to 10 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous or intraperitoneal administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Suitably the compound of the invention is administered orally, for example in the form of a tablet, or capsule dosage form. The daily dose administered orally may be, for example a total daily dose selected from 1 mg to 1000 mg, 5 mg to 1000 mg, 10 mg to 750 mg or 25 mg to 500 mg. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.
[00214] The compounds of the invention may be administered along with other active compounds as part of a treatment regime. The other active compounds may be administered simultaneously with, subsequently to or previously to the administration of the compounds of the invention. It may be that the pharmaceutical formulation comprising the compounds of the invention also comprises one or more other active compounds. The other active compounds may be anticancer, anti-inflammatory, antibacterial, antiviral, antiemetic, antithrombotic or compounds that alter the metabolism.
[00215] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
[00216] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the
steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[00217] It will be understood that various modifications may be made to the embodiments disclosed herein. Therefore the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. For example, the functions described above and implemented as the best mode for operating the present invention are for illustration purposes only. Other arrangements and methods may be implemented by those skilled in the art without departing from the scope and spirit of this invention. Moreover, those skilled in the art will envision other modifications within the scope and spirit of the specification appended hereto.
[00218] The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
EXAMPLES
Purification Methods:
Purification by preparative HPLC (prep-HPLC) employed the following instruments and conditions:
A: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 19*150 mm, 5 pm particle size; Mobile phase, water+0.05% NH3.H2O/acetonitrile, linear gradient: 80:20 to 40:60 over 8 min, flow rate: 25 mLmin-1.
B: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH F-Phenyl OBD column, 19*150 mm, 5 pm particle size; Mobile phase, water+0.1 %FA /acetonitrile, linear gradient: 3:97 to 11 :89 over 8 min, flow rate: 25 mLmin-1.
C: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep OBD C18 Column, 30*150 mm, 5 pm particle size; Mobile phase, water +10 mmol/L NH4HCO3+0.1 %NH3.H2O/MeOH; linear gradient from 66:34 to 38:62 in 8 min, flow rate: 25 mLmin-1.
D: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shieid RP18 OBD Column 30 *150 mm 5 pm;
Mobile phase, water+10 mmol/L NH^COs/acetonitrile, linear gradient from 75:25 to 60:40 over 7 min, flow rate: 60 mLmin'1.
E: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Sunfire prep C18 Column 30 *150 mm 5 pm; Mobile phase, water+0.1% TFA/acetonitrile, linear gradient from 93:7 to 80:20 over 8 min, flow rate: 60 mLmin'1.
F: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XB-C18 Column 50 *250 mm 10 pm; Mobile phase, water+0.1 % FA/acetonitrile, linear gradient from 62:38 to 42:58 over 20 min, flow rate: 100 mLmin'1.
G: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 74:26 to 42:58 in 7 min, flow rate: 60 mLmin'1.
H: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 95:5 to 80:20 in 7 min, flow rate: 60 mLmin'1.
I: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile phase, Water+0.1 %FA/ acetonitrile; linear gradient, 98:2 to 92:8 in 7 min, flow rate: 60 mL/ min-1.
J: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column 30*150 mm 5 pm; Mobile Phase: Water+0.05%TFA/acetonitrile; linear gradient, 90:10 to 50:50 in 7 min, flow rate: 60 mL/ min-1.
K: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCOs+0.1%NH3 H2O /acetonitrile, liner gradient: 75:25 to 45:55 over 8 min, flow rate: 60 mLmin'1.
L: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05%TFA/MeOH, liner gradient: 84:16 to 57:43 over 7 min, flow rate: 60 mLmin'1.
M: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 50*250 mm, 5 pm particle size; Mobile phase, water+0.1 %FA I MeOH, liner gradient: 80:20 to 50:50 over 7 min, flow rate: 60 mLmin'1.
N: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.1 %FA I acetonitrile, liner gradient: 95:5 to 85:15 over 7 min, flow rate: 60 mLmin'1.
O: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XB-C18 Column, 50*250 mm, 10 pm particle size; Mobile phase, 5 mmol NH4HCO3 + water/acetonitrile, linear gradient: 67:33 to 47:53 over 20 min, flow rate: 100 mLmin'1.
P: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05 %TFA /acetonitrile, liner gradient: 82:18 to 58:42 over 7 min, flow rate: 60 mLmin'1.
Q: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xbridge Shied RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCO3 /acetonitrile, liner gradient: 85:15 to 55:45 over 7 min, flow rate: 60 mLmin'1.
R: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+0.1 %FA/acetonitrile, linear gradient from 98:2 to 83:17 in 7 min, flow rate: 60 mLmin'1.
S: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic
separations were conducted using a Xselect CSH C18 OBD, 30*150 mm, 5 pm particle size; Mobile Phase, water+0.05%TFA/MeOH, linear gradient from 83:17 to 57:43 in 7 min, flow rate: 60 mLmin'1.
T: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150mm, 5 pm particle size; Mobile phase, water+0.1 %FA /acetonitrile, linear gradient: 95:5 to 70:30 over 7 min, flow rate: 60 mLmin'1.
U: Preparative HPLC separations were performed with a Gilson HPLC (321 pumps, 819 injection module, 215 liquid handler/injector) connected to a Gilson 155 UV/vis detector. HPLC chromatographic separations were conducted using a Waters XBridge C18 column, 19 x 100 mm, 5 pm particle size; mobile phase, water I acetonitrile +0.1% NH3; linear gradient 95:5 to 5:95 over 6.5min and then held for 1min; flow rate 18 mLmin'1.
V: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water + 10 mmol/L NH4HCO31 acetonitrile, liner gradient: 85:15 to 75:25 over 7 min, flow rate: 60 mLmin'1.
W: Preparative HPLC separations were performed with a Biotage isolera. HPLC chromatographic separations were conducted using C18 silica gel; Mobile phase, water+0.1% FA/acetonitrile, liner gradient: 95:5 to 0:100 over 20 min, flow rate: 60 mLmin'1. X: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Xselect CSH C18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+0.05% HCI/acetonitrile, linear gradient: 98:2 to 88:12 over 7 min, flow rate: 60 mLmin'1.
Y: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm particle size; Mobile phase: water+0.1% NH3 H2O/ acetonitrile, linear gradient: 90:10 to 72:28 over 7 min; flow rate: 60 mLmin'1.
Z: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water + 0.05%TFA/ MeOH, liner gradient: 79:21 to 70:30 over 9 min, flow rate: 60 mLmin'1.
AA: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm; Mobile phase: water+10 mmol/L NH4HCO3/ MeOH, linear gradient: 55:45 to 45:55 over 8 min; flow rate: 60 mLmin-1.
AB: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH^COs/acetonitrile, linear gradient from 94:6 to 74:26 in 8 min, flow rate: 60 mLmin-1.
AC: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a Sunfire prep C18 Column 30 *150 mm 5 pm; Mobile phase, water+0.05% TFA/acetonitrile, linear gradient from 92:8 to 78:22 over 8 min, flow rate: 60 mLmin-1.
AD: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH4HCO3+0.1% NH3 H2O/acetonitrile, linear gradient from 70:30 to 53:47 in 8 min, flow rate: 60 mLmin-1.
AE: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH4HCO3+0.1% NH3 H2O/acetonitrile, linear gradient from 77:33 to 50:50 in 9 min, flow rate: 60 mLmin-1.
AF: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm; Mobile phase: water+0.05% NH3 H2O/ acetonitrile, linear gradient: 98:2 to 83:17 over 10 min; flow rate: 60 mLmin-1.
AG: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a XBridge Shield RP18 OBD Column, 30*150 mm, 5 pm particle size; Mobile phase, water+10 mmol/L NH4HCO3+0.1%NH3 H2O /acetonitrile, liner gradient: 98:2 to 80:20 over 9 min, flow rate: 60 mLmin-1.
AH: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic
separations were conducted using a XBridge Prep C18 OBD Column, 30*100 mm, 5 pm; Mobile phase: water+10 mmol/L NH4HCO3/ MeOH, linear gradient: 66:34 to 48:52 over 10 min; flow rate: 60 mLmin-1.
Al: Preparative HPLC separations were performed with a Waters 2545 Binary Gradient Module connected to a Waters 2489 UV/visible detector. HPLC chromatographic separations were conducted using a YMC-Actus Triart C18, 30*150 mm, 5 pm particle size; Mobile Phase, water+10 mmol/L NH4HCC>3+0.1% NHs ^O/acetonitrile, linear gradient from 69:31 to 55:45 in 9 min, flow rate: 60 mLmin-1.
Analytical Methods:
1H NMR spectra were recorded on Bruker AVANCE III HD 300, Bruker AVANCE NEO 400 or Bruker AVANCE II 500 spectrometers. Chemical shifts are denoted in ppm (5) relative to residual protonated solvent as an internal standard as described in, for example, Gottlieb et al. Journal of Organic Chemistry (1997) 62 7512. The splitting pattern for NMR spectra are denoted as follows: s (singlet), br (broad), d (doublet), t (triplet), m (multiplet) or combinations thereof. Coupling constants ( ) are designated in Hz and reported to one decimal place.
Liquid chromatography-mass spectra were recorded using the following systems and running conditions:
A: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.05% TFA/acetonitrile +0.05% TFA, linear gradient from 95:5 to 30:70 over 1.90 min and then linear gradient to 0:100 over 0.35 min, held for 0.35 min; flow rate: 1.5 mLmin-1.
B: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.05 %TFA/acetonitrile+0.05 %TFA, linear gradient from 95:5 to 40:60 over 1.90 min and then linear gradient to 0:100 over 0.35 min, held for 0.35 min; flow rate: 1.5 mLmin-1.
C: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %FA/acetonitrile+0.1%FA, linear gradient from 95:5 to 30:70 over 1.79 min and then linear gradient to 0:100 over 0.20 min, held for 0.7 min; flow rate: 1.5 mLmin-1.
D: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %FA/acetonitrile+0.1 %FA, linear gradient from 95:5 to 30:70 over 1.79 min, then linear gradient to 0:100 over 0.20 min, and then held for 0.70 min. flow rate: 1.50 mLmin-1.
E: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %FA/acetonitrile+0.1 %FA, linear gradient from 95:5 to 30:70 over 1.79
min, then linear gradient to 0:100 over 0.20 min, and then held for 0.70 min. flow rate: 1.50 mLmin'1.
F: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 urn 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2 min; flow rate: 1.0 mLmin'1.
G: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.05 %TFA/acetonitrile +0.05 %TFA, linear gradient to 0:100 over 2:00 min and then held for 0.70 min; flow rate 1.5 mLmin'1.
H: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, Water+ 0.05 %TFA/Acetonitrile+0.05 %TFA, linear gradient from 95:5 to 40:60 over 1.90 min and then linear gradient to 0:100 over 0.35 min, held for 0.35 min; flow rate: 1.5 mLmin'1.
I: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 urn 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2 min; flow rate: 1.0 mLmin'1.
J: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 urn 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2 min; flow rate: 1.0 mLmin'1.
K: Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 nm. mobile phase, water+0.1 %FA/acetonitrile+0.1 %FA, linear gradient from 95:5 to 30:70 over 1.80 min, and then linear gradient to 0:100 over 0.2 min, and then held for 0.70 min. flow rate: 1.50 mLmin'1.
L: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 urn 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2 min; flow rate: 1.0 mLmin'1.
M: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 urn 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2 min; flow rate: 1.0 mLmin'1.
N: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %TFA/ acetonitrile+0.1 %TFA, linear gradient from 95:5 to 40:60 over 2.00 min, then linear gradient to 0:100 over 0.20 min, and then held for 0.40 min. flow rate: 1.50 mLmin'1.
O: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.1 %TFA/acetonitrile+0.1 %TFA, linear gradient from 95:5 to 40:60 over 2.00 min, then linear gradient to 0:100 over 0.20 min, and then held for 0.40 min. flow rate: 1.50 mLmin'1.
P: Shimadzu LCMS-2020 connected to Atlantis™ T3 3 um 4.6x100 mm. mobile phase, water+0.1 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 8 min and held for 2.0 min; flow rate: 1.0 mLmin'1.
Q: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.05 %TFA/acetonitrile +0.05 %TFA, 95:5 for 0 min, then linear gradient to 40:60 over 1.90 min and then linear gradient to 0:100 for 0.35 min; flow rate 1.5 mLmin'1.
R: Shimadzu LCMS-2020 connected to Ascentis Express 90 A 10 cm x 4.6 mm. mobile phase, water+0.05 %TFA /acetonitrile, linear gradient from 95:5 to 5:95 over 12 min; flow rate: 1.5 mLmin'1.
S: Shimadzu LCMS-2020 connected to Ascentis Express C18 30 mmx3.0 nm. mobile phase, water+0.05%TFA/acetonitrile +0.05%TFA, linear gradient from 95:5 to 40:60 over 1.90 min and then linear gradient to 0:100 over 0.35 min, held for 0.35 min; flow rate: 1.5 mLmin'1.
T: Shimadzu LCMS-2020 connected to Ascentis Express 90 A C18 4.6 mm x 100 mm. mobile phase, water+0.1 %FA /acetonitrile+0.1 % FA, linear gradient from 95:5 to 5:95 over 6 min and held for 2 min; flow rate: 0.8 mLmin'1.
U: Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 nm. mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 95:5 to 30:70 over 1 .5 min, and then linear gradient to 0: 100 over 1 .5 min. flow rate: 1.50 mLmin'1.
V: Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 spectrometer using a Waters Xbridge C18 column, 50 mm x 2.1 mm, 3.5 pm particle size; mobile phase, water/acetonitrile +0.1% HCOOH; 80:20 for 0.5min then linear gradient to 5:95 over 3.0min and then held for 1.5min; flow rate 0.5 mLmin'1.
W: Agilent HPLC 1100 series connected to a Bruker Daltonics MicrOTOF spectrometer using a Waters Xbridge C18 column, 50 mm x 2.1 mm, 3.5 pm particle size; mobile phase, water/acetonitrile + 0.1% NH3; 95:5 for 0.5min then linear gradient to 5:95 over 3.5min and then held for 2.0min; flow rate 0.5 mLmin'1.
X: Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 spectrometer using a Waters Xbridge C18 column, 50 mm x 2.1 mm, 3.5 pm particle size; mobile phase, water/acetonitrile +0.1% NH3; 80:20 for 0.5min then linear gradient to 5:95 over 3.0min and then held for 1.5min; flow rate 0.5 mLmin'1.
Y: Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 spectrometer using a Waters Xbridge C18 column, 50 mm x 2.1 mm, 3.5 pm particle size; mobile phase, water/acetonitrile +0.1% NH3; 80:20 for 0.5min then linear gradient to 5:95 over 5.0min and then held for 1.5min; flow rate 0.5 mLmin'1.
Z: Shimadzu LCMS-2020 connected to HALO, 50 mmx3.0 mm, 4.0 pm particle size. Mobile phase, water+0.1 % FA/acetonitrile+0.1% FA, linear gradient from 95:5 to 40:60 over 1.80
min, and then linear gradient to 0:100 over 0.2 min and then held for 0.70 min. flow rate: 1.50 mLmin-1.
AA: Shimadzu LCMS-2020 connected to EC-C18, 30 mmx3.0 mm, 1.9 pm particle size. Mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 95:5 to 40:60 over 1.80 min, , then linear gradient to 0:100 over 0.2 min, and then held for 0.70 min. flow rate: 1.50 mLmin'1.
AB: Shimadzu LCMS-2020 connected to HPH, 50 mmx3.0 mm, 4.0 pm particle size. Mobile phase, water+0.1% FA/acetonitrile+0.1 % FA, linear gradient from 100:0 to 0:100 over 1.20 min, and then held for 0.60 min. flow rate: 1.50 mLmin'1.
AC: Shimadzu LCMS-2020 connected to HPH, 50 mmx3.0 mm, 2.7 pm particle size. Mobile phase, water+0.04% NH3 H2O/acetonitrile, linear gradient from 100:0 to 30:70 over2.20 min, and linear gradient to 5:95 over 0.20 min, then held for 0.40 min. flow rate: 1.50 mLmin-1.
AD: AC: Shimadzu LCMS-2020 connected to HPH, 50 mmx3.0 mm, 2.7 pm particle size. Mobile phase, water+0.04% NH3 H2O/acetonitrile, linear gradient from 100:0 to 30:70 over 2.00 min, and linear gradient to 5:95 over 0.20 min, then held for 0.40 min. flow rate: 1 .50 mLmin-1.
AE: Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 mm. mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 100:0 to 30:70 over 1.90 min, and then linear gradient to 0:100 over 0.35 min, and then held for 0.35 min. flow rate: 1.50 mLmin-1.
AF: Shimadzu LCMS-2020 connected to Ascentis Express C18 50 mmx3.0 mm. mobile phase, water+0.05%TFA/acetonitrile+0.05%TFA, linear gradient from 100:0 to 0:100 over 2.00 min, and then held for 0.70 min. flow rate: 1.50 mLmin-1.
AG: Shimadzu LC-MS 2020 with photodiode array detector using a Thermo Hypersil Gold C18 column, 50mm x 2.1 mm 1.9pm particle size; mobile phase water/acetonitrile +0.1% formic acid; 95:5 for 0.2min then linear gradient to 5:95 over 2.0min and then held for 0.5min; flow rate 0.8 mLmin-1.
Process for Preparation:
[00219] Certain compounds of the invention may be synthesised according to the general methods disclosed herein. Certain compounds of the invention may be synthesised according to general schemes 1 to 4. Certain compounds of the invention may be synthesised according to or analogously to the syntheses provided in examples 1 to 54 and 97 to 110.
General Scheme 1 - Synthesis of Intermediates A and B
Synthetic routes to Intermediates A and B have been reported in, for example, W02003026657 A1. Alternative routes to Intermediates A and B are illustrated in General Scheme 1 and described in the following examples.
Synthetic routes to Intermediate C have been reported in, for example, WO2021228945 A1.
A route to Intermediate C is illustrated in General Scheme 2 and described in the following examples.
General Scheme 3
Compounds of Formula (I) can be synthesised from Intermediate A or B in one to two steps as illustrated in General Scheme 3. First, the reaction of the Intermediate A with an appropriate nucleophile (for example an amine or hydroxylamine), using an appropriate base if necessary (for example triethylamine, DI PEA, potassium carbonate), in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane, ethanol, methanol) with heating (conventional or by microwave irradiation) if necessary.
Subsequently, alkylation can be achieved by using an appropriate reagent (for example an alkyl halide, mesylate, tosylate or cyanogen halide), with an appropriate base (for example triethylamine, DIPEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
Acylation can be achieved by using an appropriate reagent (for example an acyl halide or anhydride), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary. Acylation may also be achieved by activating a carboxylic acid with common coupling reagents (for example EDC, HATLI, T3P), with an appropriate base (for example triethylamine, DIPEA, DMAP) in an appropriate solvent (for example DCM DMF, NMP, THF, ethyl acetate) with heating (conventional or by microwave irradiation) if necessary.
Sulfonylation can be achieved by using an appropriate reagent (for example a sulfonyl halide), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
Ureas may be formed by using an appropriate reagent (for example an isocyanate), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary. Ureas may also be formed by first activating an amine with a reagent such as GDI, phosgene or triphosgene with an appropriate base if necessary (for example triethylamine, DI PEA, potassium carbonate, DMAP), in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
General Scheme 4
Compounds of Formula (I) can be synthesised from Intermediate C in a single step as illustrated in General Scheme 4. Alkylation can be achieved by using an appropriate reagent (for example an alkyl halide, mesylate, tosylate or cyanogen halide), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
Acylation can be achieved by using an appropriate reagent (for example an acyl halide or anhydride), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary. Acylation may also be achieved by activating a carboxylic acid with common coupling reagents (for example EDC, HATU, T3P), with an appropriate base (for example triethylamine, DIPEA, DMAP) in an appropriate solvent (for example DCM DMF, NMP, THF, ethyl acetate) with heating (conventional or by microwave irradiation) if necessary.
Sulfonylation can be achieved by using an appropriate reagent (for example a sulfonyl halide), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
Ureas may be formed by using an appropriate reagent (for example an isocyanate), with an appropriate base (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary. Ureas may also be formed by first activating an amine with a reagent such as GDI, phosgene or triphosgene with an appropriate base if necessary (for example triethylamine, DI PEA, potassium carbonate, DMAP) in an appropriate solvent (for example DCM, DMSO, DMF, NMP, THF, 1 ,4-dioxane) with heating (conventional or by microwave irradiation) if necessary.
To a mixture of 1-(2-aminophenyl)ethan-1-one hydrochloride (29.0 g, 0.168 mol) in EtOH (290 mL) was added sodium dicyanoazanide (37.6 g, 0.420 mol). The resulting mixture was stirred at 80 °C for overnight. The precipitated solids were collected by filtration and washed with water (100 mLx3). The filter cake was washed with ethyl ether (3 x 100 ml) and dried under vacuum to give N-(4-methylquinazolin-2-yl) cyanamide, Intermediate 1 (11.0 g, 35%)
as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 12.9 (br, 1 H), 8.11 - 8.09 (m, 1 H), 7.88 - 7.83 (m, 1 H), 7.69 - 7.44 (m, 2H), 2.81 (s, 3H). LCMSe: Rt 0.79 min, MH+ 185.
Sodium dicyanamide (735 mg, 8.25 mmol) and 2-aminobenzaldehyde hydrochloride (1.30 g, 8.25 mmol) were heated at reflux in ethanol (15 mL). After 2h, the mixture was cooled and filtered. The collected solid was washed with ethanol, water and finally ethanol. The resulting yellow solid was lyophilised to give 2-cyanoamidoquinazoline (168 mg, 12%). 1H NMR (500 MHz, DMSO-d6) δ 13.15 (br s, 1 H), 9.42 (s, 1 H), 8.04 (d, 1 H, J = 7.8 Hz), 7.91 (t, 1 H, J = 7.5 Hz), 7.55 (d, 1 H, J = 8.4 Hz), 7.47 (t, 1 H, J = 7.6 Hz).
To a stirred solution of 2,2,4-trimethyl-1 H-quinoline (200 mg, 1.15 mmol) in aq. HCI (0.4 mL, 2.0 M) was added 2-cyanoguanidine (110 mg, 1 .27 mmol). The resulting mixture was stirred for 2 h at 100 °C. The precipitated solids were then collected by filtration and washed with water (2.0 mL) and EtOH (2.0 mL). The crude product (150 mg) was purified by Prep-HPLCa to afford 1-(4-methylquinazolin-2-yl) guanidine (46 mg, 20 %) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.95 (dd, J = 8.2, 1.4 Hz, 1 H), 7.68 - 7.65 (m, 1 H), 7.56 - 7.50 (m, 1 H), 7.29 - 7.25 (m, 1 H), 7.11 (br, 3H), 2.71 (s, 3H). LCMSa: Rt 0.73 min, MH+ 202.
Intermediate 1 (100 mg, 0.543 mmol) and /V,/V-dimethylethylenediamine (63 pl, 0.585 mmol) were mixed in ethanol (3 mL) and heated for 15 min at 160 °C. The resulting mixture was evaporated. The residue was purified by flash column chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to afford 1-(2-(dimethylamino)ethyl)-3-(4- methylquinazolin-2-yl)guanidine (54 mg, 36%). LCMSw: Rt 4.5 min, MH+ 273.
Example 2: 1 -(4-Methylquinazolin-2-yl)-3-(2-(pyridin-3-yl)ethyl)guanidine
Intermediate 1 (100 mg, 0.543 mmol), 3-(2-aminoethyl) pyridine hydrochloride (91 mg, 0.574 mmol) and triethylamine (84 pl, 0.603 mmol) were mixed in ethanol (3 mL) and heated for 15 min at 160 °C. The resulting mixture was evaporated. The residue was purified by chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give 1-(4- methylquinazolin-2-yl)-3-(2-(pyridin-3-yl)ethyl)guanidine (133 mg, 80%). LCMSw: Rt 4.2 min, MH+ 307.
To a solution of Intermediate 1 (180 mg, 0.978 mmol) in EtOH (2.0 mL) was added 1- methylpiperidin-4-amine (223 mg, 1 .96 mmol). The reaction mixture was stirred at 80 °C for 3 days. The reaction mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLCC to afford 1-(1-methylpiperidin-4-yl)-3-(4-methylquinazolin-2- yl)guanidine (90 mg, 30%) as a light yellow solid. 1H NMR (400 MHz, DMSO-cfe) δ 7.96 (d, J = 8.2 Hz, 1 H), 7.68 - 7.56 (m, 2H), 7.52 (d, J = 8.4 Hz, 1 H), 7.28 (t, J = 7.5 Hz, 1 H), 3.75 (s, 1 H), 2.71 - 2.66 (m, 5H), 2.17 (s, 3H), 2.07 - 2.02 (m, 2H), 1.91 - 1.80 (m, 2H), 1.45 - 1 .44 (m, 2H). LCMSd: Rt 0.62 min, MH+ 299.
To a solution of Example 3 (37 mg, 0.124 mmol) in DMSO (1.0 mL) was added AC2O (12.6 mg, 0.124 mmol). The resulting mixture was stirred for overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLCd to afford N-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide (20 mg, 45%) as a white solid. 1H NMR (300 MHz,
Chloroform-d, mix of rotamers) δ 14.50 (s, 0.5H), 13.07 (s, 0.4H), 10.44 (s, 0.3H), 8.84 (s, 0.5 H), 8.07 - 7.86 (m, 1 H), 7.80 - 7.78 (m, 0.4 H), 7.74 - 7.68 (m, 1 H), 7.63 - 7.60 (m, 0.5H), 7.50 - 7.44 (m, 0.5H), 7.40 - 7.35 (m, 0.5H), 4.42 - 4.41 (m, 0.6H), 4.27 - 4.17 (m, 0.4H), 2.90 (s, 1.6H), 2.87(s, 1.4H), 2.82 - 2.66 (m, 2H), 2.36 (s, 1.5H), 2.32 -2.30 (m, 5H), 2.17- 2.08 (m, 3.5H), 1.87 - 1.65 (m, 2.0H). LCMSe: Rt 0.604 min, MH+ 341 .
Intermediate 1 (100 mg, 0.543 mmol) and 1-(2-aminoethyl)piperidine (0.19 mL, 1.33 mmol) were mixed in ethanol (4 mL) and heated for 10 min at 160 °C. The resulting mixture was evaporated. The residue was purified by chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give 1-(4-methylquinazolin-2-yl)-3-(2-(piperidin-1- yl)ethyl)guanidine (74 mg, 44%). LCMSV: Rt 0.33 min, MH+ 313.
By analogous method to that described for Example 1 , with 1-(3-aminopropyl)piperidine (91 μL) as the nucleophilic amine. Afforded 1-(4-methylquinazolin-2-yl)-3-(3-(piperidin-1- yl)propyl)guanidine (46 mg, 26%). LCMSw: Rt 4.9 min, MH+ 327.
Intermediate 1 (125 mg, 0.68 mmol), 3-amino-1-methylpiperidine dihydrochloride (191 mg 1.02 mmol) and DI PEA (0.20 mL, 1.15 mmol) were mixed in ethanol (4 mL) and heated for 10 min at 160 °C. The resulting mixture was evaporated. The residue was purified by chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give racemic 1-(1-methylpiperidin-3-yl)-3-(4-methylquinazolin-2-yl)guanidine (118 mg, 58%). LCMSV: Rt 0.4 min, MH+ 299.
Example 8 1 -(3-(Dimethylamino)propyl)-3-(4-methylquinazolin-2-yl)guanidine
Intermediate 1 (200 mg, 1.09 mmol) in ethanol (3 mL) had dimethylaminopropylamine (444 mg, 4.34 mmol) added at room temperature. The resulting mixture was stirred for overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLCe to afford 1-(3-(dimethylamino)propyl)-3-(4- methylquinazolin-2-yl)guanidine (128 mg, 22%) as a yellow solid TFA salt. 1H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1 H), 9.97 (s, 1H), 9.62 (s, 1 H), 8.88 (s, 2H), 8.28 (d, J = 8.3 Hz, 1 H), 8.09 - 7.88 (m, 2H), 7.68 - 7.66 (m, 1 H), 3.52 - 3.50 (m, 2H), 3.29 - 3.08 (m, 2H), 2.94 (s, 3H), 2.82 (d, J = 4.4 Hz, 6H), 2.13 - 1.83 (m, 2H). LCMSf: Rt 3.21 min, MH+287.
Example 8 (348 mg, 1.21 mmol), triethylamine (0.37 mL, 2.65 mmol) and 4- (dimethylamino)pyridine (16 mg, 0.13 mmol) were dissolved in DCM (15 mL) and cooled in an ice bath. Acetyl chloride (0.10 mL) was added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by chromatography by chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give N-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (326 mg, 82%). LCMSV: Rt 0.3 min, MH+ 329.
By analogous method to that described for Example 1, with 1-(2- aminoethyl)pyrrolidine (73 μL) as the nucleophilic base. Afforded 1-(4-methylquinazolin-2-yl)-3-(2-(pyrrolidin-1- yl)ethyl)guanidine (30 mg, 19%). LCMSV: Rt 0.5 min, MH+ 299.
Example 11 : 1 -(2-( 1 -Methylpyrrolidin-2-yl)ethyl)-3-(4-methylquinazolin-2-yl)guanidine
By analogous method to that described for Example 1 , with 2-(2-aminoethyl)-1- methylpyrrolidine (83 μL) as the nucleophilic base. Afforded racemic 1-(2-(1- methylpyrrolidin-2-yl)ethyl)-3-(4-methylquinazolin-2-yl)guanidine (58 mg, 34%). LCMSw: Rt 4.5 min, MH+ 313.
Example 12: N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)cyclobutanecarboxamide
Example 8 (75 mg, 0.26 mmol), triethylamine (73 pl, 0.52 mmol) and 4- (dimethylamino)pyridine (3 mg, 0.02 mmol) were dissolved in 1 ,4-dioxane (4 mL). Cyclobutanecarbonyl chloride (26 pl, 0.23 mmol) added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by chromatography (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give /V-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)cyclobutanecarboxamide (45 mg, 48%). LCMSW: Rt 5.7 min, MH+ 369. Example 13: N-((( 1 -methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)cyclobutanecarboxamide
By analogous method to that described for Example 12, using Example 2. Afforded /V-(/V-(1- methylpiperidin-4-yl)-/V-(4-methylquinazolin-2-yl)carbamimidoyl)cyclobutanecarboxamide
(37 mg, 78%). LOVIS'": Rt 5.4 min, MH 381.
Example 14 1-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-(4-methylquinazolin-2- yl)guanidine
By analogous method to that described for Example 1 , with 8-methyl-8- azabicyclo[3.2.1]octan-3-amine (81 L) as the nucleophilic base. Afforded 1-(8-methyl-8- azabicyclo[3.2.1]octan-3-yl)-3-(4-methylquinazolin-2-yl)guanidine (87 mg, 49%). LCMSW: Rt 4.3 min, MH+ 325.
Intermediate 1 (200 mg, 1.09 mmmol) in ethanol (3 mL) had 4-morpholinepropanamine (626 mg, 4.34 mmol) at room temperature .The resulting mixture was stirred for overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The crude product (200 mg) was purified by Prep-HPLCk to afford 1-(4-methylquinazolin-2-yl)-3-(3- morpholinopropyl)guanidine (86 mg, 23%) as a white solid. 1H NMR (400 MHz, Chloroform- d) δ 8.00 - 7.81 (m, 1 H), 7.67 - 7.62 (m, 1 H), 7.61 - 7.52 (m, 1 H), 7.35 - 7.30 (m, 1 H), 3.76 - 3.74 (m, 4H), 3.44 - 3.41 (m, 2H), 2.83 (s, 3H), 2.50 - 2.48 (m, 6H), 1.84 - 1.82 (m, 2H). LCMS1: Rt 3.39 min, MH+ 329.
Intermediate 1 (200 mg, 1.09 mmol) in ethanol (3 mL) had 4-pyridinemethaneamine (470 mg, 4.34 mmol) added at room temperature. The resulting mixture was stirred for overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLCh to afford 1-(4-methylquinazolin-2-yl)-3-(pyridin-4- ylmethyl)guanidine (170 mg, 28%) as a yellow solid TFA salt. 1H NMR (400 MHz, DMSO- d6) δ 11.35 (s, 1 H), 9.94 (s, 1 H), 8.97 (s, 2H), 8.73 - 8.65 (m, 2H), 8.29 (d, J = 8.3 Hz, 1 H), 8.01 (d, J = 3.8 Hz, 2H), 7.67 - 7.66 (m, 3H), 4.91 (d, J = 6.5 Hz, 2H), 2.95 (s, 3H). HPLC: Rt 3.27 min, MH+ 293.
Example 17 1-(4-Methylquinazolin-2-yl)-3-(2-(pyridin-4-yl)ethyl)guanidine
Intermediate 1 (100 mg, 0.55 mmol) and 4-(2-aminoethyl)pyridine (69 μL) were mixed in ethanol (3 mL) and heated for 15 min at 160 °C. The resulting mixture was evaporated. The residue was purified (Biotage®KP-NH silica) eluted with methanol I DCM (0-5%) to give 1- (4-methylquinazolin-2-yl)-3-(2-(pyridin-4-yl)ethyl)guanidine (97 mg, 58%). LCMSW: Rt 4.2 min, MH+ 307.
Intermediate 1 (125 mg, 0.679 mmol) and A/,N-diethylethylenediamine (0.14 mL, 1.00 mmol) were added to ethanol (4 mL) and heated for 10 min at 160 °C. The resulting mixture was evaporated. The residue was dissolved in diethyl ether and allowed to stand overnight. The resulting mixture was filtered and washed with diethyl ether. The collected solid was lyophilized to give 1-(2-(diethylamino)ethyl)-3-(4-methylquinazolin-2-yl)guanidine (129 mg, 63%). LCMSV: Rt 0.3 min, MH+ 301.
Example 18 (50 mg, 0.17 mmol), triethylamine (69 μL, 0.50 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Acetyl chloride (15 μL, 0.21 mmol) was added drop-wise and the mixture stirred 2h. The mixture was evaporated and the residue purified by preparative HPLCe to give N-(((2- (diethylamino)ethyl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (57 mg, 98%). LCMSV: Rt 0.3 min, MH+ 343.
Example 20 N-(((4-methylquinazolin-2-yl)amino)((pyridin-4- ylmethyl)amino)methylene)acetamide
By analogous method to that described for Example 19, using Example 16. Afforded N-(((4- methylquinazolin-2-yl)amino)((pyridin-4-ylmethyl)amino)methylene)acetamide (28 mg, 49%). LCMSV: Rt 4.8 min, MH+ 335.
Example 21 : N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)isobutyramide
Example 8 (50 mg, 0.17 mmol), triethylamine (68 μL, 0.48 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Isobutyryl chloride (21 μL, 0.20 mmol) was added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by preparative HPLCe to give N-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2-yl)amino)methylene)isobutyramide (48 mg, 79%). LCMSV: Rt 0.5 min, MH+ 357.
Example 22: N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)cyclopentanecarboxamide
By analogous method to that described for Example 21 , with cyclopentanecarbonyl chloride (25 μL) as the acid chloride. Afforded N-(((3-(dimethylamino)propyl)amino)((4- methylquinazolin-2-yl)amino)methylene)cyclopentanecarboxamide (48 mg, 74%). LCMSX: Rt 5.4 min, MH+ 383.
Example 23: N-(((4-methylquinazolin-2-yl)amino)((2-(piperidin-1 - yl)ethyl)amino)methylene)acetamide
Example 5 (50 mg, 0.16 mmol), triethylamine (65 μL, 0.48 mmol) and 4- (dimethylamino)pyridine (2 mg, 0.01 mmol) were dissolved in 1 ,4-dioxane (2 mL). Acetyl chloride (14 μL, 0.21 mmol) was added drop-wise and the mixture stirred for 2 h. The mixture was evaporated and the residue purified by preparative HPLCe to give N-(((4- methylquinazolin-2-yl)amino)((2-(piperidin-1 -yl)ethyl)amino)methylene)acetamide (34 mg, 60%). LCMSV: Rt 0.4 min, MH+ 355.
Example 24: N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-3-methylbutanamide
By analogous method to that described for Example 21 , with isovaleryl chloride (25 μL) as the acid chloride. Afforded N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-3-methylbutanamide (35 mg, 55%). LCMSV: Rt 5.5 min, MH+ 371.
Intermediate 1 (125 mg, 0.679 mmol) and 2-(aminoethyl)morpholine (0.12 mL, 0.91 mmol) added to ethanol (4 mL) and heated for 10 min at 160 °C. The resulting mixture was evaporated. The residue was triturated with propan-2-ol and filtered. The collected solid was washed with propan-2-ol and lyophilized to give 1-(4-methylquinazolin-2-yl)-3-(2- morpholinoethyl)guanidine (116 mg, 54%). LCMSX: Rt 3.3 min, MH+ 315.
Example
N-(((4-methylquinazolin-2-yl)amino)((2- morpholinoethyl)amino)methylene)acetamide
By analogous method to that described for Example 21 , with Example 25 (50 mg) and acetyl chloride (14 μL). Afforded N-(((4-methylquinazolin-2-yl)amino)((2- morpholinoethyl)amino)methylene)acetamide (34 mg, 56%). LCMSV: Rt 0.3 min, MH+ 357.
By analogous method to that described for Example 21 , with Example 15 (50 mg, 0.15 mmol) and acetyl chloride (14 μL). Afforded N-(((4-methylquinazolin-2-yl)amino)((3- morpholinopropyl)amino)methylene)acetamide (43 mg, 77%). LCMSX: Rt 3.9 min, MH+ 371.
Intermediate 1 (150 mg, 0.81 mmol) and 4-amino-1-boc-piperidine (195 mg, 0.97 mmol) were added to ethanol (4 mL) and heated for 15 min at 160 °C. The resulting mixture was evaporated. The residue was purified by chromatography (alumina) eluting with 2 M methanolic ammonia in DCM (0-6%) to give tert-butyl 4-(3-(4-methylquinazolin-2- yl)guanidino)piperidine-1-carboxylate (190 mg). The latter was dissolved in DCM (4 mL), 2- (dimethylamino)pyridine (2 mg, 0.01 mmol) and triethylamine (0.17 mL, 1.22 mmol) were added, then acetyl chloride (42 μL, 0.63 mmol) was added drop-wise. The mixture was stirred for 2 h then evaporated. The residue was purified by chromatography (silica gel) eluted with 2 M methanolic ammonia in DCM (0-10%) to give tert-butyl-4-(2-acetyl-3-(4- methylquinazolin-2-yl)guanidino)piperidine-1 -carboxylate (132 mg). The latter was
dissolved in DCM (1.5 mL) and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred for 2 h then evaporated. The residue was purified by chromatography (alumina) eluting with 2 M methanolic ammonia in DCM (0-5%) to give N-(((4-methylquinazolin-2- yl)amino)(piperidin-4-ylamino)methylene)acetamide (69 mg, 26% over 3 steps). LCMSW: Rt 4.9 min, MH+ 327.
Example 29: 3,3,3-Trifluoro-/V-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)propanamide
By analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and 3,3,3-trifluoropropionyl chloride (19 μL). Afforded 3,3,3-trifluoro-N-(((1 -methylpiperidin- 4-yl)amino)((4-methylquinazolin-2-yl)amino)methylene)propanamide (8 mg, 11%). LCMSW: Rt 5.5min, MH+ 409.
Example 30: 2,2-Dichloro-/V-(((1 -methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
By analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and 3,3,3-dichloroacetyl chloride (17 μL). Afforded 2,2-dichloro-/V-(((1-methylpiperidin-4- yl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (14 mg, 20%). LCMSW: Rt 5.6 min, MH+ 409.
Example 31 : 2,2-Difluoro-N-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
ABy analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and difluoroacetic anhydride (20 μL). Afforded 2,2-difluoro-/V-(((1-methylpiperidin-4- yl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (22 mg, 34%). LCMSW: Rt 5.2 min, MH+ 377.
Example 32: N-(((3-(Dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-3,3,3-trifluoropropanamide
By analogous method to that described for Example 21 , with Example 8 (75 mg, 0.26 mmol), triethylamine (73 μL) and 3,3,3-trifluoropropionyl chloride (28 μL). Afforded N-(((3- (dimethylamino)propyl)amino)((4-methylquinazolin-2-yl)amino)methylene)-3,3,3- trifluoropropanamide (16 mg, 16%). LCMSW: Rt 5.1 min, MH+ 397.
Example 33: 2,2-Dichloro-/V-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin- 2-yl)amino)methylene)acetamide
By analogous method to that described for Example 32, with di chloroacetyl chloride (25 μL).
Afforded 2,2-dichloro-/V-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide (23 mg, 22%). LCMSW: Rt 5.3min, MH+ 397.
Example 34: 2,2,2-Trifluoro-/V-(((1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
By analogous method to that described for Example 21 , with Example 3 (50 mg, 0.17 mmol) and trifluoroacetic anhydride (22 μL). Afforded 2,2,2-trifluoro-N-(((1-methylpiperidin-4- yl)amino)((4-methylquinazolin-2-yl)amino)methylene)acetamide (21 mg, 31 %). LCMSW: 5.6 min, MH+ 395.
Example 35: N-(((3-(Dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-2,2,2-trifluoroacetamide
By analogous method to that described for Example 32, with trifluoroacetic anhydride (35 μL). Afforded N-(((3-(dimethylamino)propyl)amino)((4-methylquinazolin-2- yl)amino)methylene)-2,2,2-trifluoroacetamide (8 mg, 8%). LCMSW: Rt 5.7 min, MH+ 383.
Intermediate 2 (165 mg, 0.97 mmol) and /V,/V-dimethylethylenediamine (0.16 mL, 1 .46 mmol) were added to ethanol (4 mL) and heated for 10 min at 160 °C. The resulting mixture was evaporated. The residue was purified by flash column chromatography (alumina) eluting with 2 M methanolic ammonia in DCM (0-6%) to give 1-(2-(dimethylamino)ethyl)-3-(quinazolin- 2-yl)guanidine (105 mg, 42%). LCMSW: Rt 4.8 min, MH+ 259.
Example 37: N-(((2-(dimethylamino)ethyl)amino)(quinazolin-2- ylamino)methylene)acetamide
By analogous method to that described for Example 21 , with Example 36 (50 mg, 0.19 mmol) and acetyl chloride (14 μL). Afforded N-(((2-(dimethylamino)ethyl)amino)(quinazolin-2- ylamino)methylene)acetamide (20 mg, 35%). LCMSb: Rt 4.7 min, MH+ 301.
Intermediate 1 (80 mg, 0.43 mmol) in ethanol (2 mL) had tetrahydrofuran-2-ylmethanamine (48 mg, 0.48 mmol added and heated for 30 min at 160 °C in a microwave. The mixture was concentrated and the residue was purified by Prep-HPLCU to afford 1-(4- methylquinazolin-2-yl)-3-((tetrahydrofuran-2-yl)methyl)guanidine (28 mg, 22%). 1H NMR (500 MHz, DMSO-d6) δ 8.25-8.15 (m, 1 H), 7.95-7.80 (m, 1 H), 7.75-7.65 (m, 1 H), 7.50-7.40 (m, 1 H), 4.30-4.15 (m, 1 H), 4.15-4.00 (m, 1 H), 3.90-3.85 (m, 1 H), 3.75-3.55 (m, 1 H), 3.50- 3.40 (m, 1 H), 2.90 (s, 3H), 2.30-1.90 (m, 3H), 1.90-1.60 (m, 1 H). LCMSW: Rt 4.3 min, MH+ 286.
Intermediate 1 (200 mg, 1.09 mmol) in ethanol (3 mL) had benzylamine (465 mg, 4.34 mmol) at room temperature. The resulting mixture was stirred for overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep- HPLCj to afford 1-benzyl-3-(4-methylquinazolin-2-yl)guanidine (100 mg, 23%) as a white solid TFA salt. 1H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1 H), 9.81 (s, 1 H), 8.90 - 8.70 (m,
2H), 8.27 (d, J = 8.3 Hz, 1 H), 8.04 - 7.85 (m, 2H), 7.71 - 7.57 (m, 1 H), 7.44 - 7.18 (m, 5H), 4.71 (d, = 6.1 Hz, 2H), 2.93 (s, 3H). LCMSk: Rt 1.11 min, MH+ 292.
By analogous method to that described for Example 38, with cyclohexylmethylamine. Afforded 1-(cyclohexylmethyl)-3-(4-methylquinazolin-2-yl)guanidine (8 mg, 6%). LCMSy: Rt 6.1 min, MH+ 298.
To a suspension of Intermediate 1 (80 mg, 0.43 mmol) in ethanol (2 mL) was added tetrahydropyran-4-amine hydrochloride (66 mg, 0.48 mmol) and DIPEA (67 mg, 0.52 mmol) and the reaction heated at 160 °C under microwave irradiation for 30 minutes. The mixture was concentrated and the residue was purified by Prep-HPLCU to afford 1-(4- methylquinazolin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)guanidine (14 mg, 11%). 1H NMR (500 MHz, DMSO-d6) δ 8.05-7.95 (m, 1 H), 7.75-7.65 (m, 1 H), 7.60-7.50 (m, 1 H), 7.35-7.25 (m, 1 H), 4.10-3.75 (m, 3H), 3.50-3.35 (m, 2H), 2.75 (s, 3H), 2.00-1.80 (m, 2H), 1.50-1.30 (m, 2H). LCMSW: Rt 4.1 min, MH+ 286.
By analogous method to that described for Example 38, with 2- morpholinosulfonylethanamine hydrochloride. Afforded 1-(4-methylquinazolin-2-yl)-3-(2- (morpholinosulfonyl)ethyl)guanidine (7 mg, 4%). 1H NMR (500 MHz, DMSO-d6) δ 8.15-8.05 (m, 1 H), 7.80-7.70 (m, 1 H), 7.65-7.55 (m, 1 H), 7.35-7.25 (m, 1 H), 4.15-4.00 (m, 6H), 3.50- 3.35 (m, 2H), 3.30-3.10 (m, 4H), 2.75 (s, 3H). LCMSW: Rt 4.1 min, MH+ 379.
Example 43 1 -(2-( 1 H-Pyrazol-1 -yl)ethyl)-3-(4-methylquinazolin-2-yl)guanidine
By analogous method to that described for Example 38, with 2-pyrazol-1-ylethanamine. Afforded 1-(2-(1 H-pyrazol-1-yl)ethyl)-3-(4-methylquinazolin-2-yl)guanidine (25 mg, 19%). 1H NMR (500 MHz, DMSO-d6) δ 8.05-7.95 (m, 1 H), 7.75 (s, 1 H), 7.75-7.65 (m, 1 H), 7.65-7.55 (m, 1 H), 7.50 (s, 1 H), 7.35-7.25 (m, 1 H), 6.25 (s, 1 H), 4.45-4.25 (m, 2H), 3.80-3.60 (m, 2H), 2.75 (s, 3H). LCMSW: Rt 4.1 min, MH+ 296.
A mixture of Intermediate 1 (100 mg, 0.54 mmol) and 3-(dimethylamino) propyl](methyl)amine (95 mg, 0.82 mmol) in DMSO (1.0 ml ) was stirred for 5 min at room temperature. The reaction mixture was irradiated with microwave radiation for 20 min at 160 °C. The crude product was purified by Prep-HPLCq to afford 1-(3-(dimethylamino)propyl)-1- methyl-3-(4-methylquinazolin-2-yl)guanidine (42 mg, 26%) as a light yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 8.99 (br, 2H), 7.89 (d, J = 8.2 Hz, 1 H), 7.64 - 7.63 (m, 2H), 7.27 (s, 1 H), 3.49 - 3.40 (m, 2H), 3.20 (s, 3H), 2.84 (s, 3H), 2.32 - 2.30 (m, 2H), 2.24 (s, 6H), 1.77 - 1 .75 (m, 2H). LCMSr: Rt 2.68 min, MH+ 301.
Intermediate 1 (500 mg, 2.71 mmol) in ethanol (5 mL) had 1-(2,6- dichlorophenyl)methanamine (717 mg, 4.07 mmol) added at room temperature. The resulting mixture was stirred for overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The crude product (200 mg) was purified by Prep-HPLCf to afford 1-(2,6-Dichlorobenzyl)-3-(4-methylquinazolin-2-yl)guanidine (101 mg, 9%) as a white solid formic acid salt. 1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1 H), 8.67 (s, 1 H), 8.02 (d, J = 8.4 Hz, 1 H), 7.83 - 7.81 (m, 1 H), 7.66 (d, J = 8.5 Hz, 1 H), 7.56 - 7.47 (m, 1 H), 7.42 (d, J = 8.1 Hz, 2H), 7.34 - 7.28 (m, 1 H), 4.89 (s, 2H), 2.92 (s, 3H). LCMSg: Rt 1.11 min, MH+ 360.
Example 46 N-(((2,6-dichlorobenzyl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
Example 45 (120 mg, 0.33 mmol) in DMSO (4.0 mL) was treated with AC2O (31.5 μL, 0.33 mmol) for 4 h at room temperature. Evaporated to dryness and the residue was purified by Prep-HPLC9 to afford N-(((2,6-dichlorobenzyl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide (62 mg, 46%) as a white solid. 1H NMR (300 MHz, Chloroform-d, mix of rotamers) δ 14.53 (s, 0.5H), 13.04 (s, 0.5H), 10.85 (s, 0.5H), 8.75 (s, 0.5H), 8.05 - 7.96 (m, 1 H), 7.86 - 7.74 (m, 1 H), 7.67 (m, 1 H), 7.55 - 7.34 (m, 3H), 7.23 (m, 1 H), 5.19 - 5.07 (m, 2H), 2.91 (m, 3H), 2.28 (m, 3H). LCMSh: Rt 1.40 min, MH+402.
Intermediate 1 (170 mg, 0.92 mmol) in DMSO (1.5 mL) was added (4- aminobutyl)dimethylamine (161 mg, 1.39 mmol) at room temperature. The reaction mixture was irradiated with microwave radiation for 20 min at 160 °C. The crude product was purified by Prep-HPLCP to afford 1-(4-(dimethylamino)butyl)-3-(4-methylquinazolin-2-yl)guanidine (160 mg, 38.1 %) as a yellow solid TFA salt. 1H NMR (400 MHz, DMSO-d6) δ 11 .67 (s, 1 H), 10.17 (s, 1 H), 7.99 - 7.97 (m, 1 H), 7.82 - 7.80 (m, 1 H), 7.73 - 7.72 (m, 1 H), 7.52 - 7.50 (m, 1 H), 3.49 - 3.46 (m, 2H), 3.16 - 3.15 (m, 2H), 2.88 - 2.66 (m, 9H), 2.02 - 1.79 (m, 4H). LCMSq: Rt 0.64 min, MH+ 301.
Step 1: 1 -(2-((2,4-dimethoxybenzyl)amino)-4-methoxyphenyl)ethan-1 -one
To a stirred solution of 1-(2-fluoro-4-methoxyphenyl) ethanone (30.0 g, 178 mmol) and CS2CO3 (116 g, 356 mmol) in DMSO (200 mL) was added (2,4-dimethoxyphenyl)
methanamine (50 mL, 267 mmol) dropwise at room temperature. The resulting mixture was stirred for 3 h at 120 °C. The resulting mixture was diluted with H2O (500 mL). The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 :1) to afford 1-(2-((2,4-dimethoxybenzyl)amino)-4- methoxyphenyl)ethan-1-one (40.0 g, 79%) as a yellow solid. LCMS: MH+ 284.
Step 2: 1-(2-amino-4-methoxyphenyl) ethan-1-one hydrochloride
To a stirred solution of 1-(2-((2,4-dimethoxybenzyl) amino)-4-methoxyphenyl)ethan-1-one (20.0 g, 74.3 mmol) in DCM (200 mL) were added TFA (40 mL) dropwise at room temperature. The resulting mixture was stirred for overnight at room temperature. The reaction was quenched with sat. NaHCO3 (aq.) at 0 °C. The aqueous layer was extracted with DCM (3 x 150 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 :1) to afford 1-(2-amino-4-methoxyphenyl) ethanone as a yellow solid. The product was further treated with 4 N HCI in 1 ,4-dioxane (25 mL) and stirred for 30 min at 0 °C. The precipitated solids were collected by filtration and washed with MTBE (3 x 10 mL). The filter cake was dried under vacuum to give 1-(2-amino-4-methoxyphenyl) ethan-1-one hydrochloride (4.60 g, 31%). LCMS: MH+ 166.
Step 3: N-(7-methoxy-4-methylquinazolin-2-yl)cyanamide 1-(2-amino-4-methoxyphenyl)ethan-1-one hydrochloride (4.60 g, 22.9 mmol) was dissolved in ethyl alcohol (46 mL). To the above solution was added sodium dicyanoazanide (6.20 g, 69.6 mmol) in portions at room temperature. The resulting mixture was stirred for overnight at 80 °C. The precipitated solids were collected by filtration and washed with water and MTBE (3 x 100 mL). This resulted in N-(7-methoxy-4-methylquinazolin-2-yl) cyanamide (1.8 g, 34%) as a red solid. 1H NMR (400 MHz, DMSO-d6) δ 12.9 (br, 1 H), 8.11 - 8.09 (m, 1 H), 7.08 - 7.01 (m, 1 H), 6.92 - 7.89 (m, 1 H), 3.90 (s, 3H), 2.75 (s, 3H). LCMS: MH+215.
Step 4: 1-(7-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
To a stirred mixture of N-(7-methoxy-4-methylquinazolin-2-yl)cyanamide (200 mg, 0.934 mmol) in dimethylformamide (2.0 mL) was added 1-methylpiperidin-4-amine (160 mg, 1.40 mmol) at room temperature. The resulting mixture was stirred for overnight at 120 °C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLCm to afford 1-(7-methoxy-4-methylquinazolin-2-yl)- 3-(1-methylpiperidin-4-yl)guanidine (35 mg, 10%) as a red solid formic acid salt. 1H NMR (400 MHz, DMSO-d6) δ 8.33 (s, 2H), 8.10 (d, J = 9.1 Hz, 1 H), 7.30 -7.07 (m, 2H), 3.94 (s,
3H), 3.72 (s, 1 H), 2.80 (s, 3H), 2.72 (d, J = 10.9 Hz, 2H), 2.22 (s, 3H), 2.13 - 2.11 (m, 2H), 1.92 - 1.89 (m, 2H), 1.66 - 1 .63 (m, 2H). LCMSn: Rt 1 .42 min, MH+ 329.
Step 1: 1 -(3-methoxy-2-nitrophenyl) ethanone m-Methoxyacetophenone (50.0 g, 0.33 mol) had HNO3 (250 mL) added at 0 °C. The resulting mixture was stirred for 3 days at room temperature. The reaction was quenched by the addition of water (1.00 L) at 0 °C. The precipitated solid was collected by filtration, the filter cake was washed with water (100 mL) and ethanol (50 mL). The solid was further dried under vacuum to give 1-(3-methoxy-2-nitrophenyl) ethanone (30 g) as a yellow solid which was used directly in the next step. LCMS: MH+ 196.
Step 2: 1-(2-amino-3-methoxyphenyl)ethanone
To a stirred solution of 1-(3-methoxy-2-nitrophenyl)ethanone (27.0 g, 138 mmol) and Zn (27.1 g, 415 mmol) in EtOH (270 mL) was added AcOH (55.5 mL) dropwise at room temperature. The resulting mixture was stirred for 2 h at 80 °C. The precipitated solids were collected by filtration and washed with MeOH (50 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1 :3) to afford 1-(2-amino-3-methoxyphenyl)ethanone (23 g) as a yellow solid which was used directly in the next step. LCMS: MH+ 166.
Step 3: N-(2-acetyl-6-methoxyphenyl)-2, 2, 2-trichloroacetamide
To a stirred solution of 1-(2-amino-3-methoxyphenyl)ethanone (22.0 g, 139 mmol) in DCM (34.0 mL) was added trichloroacetyl chloride (20.0 mL, 161 mmol) dropwise at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The reaction was quenched with aq. HCI (1 N) at 0 °C. The mixture was neutralized to pH 7 with saturated NaHCO3. The aqueous layer was extracted with DCM (3 x 200 mL). The resulting mixture was concentrated under reduced pressure. This resulted in N-(2-acetyl-6-methoxyphenyl)-2,2,2- trichloroacetamide (35 g) as a yellow solid which was used directly in the next step. LCMS: MH+ 310.
Step 4: 8-methoxy-4-methyl-1H-quinazolin-2-one
A stirred solution of N-(2-acetyl-6-methoxyphenyl)-2, 2, 2-trichloroacetamide (34.5 g, 111 mmol) in MeOH (324 mL) had ammonium carbamate (43.4 g, 555 mmol) added at room temperature. The resulting mixture was stirred for overnight at 40 °C. The resulting mixture was filtered; the filter cake was washed with MeOH (2 x 50 mL). The filtrate was concentrated
under reduced pressure. The residue was purified by trituration with tert-butyl methyl ether (50 mL). This resulted in 8-methoxy-4-methyl-1 H-quinazolin-2-one (16 g) as a reddish brown solid which was used directly in the next step. LCMS: MH+ 191.
Step 5: 2-chloro-7-methoxy-4-methylquinazoline
A stirred solution of 8-methoxy-4-methyl-1 H-quinazolin-2-one (10.0 g, 52.6 mmol) in phosphorus oxychloride (30 mL) at 0 °C was stirred for 3 h at 60 °C. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL) and water (200 mL). The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 :1) to afford 2- chloro-7-methoxy-4-methylquinazoline (4 g, 36%) as a yellow solid. LCMS: MH+ 209.
Step 6: N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide
To a stirred solution of 2-chloro-8-methoxy-4-methylquinazoline (2.80 g, 13.4 mmol, 1.00 eq.) and cyanamide, monosodium salt (1.29 g, 20.1 mmol, 1.50 equiv) in NMP (15 mL) at room temperature. The resulting mixture was stirred for overnight at 60 °C. The residue was purified by reversed-phase flash chromatography (C18, MeCN in Water (0.1 % FA), 10 % to 100 % gradient) This resulted in N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide (1.10 g, 38%) as a grey solid. 1H NMR (400 MHz, DMSO-d6) 7.48 - 7.42 (m, 1 H), 7.12 - 6.95 (m, 2H), 3.87 (s, 3H), 2.58 (s, 3H). LCMS: MH+ 215.
Step 7: 1-(8-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
To a stirred mixture of N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide (200 mg, 0.93 mmol) in dimethylformamide (2.0 mL) was added 1-methylpiperidin-4-amine (128 mg, 1.12 mmol) at room temperature. The resulting mixture was stirred for overnight at 120 °C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC to afford 1-(8-methoxy-4-methylquinazolin-2-yl)-3-(1-methylpiperidin-4- yl)guanidine (14 mg, 3%) as a green solid TFA salt. 1H NMR (400 MHz, DMSO-d6) δ 11.48 (br, 1 H), 8.31 (s, 2H), 8.08 (d, J= 8.8 Hz, 1 H), 7.18 - 7.14 (m, 2H), 3.94 (s, 3H), 3.85 (s, 1 H), 2.79 (s, 3H), 2.72 - 2.69 (m, 2H), 2.21 (s, 3H), 2.19 - 2.13 (m, 2H), 1.91 - 1.89 (m, 2H), 1.64 - 1 .60 (m, 2H). LCMSm: Rt 6.62 min, MH+ 329.
Example 50 1 -(6-Methoxy-4-methylquinazolin-2-yl)-3-(1 -methylpiperidin-4- yl)guanidine
Step 1: 1 -(2-amino-5-methoxyphenyl)ethan-1 -one hydrochloride
To a stirred solution of 2-bromo-4-methoxyaniline (20.0 g, 99.9 mmol) and (1- butoxyethenyl)tributylstannane (116 g, 297 mmol) in toluene (200 mL) was added Pd(PPh3)2CI2 (6.95 g, 9.90 mmol) in portions under nitrogen atmosphere. The resulting mixture was stirred for overnight at 100 °C under nitrogen atmosphere. The reaction was quenched with sat. HCI (aq.) and sat. KF (aq.) at 0 °C. The precipitated solids were collected by filtration and washed with EtOAc (3 x 10 mL). The resulting mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1 :1) to afford 1-(2-amino-5-methoxyphenyl) ethanone as a brown solid. The product was treated with 4 N HCI in 1 ,4-dioxane (25 mL) and stirred for 30 mins at room temperature. The precipitated solids were collected by filtration and washed with MTBE (3 x 10 mL). This result in 1-(2-amino-5-methoxyphenyl)ethan-1-one hydrochloride (5.0 g, 25%). LCMS: MH+ 166.
Step 2: N-(6-methoxy-4-methylquinazolin-2-yl)cyanamide
To a stirred solution of 1-(2-amino-5-methoxyphenyl)ethanone hydrochloride (5.00 g, 24.8 mmol) in ethyl alcohol (50.0 mL) was added sodium dicyanoazanide (4.42 g, 49.6 mmol) in portions. The resulting mixture was stirred for 4 h at 80 °C. The precipitated solid was collected by filtration, the filter cake was washed with EtOH, water and Et20. The solid was further dried under vacuum to give N-(6-methoxy-4-methylquinazolin-2-yl)cyanamide (3.00 g, 56%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.78 (br, 1 H), 5 7.50 (dd, J = 9.1 , 2.6 Hz, 1 H), 7.45 - 7.36 (m, 2H), 3.88 (s, 3H), 2.80 (s, 3H). LCMS: MH+ 215.
Step 3: 1-(6-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
To a stirred solution of N-(6-methoxy-4-methylquinazolin-2-yl)cyanamide (200 mg, 0.934 mmol) in DMF (2.0 mL) was added 1-methylpiperidin-4-amine (160 mg, 1.40 mmol) at room temperature. The resulting mixture was stirred for overnight at 120 °C. The reaction was monitored by LCMS. The crude product was purified by Prep-HPLCn to afford 1-(6-methoxy- 4-methylquinazolin-2-yl)-3-(1-methylpiperidin-4-yl)guanidine (156 mg, 39.7 %) as a brown solid formic acid salt. 1H NMR (400 MHz, DMSO-d6, mix of rotamers) δ 11.10 (br, 0.8H), 9.58 (br, 0.2H), 8.66 (s, 2H), 7.67 (d, J = 9.2 Hz, 1 H), 7.48 - 7.46 (m, 1 H), 7.17 (d, J = 2.7 Hz, 1 H), 4.17 (br, 1 H), 3.94 (s, 3H), 3.30 (br, 2H), 2.87 (s, 4H), 2.64 - 2.62 (m, 4H), 2.41 - 2.30 (m, 2H), 2.07 - 2.00 (m, 2H). LCMS0: Rt 1.38 min, MH+ 329.
Example 51 1 -(5-Methoxy-4-methylquinazolin-2-yl)-3-(1 -methylpiperidin-4- yl)guanidine
Step 1: 1 -(2-amino-6-methoxyphenyl)ethan-1 -one hydrochloride
To a stirred solution of 2-bromo-3-methoxyaniline (20.0 g, 99.1 mmol) and (1- butoxyethenyl)tributylstannane (57.8 g, 149 mmol) in toluene (200 mL) was added Pd(PPhs)4 (11.4 g, 9.91 mmol) in portions under nitrogen atmosphere. The resulting mixture was stirred for overnight at 100 °C under nitrogen atmosphere. The reaction was quenched with sat. HCI (aq.) and sat. KF (aq.) at 0 °C. The precipitated solids were collected by filtration and washed with EtOAc (3 x 10 mL). The resulting mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with NaCI (aq.) (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 :1) to afford a brown solid which was further treated with 4 N HCI in 1 ,4-dioxane (25 mL), The precipitated solids were collected by filtration and washed with MTBE (3 x 10 mL). The filter cake was dried under vacuum to give 1-(2-amino-6-methoxyphenyl)ethanone hydrochloride (2.46 g, 15%). LCMS: MH+ 166.
Step 2: N-(5-methoxy-4-methylquinazolin-2-yl)cyanamide
To a stirred solution of 1-(2-amino-6-methoxyphenyl)ethanone hydrochloride (2.46 g, 12.2 mmol) in ethyl alcohol (24.0 mL) was added sodium dicyanoazanide (1.63 g, 18.3 mmol). The resulting mixture was stirred for 4 h at 80 °C. The precipitated solid was collected by filtration, the filter cake was washed with EtOH, water and Et20. The solid was further dried under vacuum to give N-(5-methoxy-4-methylquinazolin-2-yl)cyanamide (1.20 g, 46%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1 H), δ 7.74 (m, 1 H), 7.27 - 6.75 (m, 2H), 3.96 (s, 3H), 2.84 (s, 3H). LCMS: MH+ 215.
Step 3: 1-(5-Methoxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
To a stirred solution of N-(5-methoxy-4-methylquinazolin-2-yl)cyanamide (200 mg, 0.93 mmol) in DMSO (4.00 mL) was added 1-methylpiperidin-4-amine (117 mg, 1.03 mmol). The reaction mixture was irradiated with microwave radiation for 20 min at 160 °C. The crude product was purified by Prep-HPLC0 to afford 1-(5-Methoxy-4-methylquinazolin-2-yl)-3-(1- methylpiperidin-4-yl)guanidine (120 mg, 28%) as a brown formic acid solid salt. 1H NMR (400 MHz, DMSO-d6, mix of roatmers) δ 10.55 (br, 0.5H), 8.32 (s, 2.5H), 7.82 (t, J = 8.2 Hz, 1 H), 7.36 (d, J = 8.3 Hz, 1 H), 7.03 (d, J = 8.1 Hz, 1 H), 3.98 (s, 3H), 3.71 (s, 1 H), 2.93 (s,
3H), 2.79 (d, J = 10.7 Hz, 2H), 2.27 (s, 3H), 2.16 - 2.00 (m, 2H), 1.95 - 1.93 (m, 2H), 1.68 - 1 .66 (m, 2H). LCMSP: Rt 3.51 min, MH+ 329.
By analogous method to Example 39. Afforded 1-((1-methyl-1 H-imidazol-4-yl)methyl)-3-(4- methylquinazolin-2-yl)guanidine (39 mg, 10%) as a red liquid formic acid salt. 1H NMR (400 MHz, Chloroform-d) δ 11.85 (br, 1 H), 5 10.61 (br, 1 H), 9.34 (br, 1 H), 8.72 (s, 1 H), 8.01 (d, J = 8.4 Hz, 1 H), 7.78 - 7.74 (m, 2H), 7.58 - 7.35 (m, 2H), 6.99 (s, 1 H), 4.42 (s, 2H), 3.70 (s, 3H), 2.92 (s, 3H). LCMSj: Rt 6.43 min, MH+ 296.
Intermediate 1 (100 mg, 0.54 mmol) in DMSO (2 mL) was treated with (5- aminopentyl)dimethylamine (126 μL, 0.82 mmol) for 5 min at room temperature. The final reaction mixture was irradiated with microwave radiation for 20 min at 160 °C. The resulting mixture was purified by Prep-HPLCS to afford 1-(5-(dimethylamino)pentyl)-3-(4- methylquinazolin-2-yl)guanidine (25 mg, 10%) as a red oil TFA salt. 1H NMR (400 MHz, CDCh) δ 10.4 - 10.3 (m, 2H), 8.63 - 8.45 (m, 1 H), 7.98 - 7.96 (m, 1 H), 7.79 - 7.83 (m, 1 H), 7.56 - 7.49 (m, 1 H), 7.46 - 7.38 (m, 1 H), 3.48 - 3.26 (m, 2H), 3.21 - 3.08 (m, 2H), 2.88 - 2.81 (m, 9H), 1.89 - 1.77 (m, 4H), 1.58 - 1.56 (m, 2H). LCMS‘: Rt 3.22 min, MH+315.
Intermediate 3 (150 mg, 0.75 mmol) in DSMO (1.5 mL) had acetic anhydride (92 mg, 0.89 mmol) added. The resulting mixture was stirred for overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLCb to afford N-(amino((4-methylquinazolin-2-yl) amino) methylene) acetamide (17.4 mg, 10 %) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.81 - 9.02 (m, 3H), 8.22
- 8.07 (m, 1 H), 7.96 - 7.79 (m, 2H), 7.54 (apparent t, J = 7.5 Hz, 1H), 2.86 (s, 3H), 2.12 (s, 3H). LCMSb: Rt 0.87 min, MH+ 244.
Examples 55-96
Each of Examples 55-96 can be synthesised by way of the methods described in General Schemes 1 to 4.
Example 97 1 -(4-Methoxyquinazolin-2-yl)-3-(1 -methylpiperidin-4-yl)guanidine
Step 1: 2-aminobenzoic acid
To a stirred solution of 2-nitrobenzoic acid (3.00 g, 18.0 mmol) in EtOH (30 mL) was added Pd/C (3.0 g, 10% wt). The mixture was stirred for overnight under hydrogen atmosphere. The resulting mixture was filtered; the filter cake was washed with MeOH (3 x 30 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 :1) to afford 2-aminobenzoic acid (2.1 g, 85%) as a yellow oil. LCMS: MH+ 138.
Step 2: N'-cyano-N-(1-methylpiperidin-4-yl)guanidine
To a stirred solution of sodium dicyanamide (10.0 g, 112 mmol) and 1-methylpiperidin-4- amine (12.1 g, 106 mmol) in n-BuOH (100 mL) was added cone. HCI (9.6 mL) dropwise at room temperature. The resulting mixture was stirred overnight at 110 °C. The resulting mixture was filtered; the filter cake was washed with water (3 x 10 mL). The filtrate was dried under vacuum. The resulting /V'-cyano-/V-(1-methylpiperidin-4-yl) guanidine (9.2 g, 45%) was used for the next step without further purification.
Step 3: 1-( 1-methylpiperidin-4-yl)-3-(4-oxo- 1, 4-dihydroquinazolin-2-yl)guanidine
To a stirred solution of A/'-cyano-N-(1-methylpiperidin-4-yl)guanidine (4.00 g, 22.1 mmol) and 2-aminobenzoic acid (1.01 g, 7.35 mmol) in H2SO4 (10% wt in H2O, 8.0 mL) at room temperature. The resulting mixture was stirred for 20 min at 100 °C. The reaction was quenched with sat. NaHCO3 (aq.) at room temperature. The resulting mixture was filtered. The filter cake was washed with EtOH and dried under vacuum to afford 1-(4- chloroquinazolin-2-yl)-3-(1-methylpiperidin-4-yl)guanidine (1.9 g, 85 %) as a yellow solid. LCMS: MH+ 301
Step 4: 1-(4-chloroquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
A solution of N-(1-methylpiperidin-4-yl)-A/'-(4-oxo-1 H-quinazolin-2-yl)guanidine (300 mg, 0.99 mmol) in POCI3 (3.0 mL, 32.2 mmol) was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with water (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The organic phases were combined and dried under Na2SO4. filtered, and concentrated under reduced pressure to afford crude 1-(4-chloroquinazolin-2-yl)-3-(1-methylpiperidin-4- yl)guanidine (200 mg) as a yellow oil which was used for the next step without purification. Step 5: 1-(4-Methoxyquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine
A solution of /V'-(4-chloroquinazolin-2-yl)-/V-(1-methylpiperidin-4-yl)guanidine (100 mg, 0.31 mmol) and MeONa (20.3 mg, 0.37 mmol) in MeOH (12.1 mL) was stirred at room temperature for 2 h. The mixture was neutralized to pH 7 with aq. HCI (1 N). The resulting mixture was directly concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC‘ to afford 1-(4-methoxyquinazolin-2-yl)-3-(1-methylpiperidin-4-yl)guanidine (22 mg, 18 %) as a colorless oil formate salt. 1H NMR (400 MHz, Chloroform-d) δ 11.4 - 9.10 (br, 2H), 8.67 (s, 1 H), 8.04 (d, J = 8.1 Hz, 1 H), 7.78-7.76 (m, 1 H), 7.68 - 7.62 (m, 1 H), 7.43 (t, J = 7.6 Hz, 1 H), 4.40 - 4.21 (m, 1 H), 4.19 (s, 3H), 3.68 (d, J = 10.8 Hz, 3H), 3.40 - 3.18 (m, 2H), 2.70 - 2.51 (m, 2H), 2.38 - 2.22 (m, 2H), 2.13 - 1.95 (m, 2H). LCMSU: Rt 0.883 min, MH+ 315.
Step 1: N-(8-hydroxy-4-methylquinazolin-2-yl)cyanamide
To a solution of N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide (300 mg, 1.40 mmol) in DCE (3.00 mL) at 0 °C was added a 1 M solution of BBr3 in DCM (2.94 mL, 2.94 mmol) dropwise. The mixture was stirred for 2 h at 80 °C. The mixture was allowed to cool down to room temperature. The reaction was quenched by the addition of water/ice (5.00 mL) at 0 °C. The resulting mixture was concentrated under vacuum. The residue was purified by Prep-HPLCW to afford the title compound (80.0 mg, 28.6%) as a brown solid. LCMS: MH+ 201.
Step 2: 1-(8-hydroxy-4-methylquinazolin-2-yl)-3-(1-methylpiperidin-4-yl) guanidine
A mixture of N-(8-hydroxy-4-methylquinazolin-2-yl) cyanamide (80.0 mg, 0.400 mmol) and 1-methylpiperidin-4-amine (300 uL, 2.40 mmol) in DMSO (1.00 mL) was stirred for 5 min at room temperature. The reaction mixture was irradiated with microwave radiation for 1 h at 160 °C. The mixture was allowed to cool down to room temperature. The solution was purified by Prep-HPLCX to afford the title compound (22.4 mg, 17.5%) as a brown oil. 1H- NMR (400 MHz, Methanol-d4) δ 7.74 - 7.63 (m, 1 H), 7.52 - 7.42 (m, 1 H), 7.39 - 7.30 (m, 1 H), 4.29 - 4.00 (m, 1 H), 3.72 - 3.64 (m, 1 H), 3.61 - 3.54 (m, 1 H), 3.30 - 3.20 (m, 2H), 3.00 - 2.87 (m, 6H), 2.48 - 2.30 (m, 2H), 2.29 - 1.99 (m, 2H). LCMSZ: Rt 0.452 min; MH+ 315.
To a solution of Example 48 (100 mg, 0.304 mmol) in DCE (1.00 mL) was added a 1 M solution of BBrs in DCM (1.82 ml, 1.82 mmol) dropwise at 0 °C. The resulting mixture was stirred overnight at 80 °C. The mixture was allowed to cool down to room temperature and quenched by the addition of water/lce (10.0 mL) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLCY to afford the title compound (18.6 mg, 19.4%) as a white solid.1H NMR (400 MHz, Methanol-cL) δ 7.77 (d, J = 9.2 Hz, 1 H), 6.87 - 6.76 (m, 1 H), 6.54 (s, 1 H), 3.75 (s, 1 H), 2.82 (s, 2H), 2.68 (s, 3H), 2.33 (s, 5H), 2.11 - 2.01 (m, 2H), 1.68 (d, J = 11.6 Hz, 2H). LCMSAA: Rt 0.691 min; MH+ 315.
By an analogous method to that described in Example 99 using Example 50 (60.0 mg, 0.183 mmol). Purification by Prep-HPLCR afforded title compound (12.3 mg, 16.7 %) as a reddish brown formate salt. 1H NMR (400 MHz, Methanol-d4) δ 8.48 (br, 2H), 7.76 (d, J = 9.0 Hz, 1 H), 7.56 - 7.49 (m, 1 H), 7.38 (d, J = 2.Q Hz, 1 H), 3.84 (s, 1 H), 3.29 - 3.18 (m, 2H), 2.85 (s, 3H), 2.80 - 2.70 (m, 2H), 2.64 (s, 3H), 2.29 - 2.14 (m, 2H), 1.98 - 1.84 (m, 2H). LCMSB: Rt 0.586 min, MH+ 315.
By an analogous method to that described in Example 99 using Example 51 (150 mg, 0.457 mmol). Purification by Prep-HPLCZ afforded title compound (17.6 mg, 9.0%) as a reddish brown trifluoroacetate salt. 1H NMR (400 MHz, Methanol-^) δ 7.69 (t, J = 8.1 Hz, 1 H), 7.27 (d, J = 8.2 Hz, 1 H), 6.92 (dd, J = 8.0, 1.0 Hz, 1 H), 3.95 (s, 1 H), 3.68 (d, J = 12.8 Hz, 2H), 3.15 (t, J = 12.9 Hz, 2H), 3.07 (s, 3H), 2.94 (s, 3H), 2.44 - 1.91 (m, 4H). LCMSB, Rt 0.547 min, MH+ 315.
To a solution of N-(4-methylquinazolin-2-yl) cyanamide (200 mg, 1.09 mmol) in DMSO (4.00 mL) was added A/,1-dimethylpiperidin-4-amine (209 mg, 1.63 mmol). The mixture was irradiated with microwave radiation for 30 min at 160 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep-HPLC^ to afford the title compound (110 mg, 32.4%) as a red solid. 1H NMR (400 MHz, Chloroform-d) δ 8.12 - 7.76 (m, 3H), 7.73 - 7.46 (m, 2H), 7.30 - 7.29 (m, 1 H), 4.86 (s, 1 H), 3.10 - 2.91 (m, 5H), 2.86 (s, 3H), 2.33 (s, 3H), 2.30 - 2.20 (m, 2H), 1.94 - 1.82 (m, 2H), 1.80 - 1.71 (m, 2H). LCMSAC: Rt 1.213 min, MH+ 313.
Example 103 N-((methyl(1-methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)acetamide
To a solution of Example 102 (100 mg, 0.320 mmol) in DMSO (3.0 mL) was added acetic anhydride (32.7 mg, 0.320 mmol). The mixture was stirred for 8 h at 60 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep-HPLCAB to afford the title compound (40 mg, 35.4%) as an orange solid. 1H NMR (400 MHz, DMSO-cfe)
6 12.51 (br, 1 H), 7.98 - 7.96 (d, J = 8.0 Hz, 1 H), 7.77 - 7.70 (m, 1 H), 7.70 - 7.68 (m, 1 H),
7.52 - 7.40 (m, 1 H), 4.65 (br, 1 H), 3.19 - 3.00 (m, 5H), 2.92 (s, 3H), 2.51 - 2.29 (m, 5H), 2.18 - 2.02 (m, 5H), 2.00 - 1.89 (m, 2H). LCMSAD: Rt 0.977 min, MH+ 355.
To a mixture of N-(4-methylquinazolin-2-yl) cyanamide (200 mg, 1.18 mmol) in DMSO (2.00 mL) was added (6-aminohexyl)dimethylamine (188 mg, 1.30 mmol). The mixture was irradiated with microwave radiation for 30 min at 160 °C. The mixture was allowed to cool down to room temperature and purified by Prep-HPLCAC to afford the title compound (63.0 mg, 11.8%) as an orange trifluoroacetate salt. 1H NMR (400 MHz, Chloroform-d) δ 11.61 (s, 1 H), 10.05 (s, 1 H), 7.99 (d, J = 8.3 Hz, 1 H), 7.83 (t, J = 7.6 Hz, 1 H), 7.72 (d, J = 8.3 Hz, 1 H),
7.51 (t, J = 7.6 Hz, 1 H), 3.41 (d, J = 7.4 Hz, 2H), 3.07 (s, 2H), 2.92 - 2.79 (m, 9H), 2.01 - 1 .79 (m, 4H), 1.76 - 1.48 (m, 4H). LCMSAE: Rt 0.645 min, MH+ 329.
To a solution of Example 8 (180 mg, 0.629 mmol) in DMSO (1.5 mL) was added AC2O (64.2 mg, 0.629 mmol) dropwise at 0 °C. The resulting mixture was stirred for 3 h at room temperature. The mixture was purified by Prep-HPLCAD directly to afford the title compound (55 mg, 26.7%) as a yellow solid. 1H NMR (400 MHz, Methanol-d4) δ 8.13 (dd, J = 8.5, 4.8 Hz, 1 H), 7.97 - 7.65 (m, 2H), 7.62 - 7.45 (m, 1 H), 3.82 - 3.60 (m, 2H), 3.25 - 3.02 (m, 2H), 3.00 - 2.60 (m, 9H), 2.33 (d, J = 2.7 Hz, 2H), 2.22 - 1.89 (m, 3H); LCMS°: Rt 0.807 min, MH+ 329.1.
Step 1: N-(8-methoxy-4-methylquinazolin-2-yl)cyanamide
To a solution of 1-(2-amino-3-methoxyphenyl)ethan-1-one hydrochloride (1.12 g, 5.55 mmol) in EtOH (12.0 mL) was added 1 M HCI (4.0 mL). The reaction mixture was stirred for 2 min and then followed by the addition of sodium dicyanamide (1.24 g, 13.9 mmol). The resulting mixture was stirred for additional 1 h at 80 °C. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLCW to afford the title compound (490 mg, 40.8%) as a light-yellow solid. LCMS: MH+ 215.
Step 2: N-(8-hydroxy-4-methylquinazolin-2-yl)cyanamide
To a solution of N-(8-methoxy-4-methylquinazolin-2-yl) cyanamide (300 mg, 1.40 mmol) in DCM (3.0 mL) was added 1 M BBrs in DCM (2.80 mL, 2.80 mmol). The resulting mixture was stirred for additional 2 h at room temperature. The reaction was quenched by the addition of water/lce (30 mL) and extracted with EtOAc (3 x 40 mL). The combined organic layers were washed with brine (3 x 5 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLCW to afford the title compound (90.0 mg, 32.1%) as a yellow solid. LCMS: MH+ 201.
Step 3: 1-(3-(dimethylamino)propyl)-3-(8-hydroxy-4-methylquinazolin-2-yl)guanidine
To a solution of N-(8-hydroxy-4-methylquinazolin-2-yl) cyanamide (70.0 mg, 0.350 mmol) in DMSO (1.50 mL) was added dimethylaminopropylamine (66.0 μL, 0.525 mmol). The reaction mixture was irradiated with microwave radiation for 1 h at 160 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep-HPLCAE to afford the title compound (4.7 mg, 4.45%) as a yellow solid. 1HNMR (400 MHz, Chloroform - d) δ 7.37 (d, J = 7.8 Hz, 1 H), 7.21 - 7.10 (m, 2H), 3.41- 3.38 (m, 2H), 2.81 (s, 3H), 2.40 (t, J = 5.9 Hz, 2H), 2.25 (s, 6H), 1.80 -1 .70 (m, 2H). LCMSAF: Rt 0.479 min, 303 [M+H]+
To a solution of N-(8-hydroxy-4-methylquinazolin-2-yl) cyanamide (130 mg, 0.649 mmol) in DMSO (1.5 mL) was added 3-morpholinopropan-1-amine (112 mg, 0.779 mmol). The reaction mixture was irradiated with microwave radiation for 30 min at 160 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep- HPLCAI to afford the title compound (91 mg, 40.7%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.71 (br, 1 H), 7.42 - 7.38 (m, 1 H), 7.13 - 7.00 (m, 2H), 3.63 - 3.54 (m, 4H), 3.30 - 3.28 (m, 2H), 2.68 (s, 3H), 2.39 - 2.19 (m, 6H), 1.78 - 1.58 (m, 2H). LCMSN: Rt 0.672 min, 345.
Step 1: 1-(4-fluoro-3-methoxy-2-nitrophenyl) ethenone
To a solution of 1-(4-fluoro-3-methoxyphenyl) ethanone (4.00 g, 23.8 mmol) in AC2O (45.0 mL) was added cupric nitrate (72.5 mg, 0.386 mmol). The reaction mixture was stirred for 30 min at 0 °C. The reaction mixture was quenched by the addition of water (10 mL) and extracted with EtOAc (10 mLx3). The combined organic phases were washed with brine, dried over Na2SC>4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (6:1) to afford the title compound (2.70 g, 53.3%) as a light-yellow solid. LCMS: MH+ 214.
Step 2 : 1-(2-amino-4-fluoro-3-methoxyphenyl) ethanone
To a solution of 1-(4-fluoro-3-methoxy-2-nitrophenyl) ethanone (2.79 g, 13.1 mmol) in the mixture of EtOH (20.0 mL), THF (20.0 mL) and H2O (10.0 mL) were added Fe (2.93 g, 52.4 mmol) and NH4CI (1.40 g, 26.2 mmol). The resulting mixture was stirred for 2 h at 60 °C. The mixture was allowed to cool down to room temperature. The mixture was filtered through a short pad of Celite. The pad was washed with EtOH (10 mL). The combined filtered was concentrated under reduce pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (6:1) to afford the title compound (890 mg, 37.1 %) as a light-yellow oil. LCMS: MH+ 184.
Step 3 : [(7-fluoro-8-methoxy-4-methylquinazolin-2-yl) amino] formonitrile
To a solution of 1-(2-amino-4-fluoro-3-methoxyphenyl) ethanone (440 mg, 2.40 mmol) in 1 ,4-dioxane (4.0 mL) was added 4 M HCI in 1 ,4-dioxane (1 .0 mL). The resulting mixture was stirred for 10 min at room temperature and concentrated under reduce pressure. The residue was dissolved in EtOH (5.0 mL) and followed by the addition of sodium dicyanoazanide (428 mg, 4.80 mmol). The resulting mixture was stirred for additional 2 h at 80 °C and followed by the addition of 2nd batch of 4 M HCI in 1 ,4-dioxane (1.0 mL). The reaction mixture was stirred for additional 30 min at 80 °C. The mixture was allowed to cool down to room temperature. The reaction mixture was neutralized to pH ~7 with aq. NaHCOs. The resulting mixture was extracted with EtOAc (30 mLx3). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (7:1) to afford the title compound (253 mg, 45.36%) as a yellow solid. LCMS: MH+ 233. Step 4 : [(7-fluoro-8-hydroxy-4-methylquinazolin-2-yl) amino] formonitrile
To a solution of [(7-fluoro-8-methoxy-4-methylquinazolin-2-yl) amino] formonitrile (190 mg, 0.818 mmol) in DCM (0.5 mL) was added 1 M BBr2 in DCM (2.0 mL). The resulting mixture was stirred for additional 1 h at 40 °C. The mixture was allowed to cool down to room temperature and concentrated under reduced pressure. The residue was purified by Prep- HPLCw to afford the title compound (28 mg, 15.7%) as a yellow solid. LCMS: MH+ 219. Step 5 : 1-(7-fluoro-8-hydroxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine To a solution of [(7-fluoro-8-hydroxy-4-methylquinazolin-2-yl) amino] formonitrile (21.0 mg, 0.096 mmol, 1.00 eq.) in DMSO (0.5 mL) was added 1-methylpiperidin-4-amine (16.5 mg, 0.144 mmol, 1 .50 eq.). The reaction mixture was irradiated with microwave radiation for 30 min at 160 °C. The residue was purified Prep-HPLCAF to afford the title compound (8.8 mg, 27.51 %) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.65 (br, 2H), 7.48 - 7.38 (m, 1 H), 7.21 - 7.07 (m, 1 H), 3.75 (s, 1 H), 2.68 (s, 5H), 2.17 (s, 3H), 2.07 - 1.95 (m, 2H), 1.90 - 1 .80 (m, 2H), 1.54 - 1.37 (m, 2H). LCMSN: Rt 0.647 min MH+ 333.
Step 1 : 2-bromo-4-fluoro-6-methoxyaniline
To a solution of 4-fluoro-2-methoxyaniline (30.0 g, 212 mmol) in DCM (500 mL) was added NBS (41.6 g, 234 mmol) in portions at -78 °C. The resulting mixture was stirred for 2 h at - 78 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (9:1) to afford the title compound (15.0 g, 32.2%) as a red oil. LCMS: MH+ 222.
Step 2 : 1-(2-amino-5-fluoro-3-methoxyphenyl) ethanone
To a solution of 2-bromo-4-fluoro-6-methoxyaniline (15.0 g, 68.2 mmo) and tributyl(1- ethoxyethenyl) stannane (49.2 g, 136 mmol) in toluene (225 mL) were added Pd(dppf)Cl2.CH2Cl2 (5.55 g, 6.82 mmol) in portions at room temperature. The resulting mixture was stirred for 1 h at 100 °C under nitrogen atmosphere. The reaction was allowed to cool down to room temperature and quenched by the addition of 1 M aq. HCI (225 mL). The resulting mixture was extracted with EtOAc (1.0 Lx3). The combined organic phases were washed with brine (600 mLx3), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLCW to afford the title compound (4.5 g, 36.0%) as a yellow solid. LCMS: MH+ 184.
Step 3 : [(6-fluoro-8-methoxy-4-methylquinazolin-2-yl) amino] formonitrile
To a solution of 1-(2-amino-5-fluoro-3-methoxyphenyl) ethanone (1.00 g, 5.45 mmol) in 1 ,4- dixoane (5.0 mL) was added 4 M HCI in 1 ,4-dioxane (5.00 mL). The reaction mixture was stirred for 30 min at 0 °C. The precipitated solids were collected by filtration, the filter cake was washed with MTBE (50 mLx3) and redissolved in EtOH (10.0 mL). To the above mixture was added sodium dicyanamide (0.97 g, 10.9 mmol). The resulting mixture was stirred for additional 3 h at 80 °C. The resulting mixture was concentrated under reduced pressure. The residue was further purified by trituration with MTBE (50.0 mL) to afford the title compound (1.0 g, crude) as an off-white solid, which was used for the next step without purification. LCMS: MH+ 233.
Step 4 : [(6-fluoro-8-hydroxy-4-methylquinazolin-2-yl)amino]formonitrile
To a solution of [(6-fluoro-8-methoxy-4-methylquinazolin-2-yl)amino]formonitrile (900 mg, 3.88 mmol) in DCM (18.0 mL) was added 1 M BBr3 in DCM (7.76 mL, 7.76 mmol) dropwise at 0 °C .The resulting mixture was stirred for 2 h at 0 °C. The mixture was neutralized to pH ~10 with sat. NaHCO3 (aq.). The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLCW to afford the title compound (300 mg, 35.5%) as an off-white solid. LCMS: MH+ 219.
Step 5 : 1-(6-fluoro-8-hydroxy-4-methylquinazolin-2-yl)-3-( 1-methylpiperidin-4-yl)guanidine To a solution of [(6-fluoro-8-hydroxy-4-methylquinazolin-2-yl) amino] formonitrile (100 mg, 0.458 mmol, 1.0 eq.) in DMSO (2.0 mL) was added 1-methylpiperidin-4-amine (105 mg, 0.916 mmol, 2.0 eq.) at room temperature. The mixture was irradiated with microwave radiation for 30 min at 160 °C. The mixture was allowed to cool down to room temperature. The mixture was purified by Prep-HPLCAG to afford the title compound (10.3 mg, 6.7%) as a yellow solid. 1H NMR (300 MHz, Methanol-d4) δ 6.83 - 6.74 (m, 2H), 3.65 (br, 1 H), 3.05 - 2.58 (m, 5H), 2.49 - 2.13 (m, 5H), 2.12 - 1.90 (m, 2H), 1.89 -1.40 (m, 2H), LCMSN: Rt 0.879 min, MH+ 333.
Example 110 N-((( 1 -methylpiperidin-4-yl)amino)((4-methylquinazolin-2- yl)amino)methylene)pivalamide
To a solution of Example 3 (100 mg, 0.335 mmol) in DCM (1.0 mL) was added Et3N (116 μL, 0.838 mmol) and 2,2-dimethylpropanoyl chloride (45.4 μL, 0.369 mmol) at 0 °C. The resulting mixture was stirred for additional 1 h at 0 °C. The resulting mixture was diluted with H2O (2.0 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLCAH to afford the title compound (43.8 mg, 34.2%) as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 14.20 (s, 0.7H), 13.11 (s, 0.3H), 10.25 (s, 0.3H), 9.07 (s, 0.7H), 7.99 - 7.95 (m, 1 H), 7.81 - 7.65 (m, 2H), 7.48 - 7.36 (1 H), 4.43 (s, 0.7H), 4.18 (s, 0.3H), 2.90 (s, 2H), 2.84 (s, 1 H), 2.80 (br s, 2H), 2.38 - 2.34 (m, 5H), 2.14 - 2.10 (m, 2H), 1.75 - 1.70 (m, 2H), 1.39 (s, 6H), 1.25 (s, 3H). Rotamers observed. LCMSG: Rt 0.659 min MH+ 383.
Examples 111-138
Each of Examples 111-138 can be synthesised by way of the methods described in General Schemes 1 to 4.
BIOLOGY
Assays
Luciferase read-through assay
The read-through activity of compounds was assessed using the ADXC8 luciferase reporter cell line (generated as described in McElroy et al. PLoS Biology (2013), 11 , e1001593). Active compounds promote translational read-through of the R223X stop codon in the mutated luciferase gene which leads to generation of full-length luciferase in the compound- treated cells. The amount of luciferase is measured by adding a lysis buffer containing luciferin substrate and detecting luminescence using one of the following protocols: Protocol A
ADXC8 cells in assay media (DMEM+10% FBS) were seeded into 96-well tissue culture treated white plates (Greiner) to a density of 13,000 cells per well and incubated for 24 hours at 37 °C in an atmosphere of 5% CO2. Compounds were solubilised in DMSO at a top concentration of 10 mM, serially diluted with assay media to 25 times final concentration and added to the plate to achieve a range of final concentrations of 100 pM to 0.045 pM in a final volume of 100 μL. Plates were incubated for a further 24 hours at 37 °C in an atmosphere of 5% CO2. Cells treated with 200 pM G418 (with 1% DMSO) were used as a positive control.
Cell viability and firefly luciferase activity were measured in the same assay wells. CellTiter- Fluor™ reagent was prepared as per manufacturer’s instructions (Promega E7120) and 20 pl of 5X CellTiter-Fluor™ reagent was added to all wells, briefly mixed by orbital shaking (300-500 rpm for ~30 seconds) and the plates incubated for 30-45 minutes at 37 °C in an atmosphere of 5% CO2. Cell viability was measured by monitoring fluorescence on a CLARIOstar® plate reader (BMG Labtech). Cells containing 1% DMSO were used as a positive control and cells without addition of reagent was used as a negative control to define 100 and 0% respectively. ONE-Glo™ luciferase assay buffer (Promega E7120) was prepared according to manufacturer’s instructions and 100 pl of luciferase reagent was added to each well and the plate incubated at RT for 3 mins before measuring the luminescence on the CLARIOstar® plate reader (BMG Labtech). Cells treated with 200 pM G418 (with 1% DMSO) were used as a positive control and arbitrarily assigned a value of 100%. Cells treated with 1 % DMSO were used as the negative control to define 0% response.
Concentration effect curves were analysed using non-linear regression using the CDD Vault from Collaborative Drug Discovery (Burlingame, CA). Where datapoints at the highest concentrations tested showed bell-shaped dose-response behaviour (due to cell toxicity confirmed by viability assay), they were removed from the analysis. The bottom and top of the curves were constrained to 0 and the maximum measured response respectively. From
the fitted curves, the software derived C100% values (the concentration giving the same response as 200 pM G418) for each compound. The negative logarithm of C100% is reported as pC100%. In addition to pC100% values, the maximum fold response relative to 200 pM G418 was also captured.
Protocol B
As described in McElroy et al. PLoS Biology (2013), 11 , e1001593, ADXC8 cells were seeded into white 96 well plates (Greiner) in a volume of 100 pl and incubated for 24 hours at 37 °C in an atmosphere of 5% CO2. Compounds were solubilised in DMSO at a top concentration of 10 mM and serially diluted with media in half log steps to achieve a range of final assay concentrations of 100 pM to 1 nM. Compound at each concentration (100- fold final) was added to plates and they were incubated for a further 24 hours. Luciferase activity was measured by monitoring luminescence on a TopCount luminometer (PerkinElmer) following addition of lysis/detection buffer and calculating fold change in signal relative to DMSO only controls.
Concentration effect curves were fitted using non-linear regression with Activitybase XE (I DBS). Where datapoints at the highest concentrations tested showed bell-shaped dose- response behaviour, they were removed from the analysis. From the fitted curves, the software derived C10F values (the concentration giving 10-fold response) for each compound. The negative logarithm of C10F is reported as pC10F. In addition to pC10F values, the maximum fold response over vehicle control was also captured.
Protocol C
Cells suspended in DM EM + glutamax media containing 10% FCS were seeded into clear 384 well plates (Greiner) to a density of 3200 cells per well in a volume of 25 pl and incubated for 24 hours at 37 °C in an atmosphere of 5% CO2. Compounds were solubilised in DMSO at a top concentration of 10 mM and serially diluted with media in half log steps to achieve a range of final assay concentrations of 100 pM to 1 nM. 5 μL compound at each concentration (6-fold final) was added to plates so that the final assay volume was 30 μL and they were incubated for 24 hours at 37 °C in an atmosphere of 5% CO2. Steady Gio® Luciferase Assay System (Promega) was prepared according to manufacturers’ instructions. 30 pl of Steady Gio® Luciferase Assay System was added to each well and the plates were shaken on platform at 450 rpm for 5 minutes before reading on a PHERAstar® plate reader using LUM plus protocol and calculating fold change in signal relative to DMSO only controls. Concentration effect curves were fitted using non-linear regression with Activitybase XE (I DBS). Where datapoints at the highest concentrations tested showed bell-shaped dose- response behaviour, they were removed from the analysis. From the fitted curves, the software derived C10F values (the concentration giving 10-fold response) for each
compound. The negative logarithm of C10F is reported as pC10F. In addition to pC10F values, the maximum fold response over vehicle control was also captured.
Key
- pC100%/pC10F > 3.7 < 4.5 # Fold over Ctrl > 0 < 1 X Max Fold > 1 < 5
+ pC100%/pC10F > 4.5 < 5.0 ## Fold over Ctrl >1 < 5 XX Max Fold >5 < 20
++ pC100%/pC10F > 5.0 < 5.5 ### Fold over Ctrl >5 < 10 XXX Max Fold >20 < 50
+++ pC100%/pC10F > 5.5 < 6.0 #### Fold over Ctrl >10 < 15 XXXX Max Fold >50 < 100 ++++ pC100%/pC10F > 6.0 ##### Fold over Ctrl >15 XXXXX Max Fold >100
Read-through of R213X mutation in HDQ-P1 cells by Western Blot The ability of compounds to promote read-through in cells was assessed using the HDQ-P1 cell line which contain the R213X mutation in the p53 gene. Active compounds promote translational read-through of the premature stop codon encoded by this mutation, resulting in the detection of full length p53 protein by Western blot. An increase in truncated p53 may also be observed as a result of compounds suppressing nonsense mediated decay of mRNA.
HDQ-P1 cells (R213X) were treated with DMSO (0.3%), or test article for 24 h at various concentrations. Cells were washed once with ice cold 1X PBS and lysed in MRC lysis buffer (1 M Tris-HCI, pH 7.4, 0.5 M EDTA, 0.25 mM EGTA (Ethylene glycol-bis(2- aminoethylether)-N,N,N',N'-tetraacetic acid), 0.5 M sodium fluoride, 0.1 M sodium pyrophosphate, 0.2 M sodium 2-glycerol 1 -phosphate, 0.2 M sodium orthovanadate, 0.27 M sucrose, 10% (v/v) Triton X-100, 0.1 mM phenylmethylsulphonyl fluoride, 1 M dithiothreitol) and protease inhibitor mixture (Roche) centrifuged at 4 °C for 15 min at 16000xg, the supernatants, termed cell extracts, were collected and total proteins were quantified with Bradford protein assay kit (ThermoFisher). Cell extracts were denatured by incubation in
NuPAGE LDS sample buffer for 10 min at 95 °C. 25 pg total protein from HDQ-1 cells were subjected to sodium dodecyl sulfatepolyacrylamide-gel electrophoresis in 4-12% pre-cast Bis-Tris gels (ThermoFisher). Proteins were transferred onto PVDF membranes, and membranes were blocked for 1 hr at room temperature in 5% skimmed milk powder in Tris- buffered saline with 0.1 % Tween® 20 Detergent (TBST) and incubated overnight with the primary monoclonal antibody DO-1 (sc-126, Santa Cruz Biotechnology, 1/1000). After three washes in TBST, the membranes were incubated with the secondary antibody (horseradish peroxidase-conjugated anti-mouse IgG [1/10,000]) for 1 hr at room temperature. The membranes were washed three times with TBST and chemiluminescence was detected with ECL Western Blot reagent kit (Cytiva-VWR) or Clarity Max ECL substrate (Bio-rad). The signal was quantified with Imaged software (NIH).
Figure 1 shows the effect of treatment of HDQ-P1 cells with Example 3 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
Figure 2 shows the effect of treatment of HDQ-P1 cells with Example 4 (0.41 pM, 1.23 pM, 3.7 pM, 11 pM, or 33 pM) compared to DMSO (0.3%), and G418 (200 pM).
Claims
1 . A compound of formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof:
wherein
R1 is independently selected from H, cyano, C1-C4-haloalkyl, C0-Cs-alkylene-R1a, C2-C6- alkylene-R1 b, C(O)R1c, S(O)R1c, S(O)2R1c, and C1-C6-alkylene-R1d;
R1a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl; wherein where R1a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R1a is optionally substituted with from 1 to 4 R8 groups and where R1a is phenyl or heteroaryl, R1a is optionally substituted with from 1 to 5 R9 groups;
R1 b is independently selected from NR6aR7a and OR6;
R1c is independently selected from C1-Cs alkyl, C0-C4-alkylene-R1a and C0-C4-alkylene- NR6aR6a;
R1d is independently selected from C(O)NR6aR6a, SO2NR6aR6a and CO2R6;
R2 is independently selected from cyano, C1-C4-haloalkyl, C0-Cs-alkylene-R2a, C2-C6- alkylene-R2b, C(O)R2c, S(O)R2c, S(O)2R2c, and C1-C6-alkylene-R2d;
R2a is independently selected from C3-C8 cycloalkyl, C5-C8 cycloalkenyl, phenyl, 3- to 8- membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl and 5-, or 6-membered heteroaryl; wherein where R2a is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, R2a is optionally substituted with from 1 to 4 R8 groups and where R2a is phenyl or heteroaryl, R2a is optionally substituted with from 1 to 5 R9 groups;
R2b is independently selected from NR6aR7a, and OR6;
R2c is independently selected from C1-Cs alkyl, C0-C4-alkylene-R2a and C0-C4-alkylene- NR6aR6a;
R2d is independently selected from C(O)NR6aR6a, SC>2NR6aR6a and CO2R6;
R3 is independently selected from H and C1-C4 alkyl; or wherein R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R4 is independently selected from H, cyano, nitro, OR6b, NR6R7, CO2R6, C(O)R6, C(O)NR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
R5 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OH, OR6b, SR6, SOR6, S(O)2R6, S(O)2NR6R6, CO2R6, C(O)R6, C(O)NR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, and cyclopropyl;
R6 and R6a are each independently at each occurrence selected from H and C1-C4 alkyl; or two R6a groups, together with the nitrogen atom to which they are attached, form a 5- to 8- membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R6b is independently at each occurrence selected from C1-C4 alkyl;
R7 and R7a are each independently at each occurrence selected from H, C1-C4 alkyl and C(O)-C1-C4-alkyl; or R6a and R7a, together with the nitrogen atom to which they are attached, form a 5- to 8-membered heterocycloalkyl ring; optionally substituted with 1 to 4 R8 groups;
R8 is independently at each occurrence selected from =0, =S, halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, cyclopropyl, C1-C3-alkylene-NR6R7, and C0-C3- alkylene-phenyl;
R9 is independently at each occurrence selected from halo, nitro, cyano, NR6R7, OR6, SR6, SOR6, S(O)2R6, SO2NR6R6, CO2R6, C(O)R6, CONR6R6, C1-C4-alkyl, C2-C4-alkenyl, C2-C4- alkynyl, C1-C4-haloalkyl and cyclopropyl; m and x are each independently selected from 0 and 1 ; n is independently an integer selected from 0, 1 , 2, 3, and 4; wherein any of the aforementioned alkyl, alkylene, alkenyl, or cyclopropyl groups is optionally substituted, where chemically possible, by 1 to 5 substituents which are each independently at each occurrence selected from the group consisting of: C1-C4-alkyl, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Ra is independently at each occurrence selected from H, and C1-C4-alkyl; and Rb is independently at each occurrence selected from H, C1-C4-alkyl, C(O)-C1-C4-alkyl and S(O)2-C1-C4-alkyl.
2. A compound according to claim 1, wherein x is 0.
3. A compound according claim 1 or claim 2, wherein m is 0.
4. A compound according to any one of claims 1 to 3, wherein R1 is independently selected from H, cyano, C0-C6-alkylene-R1a, C2-C6-alkylene-R1b, and C(O)R1c.
5. A compound according to any preceding claim, wherein R1 is C(O)R1c.
6. A compound according to any preceding claim, wherein R2 is independently selected from C0-C4-alkylene-R2a, C2-C4-alkylene-R2b and C1-C4-alkylene-R2d.
7. A compound according to any preceding claim, wherein R2 is C2-C4-alkylene- NR6aR7a.
8. A compound according to any preceding claim, wherein R2 is C1-C4-alkylene-R2a.
9. A compound according to any preceding claim, wherein R2a is independently selected from 3- to 8-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- or 6-membered heteroaryl.
10. A compound according to any preceding claim, wherein R3 is H.
11. A compound according to any one of claims 1 to 6, wherein R2 and R3, together with the atom or atoms to which they are attached, form a 5- to 8-membered heterocycloalkyl ring.
12. A compound of any one of claims 1 to 10, wherein R2 comprises at least one nitrogen atom.
13. A compound according to any preceding claim, wherein R4 is independently selected from selected from C1-C4-alkyl and OR6b.
14. A compound according to any preceding claim, wherein R4 is methyl.
15. A compound according to any preceding claim, wherein n is 0.
17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16, and one or more pharmaceutically acceptable excipients.
18. A compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use as a medicament.
19. A compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use in the treatment of: a disease of the musculoskeletal system, a disease of the skin, a metabolic disease, a disease of the Nervous System, a Cardiovascular disease, an Endocrine disorder, a disease of the eye, a disease affecting the urogenital system, a haemic or lymphatic condition, a respiratory disease, an inflammatory or autoimmune condition, a disease of the Gastrointestinal system, a Neoplasm, cancer, or a disease or disorder selected from Amelogenesis Imperfecta, Anodontia, Odontodysplasia, Branchio-Oto-Renal Syndrome, Sotos Syndrome, and Waardenburg's Syndrome.
20. A compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use in the treatment of a disease selected from: Recessive dystrophic epidermolysis bullosa, Junctional epidermolysis bullosa, Xeroderma pigmentosum, Netherton syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Cystic Fibrosis, Dravet Syndrome, Aniridia,
Methylmalonic Acidemia, Colorectal Cancer, Endometrium Cancer, Breast Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Familial adenomatous polyposis, Hemophilia A, Hemophilia B, Choroideremia, Pulmonary Artery Hypertension, Ataxia telangiectasia, Shwachman-Diamond syndrome, Mucopolysaccharidosis Type I,
Mucopolysaccharidosis Type VI, Mucopolysaccharidosis type III, Niemann-Pick Disease, and Primary Ciliary Dyskinesia. A compound according to any one of claims 1 to 16, or a pharmaceutical composition according to claim 17, for use in a method of treating conditions or disorders which are associated with PTC mutations in a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2209403.1 | 2022-06-27 | ||
GBGB2209403.1A GB202209403D0 (en) | 2022-06-27 | 2022-06-27 | Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024003535A2 true WO2024003535A2 (en) | 2024-01-04 |
WO2024003535A3 WO2024003535A3 (en) | 2024-03-07 |
Family
ID=82705648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2023/051666 WO2024003535A2 (en) | 2022-06-27 | 2023-06-26 | Compounds |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202209403D0 (en) |
WO (1) | WO2024003535A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003026657A1 (en) | 2001-09-24 | 2003-04-03 | Synaptic Pharmaceutical Corporation | Compounds for the treatment of pain |
WO2021228945A1 (en) | 2020-05-12 | 2021-11-18 | Centre National De La Recherche Scientifique | Quinazoline compounds as inhibitors of premature termination codons |
-
2022
- 2022-06-27 GB GBGB2209403.1A patent/GB202209403D0/en not_active Ceased
-
2023
- 2023-06-26 WO PCT/GB2023/051666 patent/WO2024003535A2/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003026657A1 (en) | 2001-09-24 | 2003-04-03 | Synaptic Pharmaceutical Corporation | Compounds for the treatment of pain |
WO2021228945A1 (en) | 2020-05-12 | 2021-11-18 | Centre National De La Recherche Scientifique | Quinazoline compounds as inhibitors of premature termination codons |
Non-Patent Citations (25)
Title |
---|
BARTON-DAVIS, E.R. ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol. 104, 1999, pages 375 - 381 |
BEDWELL, D.M. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 1280 - 1284 |
BELGRADER, P. J. C.MAQUAT, L.E., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 482 - 486 |
CLANCY, J.P. ET AL., AM J RESPIRCRIT CARE MED, vol. 163, 2001, pages 1683 - 1692 |
DABROWSKI, M. ET AL., RNA BIOLOGY, vol. 12, 2015, pages 950 - 958 |
DAVIES, J.GORINI, L., PROC. NATL. ACAD. SCI. USA, vol. 52, 1964, pages 988 - 996 |
E. L. ELIELS. H. WILEN: "Stereochemistry of Organic Compounds", 1994, WILEY |
GOTTLIEB, JOURNAL OF ORGANIC CHEMISTRY, vol. 62, 1997, pages 7512 |
HAS, C. ET AL., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 142, 2022, pages 1227 - 1230 |
HELIP-WOOLEY, A. ET AL., MOLECULAR GENETICS AND METABOLISM, vol. 75, 2002, pages 128 - 133 |
KARAGIANNAKOS ET AL., CANCERS (BASEL, vol. 14, 2022, pages 664 |
KEELING, K.M. ET AL., HUMAN MOLECULAR GENETICS, vol. 10, 2001, pages 291 - 299 |
KEELING, K.M.BEDWELL, D.M., JOURNAL OF MOLECULAR MEDICINE, vol. 80, 2002, pages 595 - 604 |
KELLERMAYER, R., EUROPEAN JOURNAL OF MEDICAL GENETICS, vol. 49, 2006, pages 445 - 450 |
KRAWCZAK, M. ET AL., HUMAN MUTATION, vol. 15, 2000, pages 45 - 51 |
M. E. AULTONCHURCHILL LIVINGSTONE, PHARMACEUTICALS - THE SCIENCE OF DOSAGE FORM DESIGNS, 1988 |
MAQUAT, L.E., NATURE REVIEWS, MOLECULAR CELL BIOLOGY, vol. 5, 2004, pages 89 - 99 |
MCELROY ET AL., PLOS BIOLOGY, vol. 11, 2013, pages e1001593 |
MOOSAJEE, M.K. ET AL., HUMAN MOLECULAR GENETICS, vol. 17, 2008, pages 3987 - 4000 |
MORT, M. ET AL., HUMAN MUTATION, vol. 29, 2008, pages 1037 - 1047 |
NORTH ET AL.: "Approach to the diagnosis of congenital myopathies", NEUROMUSCULAR DISORDERS, vol. 24, 2014 |
STARK ET AL.: "A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders", GENETICS IN MEDICINE, vol. 18, 2016 |
WANGENGREEN, ELIFE, vol. 9, 2020, pages e52611 |
WILSCHANSKI, M. ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 139, 2003, pages 1433 - 1441 |
WOODLEY, D. T. ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol. 127, 2017, pages 3028 - 3038 |
Also Published As
Publication number | Publication date |
---|---|
GB202209403D0 (en) | 2022-08-10 |
WO2024003535A3 (en) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111153901B (en) | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | |
CN115448910A (en) | Pyridazine derivative inhibitor, and preparation method and application thereof | |
EP3173412B1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
AU2019254979B2 (en) | Macrocyclic kinase inhibitor | |
AU2005293343B2 (en) | Process for making phenoxy benzamide compounds | |
BR112020013164A2 (en) | amino-fluorpiperidine derivatives as a kinase inhibitor | |
CA2930060A1 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses | |
CN109721600B (en) | Nitrogen-containing fused ring compounds and preparation method and application thereof | |
CN110964012B (en) | Fused heterocyclic biaryl benzyl alcohol compound, preparation method and application | |
CN112094269B (en) | Saturated six-membered ring heterocyclic compound, preparation method and application | |
CN113527299A (en) | Nitrogen-containing condensed ring compounds, preparation method and application | |
AU2020386189B2 (en) | Adenosine receptor antagonist compounds | |
EP4223759A1 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
WO2021237121A1 (en) | Substituted pyridines | |
CA3055233A1 (en) | Jak kinase inhibitor and preparation method and use thereof | |
CN111320621B (en) | Indolizine compound and preparation method and application thereof | |
WO2024003535A2 (en) | Compounds | |
JP2022502448A (en) | MDM2 Inhibitors, Methods of Preparation, Pharmaceutical Compositions and Applications | |
AU2022230397A1 (en) | Covalent egfr inhibitors and methods of use thereof | |
WO2022063128A1 (en) | Aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and use thereof | |
US20220135538A1 (en) | P300/cbp hat inhibitors and methods for their use | |
WO2019141096A1 (en) | Substituted urea compound and preparation method and use thereof | |
PL236355B1 (en) | Derivatives of 7-(morpholin-4-yl)pyrazolo[1,5-α]pyrimidine as inhibitors of kinase P13 | |
CN110724076B (en) | Para-aryldiamide compound, pharmaceutical composition containing same, preparation method and application thereof | |
WO2017037604A1 (en) | Novel fyn kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23738842 Country of ref document: EP Kind code of ref document: A2 |